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 The emergence of the disease concept of Gestational Diabetes Mellitus during the 
late twentieth century was a product of collaborative efforts between physicians, medical 
researchers, businesses, and government agencies.  This work is fundamentally an 
institutional history of medicine, situated in three specific genres within the field:  disease 
creation studies, the examination of U.S. public health, and healthcare consumer history.  
This work traces changes in scientific and medical views, as well as the broader shift in 
how diseases are defined as that process moved out of the medical clinic and research lab 
into the halls of policy makers and government agencies.   
Scientific discovery and understanding emanated from the work of medical 
researchers, but the post-World War II era in the United States saw government agencies 
and healthcare businesses gain important roles in defining diseases and in creating 
consumer identities for patients.  This was especially visible with gestational diabetes 
because many of the women who made up the rising numbers of new cases in the second 
half of the twentieth century came from lower-income groups who accessed their 
healthcare through government-subsidized programs like Medicaid.  Through a range of 
historical sources, I examine the development of this dynamic relationship between 
medical knowledge and practice; business ideologies and approaches in an expanding 
healthcare market; and government policy on healthcare. 
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CHAPTER I 
INTRODUCTION 
 
This dissertation investigates how the diagnosis of Gestational Diabetes Mellitus 
(GDM) was created during the twentieth century through the collaborative efforts of 
physicians, medical researchers, businesses, and government agencies.  It traces the 
changes in scientific and medical views about the condition as well as the broader shift in 
how diseases are defined, as that process moved out of the medical clinic and research lab 
into the halls of policy makers and government agencies.  Scientific discovery and 
understanding would emanate from the work of medical researchers, but the post-World 
War II era in the United States saw government agencies and healthcare businesses gain 
important roles in defining diseases and creating consumer identities for patients.   
The intimate connections that arose by the mid-twentieth century between 
medicine, business, and the state – a system of political and economic relationships called 
the Medical-Industrial Complex – became the structure within which medical 
recommendations and public policies were created to define gestational diabetes and to 
identify its patient-consumers.  The impact of this complex became especially visible 
with gestational diabetes because many of the women who made up the rising numbers of 
new cases in the second half of the twentieth century were from lower-income groups 
who accessed their healthcare through government-subsidized programs like Medicaid.  
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Through a range of historical sources, including medical archives, contemporary 
scientific literature, patient and physician communications, oral histories, popular media, 
congressional records, and epidemiological data, I examine the development of this 
dynamic relationship between medical knowledge and practice; business ideologies and 
approaches in an expanding healthcare market; and government policy on healthcare. 
***** 
This dissertation is the story of a disease concept.  And while that story entails 
scientific debates in which newer ideas displaced older regimes, this dissertation focuses 
more on the mechanics of how the disease concept for gestational diabetes became 
formalized in public policy and how the patient-consumer identities associated with it 
were formed in the late twentieth century.  The “making” of gestational diabetes was not 
solely the result of medical discovery or of scientific “facts.”  It was also the result of 
policy formation.  The broad canvas upon which this history unfolded identified a range 
of historical subjects – the women who would be diagnosed, the researchers and 
legislators who designed public policy, the physicians in the real world of clinics, and 
even the fetuses of affected pregnancies – who themselves became “historical events in 
need of explanation.”
1
  
Understanding the imperative to reshape the importance and the meaning of 
gestational diabetes requires an explanation of the basic physiology of diabetes.  Diabetes 
actually appears in two different forms, which have two different etiologies or causes, 
                                                 
1
 Joan Scott, “The Evidence of Experience,” Critical Inquiry 17, 4 (Summer 1991):  780.  
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despite the popular modern conception of it as a single disease that is inextricably linked 
to obesity and the excesses of Western life.  Diabetes, both forms, develops along a 
continuum that involves a decreasing ability to metabolize and use the food a person eats 
along with a corresponding increase of sugar in the blood stream when the byproducts of 
that failing metabolism build up.  There is a point along that continuum, today designated 
with a number from a laboratory test, when the increased level of sugar in the blood 
stream surpasses what a person’s system can manage and becomes poisonous to organs 
and systems inside his or her body.   
For Type 1 diabetes, the movement along that continuum is rapid and complete; 
left untreated, that form can kill in a matter of hours, though it usually takes weeks or 
months.  Type 1 is a disease that usually appears in young children or adolescents (hence, 
the older name of juvenile diabetes), but frequently shows up in adults as well.  Type 1 is 
often called insulin-dependent diabetes because the complete failure of internal insulin 
production causes the person to become dependent on insulin injections for the rest of his 
or her life.  Although there is not a sole cause of Type 1, the disease emerges when the 
insulin-producing cells of the pancreas are destroyed.  Most often, that destruction is the 
result of the individual’s own immune system becoming “confused” and attacking the 
pancreatic cells as though they were an outside organism.  The destruction can also 
happen, although much more rarely, as a result of a toxic chemical or from an injury to or 
disease of the pancreas.  As pancreatic cells do not regenerate, Type 1 diabetes is 
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permanent.  And although insulin injections can successfully treat it, no cure exists and it 
cannot be reversed.  Type 1 diabetes comprises about 5 percent of all diabetes cases. 
Type 2 diabetes, which is also known as adult-onset or non-insulin-dependent 
diabetes, overwhelmingly accounts for the majority of diabetes cases in the United States 
today.  Unlike its lethal cousin, Type 2 diabetes does not emerge from a process of 
cellular destruction.  Rather, an unknown mechanism – probably several mechanisms – 
prevents the insulin that a person with Type 2 makes naturally to work properly.  The 
person with Type 2 diabetes has plenty of insulin, sometimes incredibly high levels, but 
for a variety of reasons, it does not do its job.  Type 2 diabetes is not acutely dangerous 
because even though the insulin that a Type 2 diabetic makes may not work properly, it 
still works, and the person with this form of the disease can go for years or decades with 
few symptoms and little to no awareness that any problem is present.  Increased body fat 
and inactivity magnify the problem of ineffective insulin because both of those factors 
decrease sensitivity to insulin across the board.  Hence, despite popular conception, 
obesity and inactivity do not cause this form of diabetes.   
Physicians’ current understanding of gestational diabetes is that it is most like 
Type 2 diabetes.  As the term “gestational” implies, the condition first appears during 
pregnancy.  Officially defined as “carbohydrate intolerance of variable severity with 
onset or first recognition during pregnancy,” it involves the appearance of high blood 
sugars in a pregnant woman who has not previously been diagnosed with diabetes.
2
  The 
                                                 
2
 Early on, before the condition was called gestational diabetes, it was identified by the appearance 
of sugar in a pregnant woman’s urine.  The difference in how it was diagnosed was due mainly to the 
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added physical stress of pregnancy on a woman’s body is thought to uncover a hidden 
metabolic problem.  Typically, after giving birth, the woman’s blood sugars normalize, 
but many of these women develop Type 2 diabetes within a decade of their experience 
with gestational diabetes.  Just like with Type 2 diabetes, age, weight, and racial/ethnic 
heritage factor into a person’s likelihood of developing it.
3
 
Throughout this narrative I try to refer to the condition by the name that the 
corresponding historical actors have used, but sometimes the name gestational diabetes is 
more explanatory, even if less historical.  From 1921 to the early 1950s, the condition 
was most commonly known in the medical literature as glycosuria of pregnancy.  For 
roughly the next two decades, researchers and physicians most often used the term pre-
diabetes of pregnancy.  By the mid-1970s, gestational diabetes had become the 
predominant name for the condition and would become the official name that was added 
to the compendium of diseases maintained by the World Health Organization (WHO).  
As well, throughout the narrative, although I try to refrain from the ahistorical use of the 
word “disease,” I allow the word into the narrative when the historical actors use that 
term in their own portrayals. 
                                                                                                                                                 
laboratory technology of the time.  The change to using blood sugar testing, though, becomes an important 
part of this history because it changed the symptomology used to define the condition – and the disease 
concept shifted from the idea of an internal threshold being surpassed (the kidneys “spilling” sugar over 
into the urine) to the selection of a number in a lab test that negated individual differences. 
3
 Donald R. Coustan, “Making the Diagnosis of Gestational Diabetes,” Clinical Obstetrics and 
Gynecology 43, 1 (March 2000):  99; American Diabetes Association, “What Is Gestational Diabetes?” 
http://www.diabetes.org/diabetes-basics/gestational/what-is-gestational-diabetes.html (accessed August 1, 
2013); Centers for Disease Control, “Diabetes and Pregnancy,” 
http://www.cdc.gov/Features/DiabetesPregnancy/ (accessed August 1, 2013). 
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The time frame for this dissertation, 1921 to 1991, saw the American social 
landscape change dramatically.  From the discovery of insulin in 1921 to a conference in 
1991 organized to clarify the definition of gestational diabetes, America went through the 
Great Depression, the New Deal, World War II, and the social movements of the 1960s 
and 1970s.  A time of intense efforts at social reform and of the increasing power of the 
state in the lives of everyday people, life in the United States underwent enormous 
changes.  Cities grew and then fell into decay, a culture of consumerism took shape, and 
the demographic profile of the nation shifted as huge internal migrations took place.
4
   
This time period also encompassed sweeping changes in U.S. medicine, from 
structural changes in the field itself to therapeutic advances for a bevy of health issues.  
Often called the era of “the professionalization of American medicine,” it was a time 
when healthcare became a full-fledged consumer market, a protective force in people’s 
lives, a mediator of public behavior, and a source of what many scientists believed to be 
remarkable discoveries about our bodies, our nature, the perceived similarities and 
differences between us, and the biological manifestations of our cultural and social 
concerns.
5
  During the seventy years of this narrative, American medicine was 
transformed from a disorganized and poorly regulated system of “snake oil hustlers” and 
local healers that challenged the integrity of a cadre of educated clinicians to a managed 
                                                 
4
 Thomas J. Sugrue, Origins of the Urban Crisis:  Race and Inequality in Postwar Detroit 
(Princeton, NJ:  Princeton University Press, 1996); Lizabeth Cohen, A Consumer’s Republic:  The Politics 
of Consumption in Postwar America (New York:  Alfred A. Knopf, 2003); and James N. Gregory, The 
Southern Diaspora:  How the Great Migrations of Black and White Southerners Transformed America 
(Chapel Hill:  The University of North Carolina Press, 2005). 
5
 Paul Starr, The Social Transformation of American Medicine:  The Rise of a Sovereign 
Profession and the Making of a Vast Industry (New York:  Basic Books, 1982). 
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and authoritative force of organized sanctioning bodies and formal structures for the 
education and credentialing of healthcare practitioners.
6
   
It is within these changes in American life and American medicine that a 
condition that physicians once thought to be of little significance became seen instead as 
a disease for which every single pregnant woman should be tested.  As scientific 
understanding changed, the condition took on different names and those names held 
different meanings for different historical actors.  Hence, glycosuria of pregnancy was 
not exactly the same phenomenon as pre-diabetes of pregnancy, which is not the same 
condition as gestational diabetes.  In medical clinics, glycosuria of pregnancy was the 
physiology of metabolism and pregnancy gone awry.  Businesses in the American 
healthcare market, however, came to understand and discuss a different condition, pre-
diabetes of pregnancy, and viewed it through demographic descriptors like race and 
socio-economic status, variables that informed their process of risk reduction.  In the 
offices of policy makers, the condition became the disease gestational diabetes, and 
legislators defined it in simple economic terms:  the fiscal impact of diagnosing or not 
diagnosing it.   
Even though gestational diabetes today is thought to be more closely related to 
Type 2 diabetes, examining the condition historically requires attention to the 
transformation of diabetes as a whole that was brought about by the discovery of insulin.  
                                                 
6
 Starr, The Social Transformation of American Medicine.  Also, see Andrew Delano Abbott, The 
System of Professions:  An Essay on the Division of Expert Labor (Chicago:  University of Chicago Press, 
1988); Ann Anderson, Snake Oil, Hustlers, and Hambones:  The American Medicine Show (Jefferson, NC:  
McFarland, 2000); and James Harvey Young, Toadstool Millionaires, A Social History of Patent Medicines 
in America before Federal Regulation (Princeton:  Princeton University Press, 1961).   
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This dissertation begins in 1921 with the discovery and production of insulin to treat 
diabetes.  With the discovery of insulin, diabetes was commuted from a quick death 
sentence to a chronic, but manageable, illness.  As such, even though references to the 
disease date back as far as 1550 BC, diabetes is very much a twentieth-century disease:  
scientific understanding, medical treatment, and increased prevalence are all twentieth-
century developments.   
Most scholars who have examined some aspect of diabetes history are medically 
trained and so their foci have been primarily science-driven, using a biomedical model.
7
  
The two main contemporary works are Michael Bliss’s The Discovery of Insulin and 
Chris Feudtner’s Bittersweet:  Diabetes, Insulin, and the Transformation of Illness.  
Bliss’s narrative details the contentious history of the discovery of insulin within a fairly 
antagonistic international medical community.  Feudtner examines the impact that insulin 
had on the lives of diabetic patients, both in terms of the immediate life-saving effect of 
the hormone and in terms of the long-term consequences of these patients having a fatal 
illness transformed into a chronic one.  Both narratives portray the urgency and the 
                                                 
7
 The use of the term “biomedical model” to describe the format for social science works on health 
issues emanated from scholars’ recognition of the transforming power of technological development on 
social aspects of health and healthcare; see Peter Keating and Albert Cambrosio, “From Screening to 
Clinical Research:  The Cure of Leukemia and the Early Development of the Cooperative Oncology 
Groups, 1955-1966,” Bulletin of the History of Medicine, 76, 2 (2002):  299-334.  For an explanation of 
how this model has shaped diabetes history, see Chris Feudtner, Bittersweet:  Diabetes, Insulin, and the 
Transformation of Illness (Chapel Hill:  University of North Carolina Press, 2003), xiv, 9-10, and 87.  
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despair felt by patients and their families as well as by the physicians who tried 
unsuccessfully to help them.
8
 
Like the works of Bliss and Feudtner on diabetes, histories of disease creation in 
general often focus on the social context of illness, and that focus has illustrated the 
profound impact that definitions and meanings of health and illness can have for people.  
For example, lead poisoning went from an unrecognized phenomenon at the turn of the 
century to a disease of great public concern by the 1990s, when the gentrification of 
older, historic neighborhoods exposed children in families of higher socio-economic 
status to lead paint poisoning.
9
  And such studies have given historians new and 
important ways to portray social structures like class.  But they do not explain how a 
disease can be created through government and medical policies and how certain 
individuals and groups have experienced that process differently.
10
  In the case of kidney 
                                                 
8
 Michael Bliss, The Discovery of Insulin (Chicago:  University of Chicago Press, 1982) and Chris 
Feudtner, Bittersweet.  Bliss is an exception to the spate of physicians examining diabetes history; Bliss is a 
business historian. 
9
 Peter C. English, Old Paint:  A Medical History of Childhood Lead-Paint Poisoning in the 
United States to 1980 (New Brunswick, NJ:  Rutgers University Press, 2001).  Other excellent studies 
include Carol R. Byerly, The Fever of War:  The Influenza Epidemic in the U.S. Army during World War I 
(New York:  New York University Press, 2005); Steven Epstein, Impure Science:  AIDS, Activism, and the 
Politics of Knowledge (Berkeley:  University of California Press, 1996); James H. Jones, Bad Blood (New 
York:  The Free Press, 1981); Charles E. Rosenberg, The Cholera Years:  The United States in 1832, 1849, 
and 1866 (Chicago:  The University of Chicago Press, 1962); and Keith Wailoo, Dying in the City of Blues:  
Sickle Cell Anemia and the Politics of Race and Health (Chapel Hill:  The University of North Carolina 
Press, 2001). 
10
 Gordon, Dead on Arrival, 46-89; Jeremy Alan Greene, “The Therapeutic Transition:  
Pharmaceuticals and the Marketing of Chronic Disease” (PhD diss., Harvard University, 2005); and John 
Patrick Swann, “Insulin:  A Case Study in Pharmacomedical Research,” Pharmacy in History 28, 1 (1986):  
3-13.  On the growth of the federal government, see Nell Irvin Painter, Standing at Armageddon:  The 
United States, 1877-1919 (New York:  Norton, 1987); Thomas J. McCormick, America’s Half Century:  
United States Foreign Policy in the Cold War (Baltimore:  Johns Hopkins University Press, 1989); and 
Lizabeth Cohen, A Consumer’s Republic. 
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failure, for example, government policy circumscribed what physicians could and could 
not do.  Because medicine is not isolated in the world of science, the patients who would 
be saved by the new dialysis machines, but could not afford the cost, gained access to the 
technological marvel through amendments to Medicare that brought End Stage Renal 
Disease (ESRD) into the language of Social Security legislation.
11
   
Similarly, in the case of GDM, testing for the condition would become an integral 
part of the system of prenatal care covered by Medicaid because many women who 
would face a diagnosis of gestational diabetes were poor.  That policy makers and 
clinicians recognized that connection is evidenced by the incredible similarity in the 
language of policies for expanded access to Medicaid and the guidelines and medical 
position statements for the diagnosis and treatment of GDM.  As gestationally diabetic 
pregnancies became high risk events, Medicaid coverage extended to poor women with 
“high risk” pregnancies.  At the same time that Medicaid began to include previously 
ineligible pregnant women for the third trimester of their pregnancies, testing for GDM 
became a third trimester event.  Follow-up care for Medicaid recipients who recently 
                                                 
11
 Steven Peitzman, Dropsy, Dialysis, Transplant:  A Short History of Failing Kidneys, 
Biographies of Disease (Baltimore:  Johns Hopkins University Press, 2007).  Also, for other narratives in 
the history of medicine which engage social history, see M. Jeffrey Maisels and Susan Niermeyer, 
“Neonatal Jaundice:  The Cultural History of the Creation and Maintenance of a ‘Disease’ of Newborns,” 
in Small Wars:  The Cultural Politics of Childhood, eds. Nancy Scheper-Hughes and Carolyn Fishel 
Sargent (University of California Press:  Berkeley and Los Angeles, 1998), 111-129; Joan Jacobs 
Brumberg, Fasting Girls:  The Emergence of Anorexia Nervosa as a Modern Disease (Cambridge:  
Harvard University Press, 1989); Charles E. Rosenberg, “Disease in History:  Frames and Framers,” 
Millbank Quarterly 67, supplement 1 (1989), 1-15; Sheila M. Rothman, Living in the Shadow of Death:  
Tuberculosis and the Social Experience of Illness in American History (New York:  Basic Books, 1994); 
Keith Wailoo, Drawing Blood:  Technology and Disease Identity in Twentieth-Century America 
(Baltimore:  The Johns Hopkins University Press, 1997); and Janet Golden, Message in a Bottle:  The 
Making of Fetal Alcohol Syndrome (Cambridge:  Harvard University Press, 2005). 
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gave birth came to include sixty days of postnatal care, and physicians focused on the 
first sixty days postpartum for gestationally diabetic women as well. 
Women’s relationship to medicine has drawn an increasing amount of attention 
from historians outside of the realm of medical tomes, and much of the earliest of that 
scholarship focused on women as patients.  But many of those works presented women as 
victims or as objects of study.
12
  Carroll Smith-Rosenberg opened a new perspective that 
has endured into more recent scholarship, presenting the relationship between women 
patients and their physicians instead as a site of negotiation in which women retained a 
significant amount of control.
13
  Judith Walzer Leavitt took the ideas of doctor-patient 
negotiation and of the medicalization of female lives and demonstrated that in the move 
of childbirth from the home to the hospital, women in fact exercised a great deal of 
control.
14
  Likewise, diabetic women played an active and important role in the 
emergence of the specialty field of obstetrical diabetes by refusing to avoid pregnancy 
                                                 
12
 Barbara Ehrenreich and Deirdre English, Witches, Midwives, and Nurses (New York:  Feminist 
Press, 1971); idem, For Her Own Good:  150 Years of the Experts’ Advice to Women (New York:  Anchor 
Books, 1978); and Edward Shorter, Bedside Manners:  The Troubled History of Doctors and Patients (New 
York:  Simon and Schuster, 1985).  
13
 Carroll Smith-Rosenberg, “The Hysterical Woman:  Sex Roles and Role Conflict in Nineteenth-
Century America,” Social Research 39 (Winter 1972):  652-678. 
14
 Judith Walzer Leavitt, Brought to Bed:  Childbearing in America, 1750-1950 (New York:  
Oxford University Press, 1986).  While certainly not an exhaustive list, for an understanding of the 
scholarship that Leavitt challenged in her argument that women retained control over decisions regarding 
childbirth and that they often chose the care of doctors in hospitals, see Frances E. Kobrin, “The American 
Midwife Controversy:  A Crisis of Professionalization,” Bulletin of the History of Medicine 40 (Fall 1966):  
350-363; Joan M. Jensen, “Politics and the American Midwife Controversy,” Frontiers 1 (Spring 1976):  
19-33; Ann H. Sablowsky, “The Power of the Foreceps:  A Comparative Analysis of the Midwife, 
Historically and Today,” Women and Health 1 (January-February 1976):  10-13; Catherine M. Scholten, 
“’On the Importance of the Obstetrik Art’:  Changing Customs of Childbirth in America, 1760-1825,” 
William and Mary Quarterly 34 (July 1977):  426-445; and Richard Wertz and Dorothy Wertz, Lying-In:  A 
History of Childbirth in America (New York:  Free Press, 1977). 
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and by refusing to end their diabetic pregnancies.  And women patients in the 1950s and 
1960s would help physicians make the connection between the temporary condition of 
glycosuria of pregnancy and a diagnosis of diabetes later in their lives.   
 
Part I:  Diabetic Identity in the Twentieth Century 
Part I of this dissertation addresses the scientific, medical, business, and social 
elements that together created the context within which a disease concept for gestational 
diabetes would develop.  Chronic diseases were long imagined as a natural process of 
aging.  But that view had changed by the middle of the nineteenth century, and certainly 
by the early twentieth century.  Instead, chronic diseases like diabetes became seen as a 
problem of epic proportions with the taming of infectious agents like polio, smallpox, and 
measles.  In some ways, the privileging of research and experimentation that had led to 
success in combatting infectious diseases served as an organizing element for connecting 
medicine to the growing social concerns over chronic illness.  The constitutionalism that 
had scientists asking what made the pancreas dysfunctional in diabetes and had doctors 
enamored of insulin, gave way to a pragmatism that brought the new actuarial scientists 
of insurance companies into physicians’ clinics.
15
  As diabetes physician Elliott Joslin 
                                                 
15
 Sarah W. Tracy, “George Draper and American Constitutional Medicine, 1916-1946:  
Reinventing the Sick Man,” Bulletin of the History of Medicine 66, 1 (1992):  53-89; Thomas Schlich, 
“Making Mistakes in Science:  Eduard Fluger, His Scientific and Professional Concept of Physiology, and 
His Unsuccessful Theory of Diabetes (1903-1910),” Studies in History and Philosophy of Science 24 
(1993):  411-441; idem., “Changing Disease Identities:  Cretinism, Politics, and Surgery (1844-1892),” 
Medical History 38 (1994):  421-443; idem., “”Objectifying Uncertainty:  History of Risk Concepts in 
Medicine,” Topoi, An International Review of Philosophy 23 (2004):  211-217; Carsten Timmermann, 
“Constitutional Medicine, Neo-Romanticism, and the Politics of Anti-Mechanism in Interwar Germany,” 
Bulletin of the History of Medicine 75, 4 (2001):  717-739; idem., “Chronic Illness and Disease History,” 
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proclaimed that Metropolitan Life “furnished practically all the statistical data I ever 
quote,” physicians began to worry about the looming economic impact of the expanding 
numbers of diabetics.
16
  Investigators tried to put a dollar amount to such amorphous 
elements as missed work days, unpaid medical bills, and decreased productivity.   
Scholars have posited that the problem of infectious disease was merely 
supplanted by the rise of debility from chronic illnesses – because of the greater visibility 
of chronic ailments that came with medical knowledge and also because people simply 
lived long enough to experience chronic illnesses more often when acute infections 
became less life-threatening.
17
  Concurrently, a new line of actuarial scientists sought to 
protect the bottom line of an emerging host of insurance and health maintenance 
businesses, with government agencies entering as well into the fiscal support of the 
American public’s health.
18
   
At the same time that chronic illness was gaining much more public visibility, 
pregnancy was being transformed in science labs, in popular perception, and in 
courtrooms and congressional hearings.  As pregnancy became envisioned less and less 
as a private and personal experience for women – and more as an environment for the 
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growing baby, the unborn child, the “potential human life” – women found they could be 
held liable for the impact of their behavior, or even their inaction, on the fetus inside 
them.
19
  In the post-Roe v. Wade era, that shift would bring professional medical journals 
to posit that “the care of a pregnant woman involve[d] two patients, the mother and the 
fetus” and would lead to headlines on Fetal Alcohol Syndrome (FAS) and “crack 
babies.”
20
   
Chapter III, the first chapter of Part I, begins with the early twentieth century 
transformation of diabetes.  Long considered a relatively uncommon condition that was 
both acute and lethal, it was believed to strike mostly young, white children.  By mid-
century, however, it would be understood as a chronic illness that afflicted a much 
broader cross-section of society, and that posed the potential for great public expense.  
Insulin was an important facet in that transformation, but this chapter argues that insulin’s 
transformative power was not just in the therapeutic value it brought.  Insulin created one 
of the largest healthcare consumer markets to date, and the consumer identities that 
emerged from that new market transformed the perception of diabetes and of its patients.  
                                                 
19
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Brad Segelstad, “Fetal versus Maternal Rights:  Medical and Legal Perspectives,” Obstetrics and 
Gynecology 58, 2 (August 1981):  209.  
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The construction of this new patient-consumer identity embedded ideas about what 
constituted responsible health behaviors and acceptable public costs into notions of what 
it meant to be diabetic. 
Chapter IV examines the emergence of a specialty field in medicine concerned 
specifically with diabetic pregnancy:  obstetrical diabetes.  The key figure in building the 
field was Boston physician Priscilla White.  But White was not the sole catalyst.  Women 
with diabetes played an essential role as well.  As insulin saved the lives of young Type 1 
diabetics and improved the health of Type 2 diabetics, those women found they were 
finally able to become pregnant.  Although insulin did not make diabetic pregnancy safe 
– both mother and baby often died – diabetic women refused to acquiesce to medical 
recommendations to avoid pregnancy and they refused to end their pregnancies.  Their 
actions forced the creation of the specialty field because it gendered the medical 
perception of diabetes patients.  
Chapter V introduces the condition that preceded gestational diabetes – called 
glycosuria of pregnancy until mid-century, and then referred to as pre-diabetes of 
pregnancy.  Along with the transformation of diabetes, the rise of risk factor ideology 
sparked research interest on the condition, both in America and across the Atlantic in 
European locales.  Risk factor ideology was based on the business concept of limiting 
fiscal risk by identifying economic threats.  In the healthcare market, that meant 
identifying chronic diseases before they could wreak havoc.  For pregnant women who 
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were found to have sugar in their urine, normally a tell-tale sign of diabetes, risk factor 
ideology made researchers ask what possible health problems that condition portended. 
 
Part II:  Making Gestational Diabetes 
Part II of this dissertation chronicles the “mechanics” of creating the diagnosis of 
gestational diabetes.  The process of creating and defining gestational diabetes became a 
task of making policies that specified who was at risk and what fiscal and social problems 
could result from not identifying those at risk.  During the 1970s and 1980s, a definition 
for gestational diabetes developed within the framework of social welfare policy.  As 
such, state policies became embedded in this new disease concept.     
Due to an increasing role of the federal government, the rise of a pharmaceutical 
market, and the emergence of a third-party payer system, medical care became 
commodified during the twentieth century.
21
  Historians have investigated that transition 
and have recognized that a binding element was the rapidly expanding enterprise of 
federally-funded medical research.  This dissertation expands on those studies by 
demonstrating how the structure of medical research also became the conduit for bringing 
business and the state into the formula for defining health and illness.  Medical research 
became a billion dollar industry.  It made new career paths for physicians, built new 
businesses in the healthcare market, and created new agendas for many federal 
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agencies.
22
  Medicine, business, and government became bound by a network of grants, 
new investigative centers, and congressional committees that brought physicians into 
public policy positions.
23
   
Chapter VII, the first chapter in Part II, examines the rise of a massive diabetes 
research and healthcare industry that created and supported the careers of many new 
doctors and researchers.  The research enterprise that emerged during the mid-twentieth 
century, which was funded and supported by healthcare companies and by the U.S. 
government, brought physicians and scientists together with businessmen and legislators 
to create fellowships, research centers, and lobbyist positions that brought money and 
attention to the issue of diabetes and pregnancy.  During the 1950s and 1960s, diabetic 
pregnancy research became a central feature of a growing diabetes industry, bringing 
scientific interest to the condition of glycosuria of pregnancy.  This chapter traces the 
convoluted paths that research monies followed, using government documents, 
interviews, committee publications, and institutional publications to demonstrate the deep 
connections that grew out of those funding efforts. 
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Chapter VIII argues that an examination of the actual process that reframed the 
condition of glycosuria of pregnancy – or pre-diabetes of pregnancy – demonstrates the 
influential role that the state has gained in defining health and illness.  Historians of 
medicine have oft argued that social context influences how diseases are defined and 
created.  This chapter expands that lens by examining instead how the process of creating 
gestational diabetes conversely shaped the social meaning of the disease in important 
ways.  The creation of gestational diabetes occurred within the bifurcated system of 
social welfare policy, which mattered for how the disease and its patients became 
understood.
24
  During the 1980s, an increasing number of women being diagnosed with 
the “new” disease received their healthcare through government-subsidized programs for 
the poor.
25
  Efforts to open access to care for those women embedded the language of 
federal policies into the definition of the disease.  Medical recommendations for 
diagnosing and treating gestational diabetes were worded to mirror the eligibility text of 
federally-supported programs for the poor like Medicaid and Aid to Families of 
Dependent Children (AFDC).   
Physicians and researchers realized that disease creation was influenced 
increasingly less by scientific endeavor and more by public policies in the post-World 
War II environment of connections between medicine, business, and the state.  In fact, the 
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disparity associated with gestational diabetes, from unequal access to care to a 
disproportionate incidence of health problems for minority women, cannot even be 
understood without attention to this historical context. 
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CHAPTER II 
PART I:  DIABETIC IDENTITY IN THE TWENTIETH CENTURY 
 
 The discovery of insulin in a small laboratory at the University of Toronto during 
the summer of 1921 has been hailed as one of the greatest miracles of modern medicine.  
Indeed, insulin saved the lives of countless diabetics and transformed physician-turned-
researcher Fred Banting into an instant celebrity in medical circles around the world.  But 
“discovery” is a misleading description.  Several prominent scientists across the globe 
had already succeeded in isolating the mysterious secretion of the pancreas.  Georg 
Ludwig Zuelzer in Germany, Ernest Lyman Scott in the United States, the biochemist 
Israel Kleiner, and the Romanian physiologist Nicolae Paulescu, all had managed to 
isolate the extract and had demonstrated its effectiveness in dissipating urinary sugar in 
diabetics well before the Toronto work.
1
  Moreover, far from being the miracle cure that 
media reports portrayed, insulin quickly became a double-edged sword.  In fact, it did not 
cure the dread disease at all; rather, insulin “transmuted” diabetes into a chronic illness, 
which was difficult to manage and rife with ancillary health problems.
2
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Understanding this historical misperception of diabetes and of the impact of 
insulin is necessary in order to contextualize how, later in the twentieth century, 
physicians would redefine a condition in pregnant women that had long been depicted as 
a diabetes mimic.  What was called glycosuria of pregnancy early in the twentieth 
century would become the disease gestational diabetes later in the century.  Described in 
the early decades of the insulin era as transient and relatively benign, it would by 1980 
become a disease that garnered significant federal fiscal support for research and attained 
formal recognition within and without the medical community through its addition to the 
World Health Organization’s international disease coding manual, the ICD-9.  While the 
actual mechanics of how gestational diabetes was redefined and the specific details of 
how it became formalized in the healthcare market constitute Part II of this dissertation, 
Part I addresses the scientific, medical, business, and social elements that together created 
the context within which that process would play out.   
The privileging of insulin as the pivotal event that transformed diabetes has 
resulted in a misunderstanding of the historical forces that played important roles in 
shaping the social understanding of the disease and its patients – both before insulin and 
after.  Most scholars today recognize disease and health as concepts that have been 
socially and culturally constructed, dependent on time and place for their meanings.
3
  Yet 
scientific discovery still too often monopolizes the narrative.  Such a focus has caused 
scholars to neglect a shift during the late nineteenth and early twentieth centuries from 
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conceptualizing illness as a solid, perceptible break from good health caused by a trigger 
– an insult, an injury, a germ – to seeing illness and health as relative states along a 
continuum, with “homeostasis” somewhere in the middle.
4
  It is an important shift, not to 
be overlooked or minimized in this history.  Leading up to the “discovery” of insulin, the 
scientific and medical understandings of diabetes had already begun to change.  By the 
mid-1800s, scientists had begun to think of diabetes as a perfect example of the relativity 
of health versus illness.  They recognized that even though some level of sugar must 
remain in the blood to support life, extremes at either end represented illness and in 
between lay a large, grey area between normal and pathological.
5
  The experiments and 
writings of these scientists – like Claude Bernard, Thomas Addison, and Charles Brown-
Sequard – contributed to greater knowledge of human physiology at a time when 
biochemists were finding new ways to identify and measure the constituents of bodily 
fluids.
6
   
In addition to the scientific and medical environment that gave physicians and 
researchers a new lens through which to understand the myriad systems of our bodies, 
healthcare in the early twentieth century was a fledgling consumer market that likewise 
                                                 
4
 Garabed Eknoyan, “History:  Emergence of the Concept of Endocrine Function and 
Endocrinology,” Advances in Chronic Kidney Disease 11, 4 (October 2004):  371-376; and Georges 
Canguilhem, “Claude Bernard and Experimental Pathology,” in The Normal and the Pathological, transl. 
Carolyn R. Fawcett (Brooklyn, NY:  Zone Books, 1989), 65-90.  Bernard coined the term homeostasis to 
explain the body’s natural tendency to return to a set state.  He used the condition of diabetes to 
demonstrate the idea that health and illness existed along a continuum in which drawing a clear line of 
distinction was difficult, if not impossible.   
5
 Canguilhem, The Normal and the Pathological.  Canguilhem examined the impact of nineteenth-
century scientists like Bernard in the ideological shift from an infectious disease model to a chronic disease 
model in medicine.   
6
 Eknoyan, “History,” 374-375. 
23 
 
shaped the public perception of diseases like diabetes.  And patients labeled with a 
chronic illness, rather than one of the many infectious diseases ceding to medical 
advances like vaccinations, took on a whole new assortment of social definitions.  Costly 
diseases like diabetes stratified these new patient-consumers by their purchasing power, 
or lack thereof.
7
  Gender also became a dividing line for treating patients, for prioritizing 
their needs, and for identifying that gray area between healthy and ill.
8
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CHAPTER III 
“IT IS TRULY MIRACULOUS”  
INSULIN AND THE TRANSFORMATION OF DIABETES 
 
 On September 24, 1922, Elizabeth Evans Hughes, daughter of then U.S. Secretary 
of State and eventual Supreme Court Chief Justice Charles Evans Hughes, wrote to her 
mother from Toronto, “I look entirely different everybody says … gaining every hour it 
seems to me in strength and weight … it is truly miraculous.”
1
  In August of that year, the 
young Hughes had been taken to Dr. Frederick Banting in Toronto with the hope that a 
newly discovered treatment for diabetes – insulin – might save her life.  Elizabeth 
Hughes turned fifteen within a few days of her arrival in Toronto yet she was so weak 
from the effects of diabetes that she could barely walk, and at five feet tall, she weighed 
only forty-five pounds.
2
   
As Elizabeth Hughes left for her miraculous trip to Toronto, a major shift began 
in the way that physicians and the general public understood diabetes and in the way that 
diabetics experienced their disease.  At the beginning of the century, diabetes was 
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considered a relatively uncommon disease.  With an acute onset and often rapidly lethal 
outcome, it was believed to be a disease that struck mostly young, white children.  By 
mid-century, however, diabetes was conceptualized in a very different way.  The disease 
would be understood instead as a chronic illness that afflicted a much broader cross-
section of society and that was believed to pose the potential for great public expense.   
Scientific discovery and increased medical knowledge certainly played important 
roles in the twentieth century transformation of diabetes, as the introduction of insulin 
therapy dramatically changed the trajectory of the disease.  But the discovery of insulin 
was not the magical, pivotal event that our historical memory has assigned to it.  As with 
most medical advances, the “discovery” of insulin actually involved a long process of 
accumulating knowledge that progressed in fits and starts.  Moreover, its impact reached 
beyond simply treating the symptoms of a disease, as it became the cornerstone of one of 
the first major healthcare markets in the United States. 
The privileging of insulin as the pivotal force or moment in a sharply 
reconfigured disease has emanated, to a great degree, from the vestiges of an old 
“professional history” edict in studies of medicine and disease.  Although the “great men” 
and “great events” stories told by older, male physicians of years past has given way 
within the field to complex and nuanced narratives which are more appropriately situated 
on a broader canvas of social history, studies on medicine and disease still do not attract 
many historians without a medical degree or some type of scientific training.
3
  For 
                                                 
3
 See, for example, works by William Osler, The Evolution of Modern Medicine:  A Series of 
Lectures Delivered at Yale University on the Silliman Foundation in 1913, 
http://www.gutenberg.org/files/1566/1566-h/1566-h.htm (accessed August 1, 2012); Harvey Cushing, The 
26 
 
historical works on diabetes, a limited set of scholars has resulted in a dearth of studies 
overall.   
The new insulin therapy indeed catalyzed a significant transformation in the 
disease during the decades between its discovery in 1921 and the mid-century mark.  
Perhaps most important, the new extract immediately altered the very course of the 
disease (insofar as what physicians understood diabetes to be in 1921) by staving off the 
almost certain death sentence that had previously come with diagnosis.  And, as insulin 
brought increased attention to diabetes, its prevalence rose in tandem with a greater 
awareness of the disease and of its early symptoms, particularly with the variant that 
doctors of that time period referred to as mild diabetes, but now call adult-onset or Type 
2 diabetes.   
Such a narrow focus on insulin in the literature, however, has resulted in the 
neglect of important social elements that also factored into the transformation of diabetes.  
For example, diabetic patients became consumers of diabetes care and found their lives 
defined and stratified to a great degree by their purchasing power within that market.  
That development, within a political and economic climate that brought American 
physicians and researchers into business complexes and federal policy roles, contributed 
significantly to the rapid increase in public concern about the disease.  As diabetes shifted 
from a fatal illness to a chronic and costly disease, new ideas emerged about the personal 
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responsibility of diabetic patients to “manage” their disease in order to prevent costly 
health complications that might be borne by public structures. 
Insulin became the foundation of an expansive diabetes healthcare market, which 
was nurtured by the growing connections between medicine, business, and the federal 
government during the first half of the twentieth century.  Changes in how the medical 
community and the general public understood diabetes, and related changes in the lives of 
diabetic patients, were intimately connected to the emergence of this consumer market.  
Efforts by physicians, businesses, and policy makers to inform Americans of new 
medical and scientific ideas about diabetes contributed to the changing social definition 
of the disease and to the popular perception of its patients.  Public discourse by 
physicians and policy makers on the growing fiscal concerns associated with diabetes, for 
instance, created a general fear of the disease and its patients, a concern that seemed at 
times out of proportion to the actual impact of diabetes.  As well, the public and private 
controls on supply, pricing, and access to insulin were under constant pressure, as 
participants within that market negotiated for any amount of leverage.   
This chapter examines the broad transformation of diabetes and diabetic patients 
in the first half of the twentieth century through the articles that physicians published in 
their medical journals and the textbooks and self-help books that they wrote for their 
colleagues and patients; through the actuarial data sets and government committee reports 
tracking the anticipated fiscal impact of diabetes; and through the popular media stories 
and the letters and voices of patients and caregivers who encountered the dread disease.   
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The Long Road to “Discovery” 
The introduction of insulin therapy in the early twentieth century changed the 
trajectory of a diabetes diagnosis for millions, but a long road of inquiry and research had 
paved the way for the “discovery” of insulin in 1921.  Even though diabetes had gone for 
centuries without any viable therapeutic options, physicians and scientists had long been 
interested in the disease.  Known references to diabetes date back as far as 1550 BC with 
the Ebers papyrus, an Egyptian document of medical treatments.  For the three thousand 
years leading up to the discovery of insulin, however, very little progress had occurred in 
terms of treatment.
4
  The lack of success in treating the disease likely played a role in 
dimming our historical recognition of the scientific work that presaged the Toronto 
research of the 1920s.  During the pre-insulin era, doctors who encountered a suspected 
case of diabetes usually documented the familiar symptoms of extreme hunger, insatiable 
thirst, and excessive urination but then could do nothing more than simply wait for the 
patient’s demise to confirm the diagnosis of diabetes.  By the mid-eighteenth century, the 
presence of sugar in the urine had become the key diagnostic criterion, assessed either by 
the attraction of ants to the patient’s urine or by the less palatable “taste test” and, 
eventually, by chemical urine tests.  Yet nothing succeeded in commuting the death 
sentence associated with the disease.
5
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While attempted treatments varied widely across time and space, the course of the 
illness continued unabated.
6
  New treatment strategies arose and then fell into disfavor 
and, unfortunately, patients continued to die.  Even with immense scientific interest in 
diabetes, researchers vacillated on their theories about the etiology of the disease.  
Theories ranged from an infectious agent to some sort of organ failure.  Well into the 
nineteenth century, doctors and researchers believed that diabetes was a disease of the 
kidneys because of its distinctive urinary symptoms.  Only when they shifted their 
attention away from the kidneys did they begin to look for an internal secretion to explain 
the source of the disease – a secretion believed to be one of the newly discovered  
hormones that scientists had identified as internal regulators of our daily functioning.
7
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The realization that a connection existed between diabetes and a small, greenish 
organ adhered to the side of the stomach – the pancreas – initiated the search for a 
mysterious internal substance that turned the food we ate into usable fuel for our bodies.  
Two discoveries directed attention toward the pancreas in the search for that substance.  
One of those discoveries came from a German medical student, Paul Langerhans.  In 
1869, Langerhans discovered that the pancreas actually contained not one but two types 
of cells, the acini, which were known to secrete acidic digestive juices, as well as a 
second set of smaller cells which were embedded like little islands or clusters within 
groups of acini cells.  Although Langerhans himself never figured out the function of this 
second set of cells, scientists by the end of the nineteenth century would focus on these 
“islets of Langerhans” after a second discovery turned their attention toward the 
pancreas.   
Roughly twenty years after Langerhans had found those small islands of cells in 
the pancreas, Oskar Minkowski and Joseph von Mering made an inadvertent discovery in 
their research work on digestion.  After removing the pancreas of a dog to demonstrate 
the primary importance of the small organ in digestion, the pair encountered an 
unanticipated result:  the dog awoke from surgery showing the tell-tale signs of diabetes, 
including extreme thirst and frequent urination.  Then, sugar appeared in the dog’s urine, 
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and finally, the dog fell into a coma and died.  Repeat experiments produced the same 
result.  Removing the dog’s pancreas resulted in the rapid onset of severe diabetes.
8
  By 
the end of the nineteenth century, with the discoveries of Langerhans and of Minkowski 
and von Mering to guide them, scientists began to look in earnest for an elusive internal 
secretion of the pancreas believed to be missing in diabetes patients.  The experiments by 
Minkowski and von Mering had turned their attention toward the pancreas, and 
Langerhans’s discovery had pointed toward specific cells within the pancreas.
9
     
The search for an internal secretion to explain the cause of diabetes was also born 
from excitement over new interpretations of older, Renaissance ideas that an “internal 
balance of humors” controlled bodily fluids, which in turn maintained good health and 
function.  In the 1860s, French physiologist Claude Bernard began to call this system of 
balance within the body the milieu interieur.  And by the 1930s, Walter Cannon, a 
physiologist at Harvard Medical School, expanded Bernard’s work into a theoretical 
concept on the functioning of balance and regulation inside our bodies, which he called 
homeostasis.  Homeostasis, Cannon explained, kept the pH of our bodies at a constant, 
maintained our core temperature within a narrow range, and provided a system of 
internally produced fluids to maintain vital levels of sugar in our bloodstream.  Scientists 
had begun to call these regulatory fluids hormones by the early twentieth century and the 
fluids were viewed as essential to the proper functioning of the human body.  Despite 
their inability to isolate or even see many of them, early-twentieth century physicians and 
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scientists tried to create concoctions from the ground-up organs and glands from which 
the fluids seemed to emerge, hoping to capture the important extracts.
10
     
Without a name for the mysterious secretion of the pancreas, researchers the 
world over tried to isolate the substance for decades prior to the group in Toronto 
producing their injectable serum to treat diabetes.  Few narratives on the discovery of 
insulin acknowledge the work of those prior researchers.  Nor do they acknowledge the 
social forces which influenced the emergence of new scientific ideologies guiding 
research efforts of the era.  In The Discovery of Insulin, however, Michael Bliss brought 
to light the successes of some of these previous researchers, such as the Romanian 
physiologist Nicolae Paulescu.  Bliss has suggested that the work of scientists like 
Paulescu received little to no acclaim, while the Toronto research team’s similar work 
quickly garnered recognition, because of differences in the contemporary state of 
technology and in the accompanying political environment.  Paulescu had results just as 
dramatic as the Toronto researchers but lacked the technology to analyze or purify the 
experimental serum.  Moreover, publication and dissemination of his work was halted 
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with the outbreak of World War I, and being quite the vocal anti-Semite, Paulescu met 
with resistance for any level of acceptance within the European and North American 
scientific communities.
11
   
In the lead-up to the work that came out of Toronto, treatments for diabetes 
continued to fluctuate along with scientific theories on the cause and course of the illness.  
As physicians understood the role of acid balance in the body and recognized the 
presence of acidosis (a dangerous drop in blood pH) in diabetic patients, treatment 
focused on feeding patients alkaline substances to neutralize the pH shift.  Sodium 
bicarbonate became a standard part of the treatment arsenal.  In addition, opium treatment 
lasted well into the twentieth century for a long list of ailments, diabetes included, 
because the narcotic reduced patients’ discomfort.  Not surprisingly, dietary treatments 
abounded as well.  Dietary treatments, however, were originally based on the notion that 
patients needed calorie replenishment to forestall the rapid weight loss – a fatal mistake 
for diabetic patients who were unable to process any but the smallest bits of food.  Once 
that error was recognized, calorie restriction was found to be a more effective remedy.
12
  
No matter what type of treatment was pursued during the pre-insulin era, the 
prognosis for diabetic patients remained poor.  Families watched their loved ones 
succumb either to the disease itself or, by the late nineteenth century, to the starvation 
diet that was the only known treatment to extend life for a few short months or, for a 
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fortunate few, maybe a year.  Even for those adults who presented with a mild case of the 
disease, the battle may have drawn out longer but still ended with blindness, kidney 
failure, and rampant infections that resulted in amputations of toes, feet, or whole legs.  
The children and few adults who developed the severe form of the disease were struck 
with incredible swiftness and ferocity, many losing their lives within days or weeks.  
They first developed thirst and hunger while losing weight rapidly and urinating 
frequently.  The shift in blood pH that occurred with the ensuing metabolic failure in 
severe diabetes, what today is called diabetic ketoacidosis, was usually the immediate 
cause of death.  It was a disturbing death that began with nausea and vomiting and ended 
with convulsions, a rattled breathing called Kussmaul respirations, and then coma and 
death.   
Dr. Elliott Joslin, a leading expert in diabetes during the first half of the twentieth 
century, lamented that before insulin most diabetic children died in less than a year even 
with the best medical management.  The only “treatment” that extended their lives at all 
was the undernutrition of a starvation diet, which often “was permitted by the despairing 
parents simply for the hope set before them that someone would discover something 
which might save their child.”
13
  At the beginning of the twentieth century, as physicians 
and researchers made huge strides in conquering infectious diseases through vaccinations 
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and sanitary practices, Joslin explained that diabetes care had “undergone no essential 
alteration.”
14
   
Even during the first years when insulin therapy became available, coma from 
ketoacidosis remained the most prevalent cause of death for diabetics.   In 1922, the year 
that insulin became available on a limited experimental basis, Dr. Joslin had eight 
children die at his clinic in Boston, all eight from diabetic coma.  Toward the end of the 
1920s, insulin became available commercially, and by that time, nearly all of Joslin’s 
patients had started insulin therapy, virtually eliminating diabetic acidosis and coma as 
causes of death.   
As the insulin era progressed, as diabetes became a disease of chronic 
complications, lifespans for these patients remained shortened and complicating health 
problems like “coronary” quickly replaced diabetic coma as the predominant cause of 
death for diabetics.
15
  In fact, about a decade after insulin therapy was introduced, a 1934 
editorial in the New England Journal of Medicine suggested to its readers that sparing 
diabetics from coma with insulin simply changed the cause of death.  The author asked if 
diabetics would now die instead from stroke, heart attack, or some other representation of 
poor control of their health.
16
  Even though the “so often hopeless” affliction was 
manageable with insulin, it had become a chronic disease and many physicians felt it still 
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remained dangerous.  “Survival” would come with life-long difficulties and potentially 
serious and expensive complications.
17
 
 
Diabetes in the 1920s 
During the 1920s, insulin became widely hailed as proof of the progress of 
modern medicine.  Within the confines of medicine, the transformation of diabetes served 
as sufficient evidence of that progress, even if by the 1930s physicians’ enthusiasm for 
insulin’s success would wane.  For the general public, however, the transformation of 
diabetes involved more than a scientific discovery or a medical advance.  The life-saving 
effect of insulin therapy had changed the medical approach to diabetes, but the marketing 
of insulin had shaped a broader and more public set of ideas about diabetes and about the 
patients living with it.  Outside the medical community, as diabetes was increasingly seen 
as a disease of debilitating medical problems and great public expense, ideas about 
responsible health behaviors began to develop.  Newspapers and popular magazines 
presented the new image of diabetes as a disease of cost and complications.  The new 
insulin therapy could alter the deadly course of diabetes for many, but the treatment was 
expensive and its supply was limited.
18
   
Insulin quickly became the foundation of an enormous market for diabetes 
healthcare at a time when physicians, pharmaceutical companies, and policy makers were 
building new connections.  In their concerted efforts to curb the fiscal toll that they 
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believed chronic diseases and poor health could take on the nation, a new force of 
government-employed epidemiologists and actuarial statisticians for insurance companies 
began studying and explaining the monetary impact of disease.  From lost workdays due 
to illness to the need for charity or government-subsidized care for lower-income 
patients, chronic diseases like diabetes replaced contagions like yellow fever and 
tuberculosis as the biggest impending threats to the health of the nation’s workforce.
19
   
Tracing the changes in both medical and popular ideas about diabetes within the 
context of an expanding consumer market for insulin illuminates important shifts in the 
emerging beliefs and social perceptions about the disease and its patients.  A growing 
public fear of diabetes arose in large part from beliefs that the associated health 
complications placed a multitude of hidden costs on public structures.  With insulin 
rerouting its course, diabetes became one of the newly feared chronic diseases.  Insulin 
therapy was an expensive commodity for which demand sharply outpaced its availability.  
Diabetics found that they were increasingly expected to take on responsibility for 
managing their disease, and they found that ensuing health complications were often 
attributed to their own personal neglect instead of to the disease process.  The popular 
media amplified these fears among their readership with stories about the “unknown 
diabetic,” suggesting the possibility that a huge number of people were walking around 
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with diabetes while somewhat irresponsibly unaware of the health complications that 
were developing.   
Insulin was certainly a major catalyst for these new beliefs, ideas, and perceptions 
about the disease and its patients.  The contemporary understanding of the disease also 
played a role in how public ideas developed.  The medical understanding of diabetes was 
quite different in the early 1920s, when insulin appeared on the scene, than our current 
set of ideas.  Today, physicians view diabetes as two diseases:  Type 1, which has an 
acute onset of great severity caused by a complete failure of internal insulin production, 
and Type 2, which usually begins with a mild presentation and very subtle, fleeting 
symptoms that can take years to be recognized because insulin is still being produced as 
its effectiveness decreases.  By contrast, in the 1920s, diabetes was generally viewed as a 
single disease with varying levels of severity.  The most severe cases usually began in 
childhood and the more mild cases in adulthood.
20
  Physicians’ views on diabetes shaped 
the way they presented information about the disease to the media and to the public.  By 
presenting diabetes as a single disease, attributes that might be specific to only one type 
of the disease – rapid accumulation of urinary sugar for Type 1 or the beneficial effect of 
diet and weight loss for Type 2 – were incorporated into a broad misunderstanding of the 
potential outcomes and of the effective interventions for diabetic patients.  For example, 
in a landmark study on the prevalence and outcomes of diabetes that was published in 
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1898, Elliott Joslin and a collaborator reviewed all cases of diabetes at the Massachusetts 
General Hospital over a seventy-four year period but did not distinguish between types or 
severity in their findings.  In their comprehensive study, diabetes was simply diabetes.  
All outcomes, from recovery to amputations and to death by coma, were presented as 
potential effects for anyone who encountered the disease.
21
   
With the predominant scientific concept of diabetes as a single disease, the 
discovery of insulin initially seemed to solve the riddle of what caused the disease.  At 
that time, most scientists believed that an internal lack of the hormone caused diabetes 
and that some individuals were simply lucky not to have lost all of their insulin 
production.  While that idea is not far from the current understanding of how diabetes 
develops, insulin would eventually complicate that early theory because the treatment 
worked miracles for severe diabetic patients but not for mild cases.  In many of the mild 
cases, no injected amount of the hormone seemed to work.  While that realization would 
bring scientists and physicians to develop new concepts about the disease, its variants, 
and its patients, in the 1920s it resulted in a confused portrayal of the transformed disease 
to the public.
22
  A complete or near-complete lack of insulin would eventually become 
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the hallmark feature of only one form of diabetes, the severe form.  An inability to utilize 
insulin despite an apparent abundance of it came to define the mild form.  For the general 
public, however, insulin “cured” diabetics … unless they in some way did not comply 
with doctors’ orders.
23
   
The realization that insulin was frequently ineffective for the mild type of diabetes 
would serve to reinforce ideas about (and confusion over) the social characteristics that 
were beginning to be associated with that form of the illness.  Certain social 
characteristics, like obesity and a sedentary lifestyle, were understood by the 1920s to be 
factors that aggravated the mild presentation of diabetes.  Many patients who presented 
with the mild form of the disease were overweight, and weight loss through special diets 
almost always cleared up the symptom of urinary sugar in those patients.  The fact that 
the hallmark diabetes symptom of urinary sugar was modifiable through changes in 
health behaviors brought physicians early on to criticize the mild diabetic whose disease 
progressed.  In addition, the connection between weight loss and clearing of urinary sugar 
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led to the misconception that poor diet, overweight, and obesity caused diabetes.  In 
1924, for example, physician Haven Emerson claimed that the mild form of diabetes was 
increasing in the United States because Americans were “the grossest feeders … dying of 
overeating.”
24
  The editors of the magazine Science told readers that diabetes was on the 
rise and diabetics suffered complications because of “the dietary excesses practiced by 
the American people.”
25
  Elliott Joslin warned that those who were overweight or obese 
and continued to ignore the recommendations of their doctors were killing themselves, 
that death and debility from diabetes would be their “penalty of obesity.”
26
  As evidence 
of his assertion, Joslin even went so far as to proclaim that the Jew was prone to diabetes 
“because he is fat.”
27
   
Into the early decades of the twentieth century, diabetes was believed to be more 
prevalent in whites, to have a higher incidence in urban areas, and to be increasing 
rapidly among higher-income earners.
28
  That perception, which is so different from our 
current understanding, emanated in large part from the types of patients seen by 
physicians of that era.  People who were poor, non-white, or lived in a rural location were 
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less likely to be diagnosed with diabetes, or with any non-infectious illness for that 
matter, because of their limited access to even the most basic health care.   
At least with contagious illnesses, patients with marginal access to healthcare 
could often gain some level of treatment, if for no other reason than the fear that they 
could infect others.  Diabetics, however, were not contagious and they were increasingly 
seen as responsible to some degree for the public impact of their poor health outcomes.  
The contemporary image of diabetes on the eve of insulin was reflected in the standard 
medical training and reference manual of the time, Osler and McCrae’s The Principles 
and Practice of Medicine.  The widely-used textbook shaped its recommendations to an 
upper-class type of patient.  Diabetics should live in an “equable climate,” make use of 
Turkish baths, and have frequent massages – therapies typically not accessible to lower-
income, rural, or non-white patients.
29
   
During the twentieth century, the social address of diabetes would shift.
30
  Early 
in the century, when descriptive statistics of those affected by such diseases were largely 
limited by matters of who presented for medical care (or in the case of actuarial 
summaries, by who purchased life insurance), diabetes was seen most often in middle- to 
upper-class homes, and it struck the children in those homes with a certain 
aggressiveness.  Regardless of the various faults or disparities associated with public 
health programs for the poor and the uninsured today, the mere creation of such programs 
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fundamentally changed our understanding of the prevalence of non-infectious, chronic 
diseases across the socio-economic strata.
31
  In the early decades of the twentieth century, 
however, lower-income patients who encountered diabetes usually found themselves left 
out of the miracle of survival.  As Boston diabetes physician Elliott Joslin noted, “It is the 
uneducated, untrained, uncared for child in a family with limited resources who is lost.”
32
   
The small handful of North American physicians who received insulin during the 
latter months of 1922 for treatment trials with patients in their clinics would continue to 
present this particular social address for diabetes in the way they reported on their trials.
33
  
The Journal of the American Medical Association and the Journal of Metabolic Research 
published the results from that first experimental distribution, and their articles included 
photographs of patients before and after insulin therapy.  These before-and-after 
photographs both informed and reflected the contemporary public image of diabetes as a 
disease transformed by modern medicine.
34
  However, although the dramatic photographs 
intended simply to put the medical transformation of diabetes on display, they also 
identified the medical community’s perception of the social address of these early insulin 
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consumers by featuring well-to-do white patients.  As Lisa Cartwright and others have 
argued, medical images displayed for public consumption represent scientific as well as 
social facets of their subjects.  Hence, these medical images of diabetic patients presented 
a particular social element seen in the definitions of many diseases:  class and race.  
Historian Keith Wailoo has explained as well in his study on sickle cell anemia, an illness 
particularly associated with African Americans, “The ways in which diseases are defined, 
characterized, and dramatized provide a window on social relations and social values.”
35
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Figure 1.  Before and after photos of insulin patient.  Copyright 1923 American Medical 
Association.  All rights reserved.  Reprinted, with permission, from the Journal of the 
American Medical Association. 
 
 
The pictures elicited reactions of shock and wonderment as the world met Billy 
Leroy, the three-year-old patient of Dr. Ralph Major.  A set of two photographs, a before-
and-after complement, presented the remarkable outcome of three months of treatment 
with insulin.  The physical changes in the young boy were nothing but spectacular.  The 
first picture showed the emaciated child crying in his mother’s arms as she stood gazing 
directly into the camera, clad in a dress of high quality fabric and detailed trim.  In the 
accompanying “after insulin” photograph, the young, white patient looked healthy and 
chubby-faced, dressed in his class-conscious sailor suit.
36
  Although the articles on these 
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first trials with insulin therapy were printed in strictly medical publications, they were 
picked up by the popular media in widely-read publications like Time magazine and the 
New York Times newspaper, thus transporting these presentations of diabetic patients to 
the general public.
37
  
Tracing insulin’s quick leap from discovery to market offers a new perspective on 
what historians of medicine refer to as the social construction of disease.  While Charles 
Rosenberg brought attention to the need for historians to examine the social context of 
disease, the formation of a consumer identity for patients has typically not been part of 
that examination.
38
  Yet the introduction of insulin therapy was not just a medical event.  
Almost immediately from its discovery, insulin became an important commodity in a 
rapidly expanding healthcare market.  As such, insulin quickly created a consumer 
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identity for diabetic patients.  Just as people took on consumer identities in other markets, 
diabetics took on identities as patient-consumers in a growing diabetes market as well.   
Despite the broad recognition that social and cultural elements factor significantly 
in contemporary definitions of diseases and patients, this relationship of insulin’s 
marketing to changes in popular conceptions of the disease and its patients has received 
surprisingly little attention.  The neglect of this aspect of diabetes history is likely bound 
up in the hesitancy among scholars to equate a person’s “patient-hood” with a consumer 
identity, particularly when that identity includes pejorative elements.  As historian Nancy 
Tomes has so deftly explained, “The language of consumerism seems to endorse a market 
logic that many contemporaries find disturbing when applied to doctor-patient 
relationships.”
39
  With many medical advances, social forces worked in tandem with 
scientific developments to shape the trajectory of events, and such was the case for 
insulin.   
A new definition of diabetes emerged from the medical impact of insulin and 
from the social impact of its marketing at a time when American medicine was in the 
midst of an enormous transformation itself.  Physicians organized themselves with the 
construction of professional societies to implement controls over the education and 
credentialing of their peers; the federal government collaborated with philanthropic 
associations to review the nation’s healthcare facilities and to draft measures to move 
control of hospitals out of the hands of churches and local aid societies; physician groups 
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such as the American Medical Association (AMA) began to press for salary subsidies and 
federal fiscal support of medical education; and government agencies were created to 
regulate the production and sale of healthcare products in order to protect the public from 
unscrupulous businessmen and questionable treatments.
 40
   
The growing connections between American physicians, government agencies, 
and businesses during the first half of the twentieth century formed the bedrock of a 
nascent healthcare market within the United States.  The developing American healthcare 
market quickly became grounded in the paradigm of risk factor ideology, and medicine in 
the United States emerged as a powerful force in the everyday lives of the nation’s 
people.  By promoting such measures as the implementation of sanitation practices and 
the monitoring of the health of the nation’s populace, the AMA and other physician 
groups came to play key roles in weaving healthcare issues into public policy.  The 
broadening influence of physicians in conveying scientific and medical information 
would come to play a significant role in creating public interest in diabetes as well. 
 
From Discovery to Market 
Popular accounts of diabetes history invariably cite 1921 as that pivotal moment 
in time when insulin was “discovered,” the scientific understanding of diabetes was 
transformed, and the medical approach to treating diabetic patients was forever changed.  
The usual storyline has Dr. Frederick Banting awakening from a dream in which he had a 
vision of how to isolate a mysterious substance from the acidic environment of the 
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pancreas without destroying it, thus, allowing doctors to capture it and turn it into a life-
saving treatment for diabetes.  The substance was thought to be one of the many 
hormones inside the human body.  By 1921, most scientists believed that the substance 
was secreted by the pancreas:  a small, greenish, fleshy organ nested beside the stomach.  
The story continues that Banting engaged the help of several researchers at the University 
of Toronto during the summer of 1921 and produced an injectable “cure” for diabetes by 
winter.  Not surprisingly, the actual chain of events was much more complicated. 
Throughout the summer and fall of 1921, Banting and two colleagues, Charles 
Best and J. Bertram Collip, worked in a small, under-funded lab at the University of 
Toronto practicing experimental treatments for diabetes on whatever groups of stray dogs 
they could round up.  They made the dogs diabetic by removing their pancreases and then 
tried to cure the dogs by injecting concoctions from ground-up parts of those organs.  
They used the surgically-removed pancreases of the research dogs at first but quickly 
moved on to acquiring the organs of cows and pigs from local slaughterhouses because of 
the large quantities they needed to produce a serum.  In spite of tremendous conflict 
among the group, replete with arguments, fist fights, and relentless threats over secret 
recipes for their new pancreatic serum, the university’s administration contracted with 
Toronto’s Connaught Laboratories to help the team purify their serum, increase its 
production, and attempt treatment in human subjects.
41
   
When they made the leap from keeping a lab dog, Marjorie, alive for seventy days 
to injecting their experimental extract into the buttocks of public ward patient Leonard 
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Thompson, the Toronto researchers put into play what has been called the greatest 
miracle of modern medicine.  By the end of 1921, the team’s incredible successes in the 
research lab had brought them to the proposition of the first human trial.  In January, they 
selected a fifteen-year-old boy who was dying in the public ward of the Toronto General 
Hospital to be given injections of the experimental extract.  Thus, Leonard Thompson 
became the first person saved by insulin.  The initial injections, on January 11, 1922, had 
little clinical effect, but a second set of injections with a new batch of serum on Monday 
morning, January 23, produced incredible results.  By the week’s end, Leonard 
Thompson was very much alive.
42
   
News of the Toronto group’s new serum to treat diabetes swept headlines 
throughout the spring and summer of 1922.  With their daughter Elizabeth nearing death, 
Antoinette and Charles Evans Hughes hastily arranged for a trip to Toronto.  Until that 
point, the prominent diabetologist, Dr. Frederick Allen, had been treating young 
Elizabeth.  As the severity of her diabetes increased and her health deteriorated, Allen 
placed his patient on a starvation diet.  The diet forestalled her impending death by 
limiting the toxic effect of rising levels of sugar in her blood, the result of diabetes 
preventing Elizabeth’s body from metabolizing the food she ate.  By the time she left for 
Toronto, the severity of her diabetes had reduced her manageable diet down to an average 
of 405 calories per day along with several days of complete fasting.  The diet treatment 
had kept the young girl alive for three years, an incredible result by any means, but 
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Elizabeth Hughes paid a high price for those three years.  At fifteen years old, she was a 
semi-invalid.  Her life revolved around a horrible diet, with the fasting days “a special 
nightmare.”  In August of 1922, as Elizabeth Hughes was reaching adolescence, a time 
when she should have been growing taller and stronger, when she should have been 
entering puberty, she had instead lost nearly half of her body weight and could barely 
walk.  By the end of that year, however, insulin had saved her life.
43
 
As news of the miracle treatment for diabetes spread throughout the medical 
community, Danish researcher August Krogh came to Toronto to request access to the 
new treatment.  Krogh was a Nobel Prize-winning physiologist whose wife had recently 
developed diabetes, and he came to request permission to manufacture insulin himself.  
The Toronto group approved his request, and in collaboration with a prominent Danish 
physician, Krogh established a laboratory which eventually became one of Europe’s 
leading pharmaceutical companies, Novo Nordisk.  In less than a year, through the work 
of Krogh and Dr. Hans Christian Hagedorn, insulin became available for sale to 
European patients.
44
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Insulin changed the lives of thousands of people; indeed, the new treatment saved 
lives.  Examples of dramatic recoveries like those of Marie Krogh, of Elizabeth Evans 
Hughes, and of Leonard Thompson certainly demonstrate how quickly insulin altered the 
medical definition of diabetes.  In fact, as one young intern at the Toronto General 
Hospital during those years wrote later, “After 1922 the chapter on diabetes in every 
textbook had to be rewritten.”
45
  The new extract changed the prognosis, the treatment, 
and the course of the disease.   
With the commodification of the new treatment, however, a unique consumer 
identity developed for diabetic patients – one that conflated an inability to participate in 
the emerging consumer market with irresponsible health behaviors.  Diabetic patients 
found themselves transformed into insulin consumers nearly overnight.  Insulin was not a 
cure, but rather a life-long treatment, and its price became a complicated matter for 
diabetics, insulin manufacturers, physicians, and the general public.  An inability to 
afford insulin had a direct, negative impact on a diabetic patient’s health.  The mounting 
health complications that could follow became seen as a reflection of personal negligence 
and as a potential burden on society rather than as a reflection of an imbalanced market.   
This new populace of insulin consumers emerged toward the end of the 
Progressive Era in what historian Lizabeth Cohen has called the “first-wave consumer 
movement.”  During a time dominated by the power of business, Cohen explains that 
these “first-wave” consumer identities were largely shaped by the amount of market 
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participation individuals could gain.  Unlike Cohen’s “citizen-consumers” that emerged 
later, during the New Deal and post-World War II eras, these “proto-consumers” of the 
earlier decades of the twentieth century did not experience the same political 
inclusiveness and personal agency afforded by the purchasing power that later consumers 
held.
46
  Many of these new insulin consumers struggled to afford the only treatment 
available.  Those who experienced a repeated inability to participate in the new market 
economy found that their identity as diabetic patients was shaped by a critical assessment 
of their roles as undesirable consumers in the diabetes marketplace.  And just when 
manufacturing of the new diabetes treatment was on the verge of taking a favorable 
course, with the output of insulin manufacturing rising and production costs beginning to 
drop, the Great Depression would again place the treatment out of reach for many.
47
   
Ironically, just as insulin brought survival to many diabetics, their encounters with 
the complexity and cost of treatment and with the looming risk of debilitating 
complications made for a difficult lifestyle.  The complexity of the treatment regimen, the 
general confusion between the specifics of the two forms of diabetes, the direct and 
indirect costs of the disease, the host of related debilities, and the mounting evidence that 
changes in some health behaviors helped, all created an ideology that diabetic consumers 
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had to take personal responsibility for their disease and that they were in some way 
accountable for the problems that ensued.
48
   
As severe diabetics shifted from struggling with a deadly disease to living with a 
life-long malady, they adapted to a regimented schedule of multiple daily injections and 
complicated chemical self-testing of urine samples.  Even though insulin treatment 
replaced the extreme starvation diets of the pre-insulin era, diabetics still had to maintain 
a strict diet because diet therapy did not become obsolete for either type of diabetes, 
severe or mild.  Along with the laboratory set-up in their bathrooms, diabetics’ kitchens 
became stations for weighing and measuring all foods and liquids.  In addition, patients 
and physicians quickly realized that insulin therapy was not a simple formula.  Normal 
variations in bodily functions, coupled with irregularities in the strength of new batches 
of insulin, made patients’ physical responses unpredictable and dangerous – an issue that 
remains problematic even today.  Injected insulin did not act in the exact same fashion as 
a non-diabetic person’s naturally-produced insulin, and diet still had to be managed 
around insulin therapy.  Too little insulin left an excess of sugar in the blood stream and 
urine, slowly poisoning organ systems over time; too much insulin, sometimes in an 
amount as small as the head of a pin, could result in a near complete lack of sugar in the 
blood stream, followed by convulsions, unconsciousness, and even death.  Diabetic 
patients could not live at their doctors’ offices, however, and so they had to learn to 
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manage the new treatment, the new dietary restrictions, and the growing list of 
unexpected issues on their own.   
Along with these unexpected lifestyle changes and the inherent dangers of insulin 
therapy, diabetes became an incredibly costly disease as insulin prices rose dramatically 
during the 1920s.  During those first years when insulin therapy became available, 
diabetics could expect to pay $1.20 per day or more, a cost that today would be the 
equivalent of at least $20 to $37.
49
  Although the daily cost would fluctuate somewhat, it 
would continue to increase throughout the 1920s.  While these new diabetic consumers 
were directly confronted with the tremendous cost of insulin, the popular media indirectly 
brought insulin’s financial impact into the homes of the reading public as well.  In 1922, 
for example, the New York Times’ end-of-year listings of needy families highlighted one 
story, “Breadwinner Dying.”  The family had three children between the ages of eight 
and fifteen and the mother, “the only one in the family capable of earning a living,” had 
to spend all of her time caring for her husband, who was dying from diabetes.  They 
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could not afford insulin.  In 1922, the case was the paper’s first diabetic listing in the 
column, “New Neediest Cases.”  By the end of the decade, however, similar cases packed 
the column and instructed the reading public on the fiscal impact of diabetes.
50
   
In the decades following the discovery of insulin, the medical community and the 
general public increasingly came to expect diabetics to take personal responsibility for 
the management of their illness.  These new ideas about diabetes were often voiced in a 
language that spoke of control, management, and responsibility.
51
  Less than a decade 
into the insulin era, the language of patient responsibility could be seen in a new type of 
publication in the field of diabetes – self-help books for diabetics.  Because the diabetic 
was “his own nurse, doctor’s assistant, and chemist,” physicians began to write texts on 
diabetes treatment for the non-medical public.
52
  The preface of one of the time period’s 
most influential and best-selling self-help books, The Diabetic Life, instructed diabetics 
to practice “intelligent co-operation” and “accept the diabetic creed” in order to lead a 
“normal life.”  The author, Dr. Robin D. Lawrence, was a well-known diabetes physician.  
He insisted that patients follow a prescribed diet that matched with their insulin injections 
rather than dosing their insulin to meet their eating choices.  Allowing patients to eat 
what they preferred was a “slip-shod” method because “anyone can fatten a diabetic with 
insulin.”  Lawrence recounted an anecdote about two female patients who died because 
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they “refused to control their diet” despite warnings from doctors.  Not only were their 
deaths reflective of negligent behavior, “The use of insulin in this way is naturally 
expensive.”
53
 
As early as 1922, diabetes physician Elliott Joslin had begun to speak a similar 
language of patient responsibility, telling physicians that if they advised their patients on 
a diabetic regimen, the patient with complications could only be “compelled to say, 
‘Doctor … you are not to blame for my present condition.’”
54
  It was a language that 
Joslin would propagate through books and pamphlets similar to Lawrence’s Diabetic 
Life.  In 1937, in A Diabetic Manual for Mutual Use of Doctor and Patient, Joslin hailed 
the benefit of insulin for helping diabetics to manage their disease responsibly.  But, he 
warned, failure to manage their disease responsibly was no longer a private matter 
because “the public is watching.”
55
  In the next edition, which came out only four years 
later, Joslin increased his warning to diabetics on the potential for public scrutiny if they 
failed to manage their care.  Joslin added that “carelessness” and “indiscretions” harmed 
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other diabetics as well by creating a poor public image that could even make it difficult 
for diabetics in general “to get jobs and keep them.”
56
   
In concert with messages from the medical community about accountability, 
ongoing problems with access to insulin also helped to shape ideas about what 
constituted personal responsibility for diabetics in managing their disease.  Even before 
the full-fledged marketing of insulin began, access to it was unequal.  Requests for 
insulin flooded into the Toronto lab after every presentation, research paper, or news 
story.  However, the supposedly standard reply that the new serum still needed testing 
and refinement was not uniformly applied.
57
  Some of those initial requests came from 
physicians of prominent and influential families.  For example, a physician from 
Rochester, New York, Dr. John Williams, who was treating the son of James Havens, Sr., 
a prominent lawyer and vice-president of Eastman Kodak Company, pulled strings to 
secure insulin.  Jim Havens became the first U.S. patient treated with the new pancreatic 
extract from Toronto.  One of the co-discoverers of insulin, Frederick Banting, went to 
Rochester himself and then had insulin delivered regularly by train to the Havens’s 
physician.  The senior Havens reportedly paid substantial bribes to customs officials to 
ensure delivery of the extract.
58
  Limited access to insulin therapy made compliance with 
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doctors’ orders difficult, and the handling of requests for the drug illustrates that even 
though diabetics were expected to take responsibility for their disease, the ability to 
manage it was often hampered by factors outside of their control. 
By the end of the 1920s, although each new vial of insulin had less variability, the 
issue of access would linger.  For example, even those who could actually afford the cost 
of insulin still needed a physician with access to the new drug.  In the early decades of 
the twentieth century, patients rarely got medications by simply walking into a drug store 
with a prescription in hand.  The U.S. pharmaceutical firm, Eli Lilly and Company, had 
gained partial patent rights for insulin and distributed it directly to physicians, who then 
distributed it to their patients.
59
  Doctors with a supply of insulin remained a very select 
group, as did their patients.  For one major hospital in New York City, the two thousand 
units of insulin they received each week barely covered 1 percent of their cases and the 
hospital had to convene a committee to decide on matters of distribution.
60
 
While unequal access to insulin continued to frustrate and frighten diabetics and 
their families, it also frustrated clinicians who could not acquire the new drug, and drove 
some to levy intense public criticism for what they saw as professional elitism.  George 
Clowes, the director of research and the supervising chemist for insulin production at Eli 
Lilly, frequently discussed accusations of an “insulin aristocracy” in his letters and 
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memos, and tried to use the brewing conflict to persuade the Toronto team to allow Lilly 
to move “as rapidly as possible toward very widespread production.”
61
   
The cost of insulin stratified diabetic patients, which effectively erected a 
substantial barrier to any expansion of their consumer identities into the larger healthcare 
market that was developing in the United States.  That limited consumer identity 
significantly influenced social perceptions about diabetic patients.  The inability to afford 
insulin, for example, resulted in many lower-income patients being perceived as 
neglectful of the management of their disease.  The pervasiveness of such ideas can be 
seen in the approach of insurance companies to diabetic customers.  Until 1940, diabetics 
were universally ineligible for life insurance.  By the 1950s, some group insurance 
policies became available, but at much higher premiums for diabetic customers.  As 
historian Jeremy Greene has noted, “Once labeled as diabetics, patients found themselves 
ineligible for life insurance and were charged double premiums for health insurance.”
62
  
The inability of diabetic patients to extend their consumer identities into the broader U.S. 
healthcare market, such as into the market economy for insurance, would become an 
increasingly important topic in lay diabetes publications as the century progressed.
63
   
Concurrently, the medical understanding of diabetes progressed so rapidly in 
those first decades of the insulin era that efforts to incorporate new information into the 
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evolving definitions of the disease resulted in a progression of confusing naming rubrics.  
Throughout the 1920s and 1930s, physicians tried to convey new scientific discoveries 
about diabetes to their colleagues and to the general public.  What began centuries before 
as simply “diabetes” moved through a series of delineative labels for physicians:  severe 
versus mild, thin versus obese, insulin dependent versus non-insulin dependent, juvenile 
versus adult-onset, pancreatic versus insulin-resistant, Type 1 versus Type 2.  The chaotic 
litany of labels reflected the difficulty that physicians faced in staying on top of such 
rapid changes in the scientific as well as social understanding of diabetes.  
The medical community’s differentiation between types of diabetes in 
professional articles and in their public comments became more common as insulin 
revealed differences between severe and mild presentations.  But the general public’s 
understanding lagged behind.  That confusion emanated in large part from portrayals of 
the disease in newspapers and popular magazines, which continued to group all 
information under a single label:  diabetes.  A New York Times article that reported on the 
death rate for diabetes extolled the paper’s use of the most recent medical information 
and actuarial data.  Yet the article mixed together different symptoms and causes for each 
form of the disease into a singular description.  Even as the article included a clarification 
from the Metropolitan Life Insurance Company, which stated that a previous article by 
the paper had incorrectly implied that insulin was useless instead of explaining that it was 
helpful only for a particular form of the disease, the article again blurred details on the 
rise of the milder, adult, diet-controlled form of the disease with the severe, juvenile, 
insulin dependent form.  The paper quoted Metropolitan Life’s disclaimer, “Insulin has 
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been a great benefit in prolonging the life of young diabetics,” yet broadly posited that 
insulin still “cannot control the increase of diabetes.”
64
   
As physicians continued their efforts to inform the public about diabetes with the 
most up-to-date information possible, the reporting of healthcare statistics became an 
important activity in their efforts.  The source and compilation of those statistics played a 
significant role in shaping the message conveyed.  The first comprehensive attempts to 
describe disease epidemiology were based on data from the actuarial tables created by 
insurance companies.  Large insurance companies, such as Metropolitan Life, undertook 
the task of creating actuarial tables (a method of illustrating the probability of death or 
disability for individuals and groups) to assess risk investment and to develop health 
interventions that might extend the life span of policyholders.  Of course, then and now, 
longer life spans for policyholders meant better fiscal outcomes for a life insurance 
company.   
While the adoption of actuarial science by life insurance companies did not 
dictate public opinion, the ways in which these companies used the information certainly 
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did.  Actuarial tables created the foundation for an ideology of risk factor identification, 
where non-symptomatic individuals could be assigned a disease label based on their 
statistical potential for developing a frank case of an illness.  In addition, companies like 
Metropolitan Life fed their interpretations of actuarial data to the media, to the medical 
community, and to policy makers.
65
  At the turn of the century, the Metropolitan Life 
Insurance Company began publication of its annual newsletter, The Statistical Bulletin.  
The Bulletin listed the prevalence and incidence of a variety of diseases as well as other 
calculations on health in the United States.  The data presented in the Bulletin, however, 
came from limited sources:  information on life insurance policy holders and, later, from 
local death certificates as well.  Although the addition of death certificates brought the 
analyses up to a more sophisticated level, the information was still subject to the inherent 
bias of limited data sources in a newly developing but rapidly expanding market for 
medical care and for healthcare products.
66
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Metropolitan Life’s actuarial tables became the bible of health statistics.  The 
popular media anxiously anticipated the release of the Bulletin each year.  Even clinicians 
awaited Met Life’s numbers; Elliott Joslin remarked that Metropolitan Life “furnished 
practically all the statistical data I ever quote.”
67
  The fact that these statistics were 
skewed because they were based on limited data sources did not stop the media from 
confidently presenting the reports for public consumption.  For example, as early as 1923, 
Time magazine printed an article titled “Medicine:  War on Diabetes” and summarized 
statistics on diabetes from the Bulletin.  Diabetes mortality was on the rise, the article 
explained.  At that early date of 1923, the disease was particularly prevalent in the big 
urban centers like New York, with a higher incidence among whites.  Rates were “lowest 
in the southern and western states, largely because Negroes are less susceptible than 
whites.”
68
  Between 1921 and 1939, the identified diabetic population expanded, and 
researchers for Metropolitan Life predicted a continued and rapid escalation through the 
1940s.
69
  By the end of the 1930s, in fact, the U.S. Public Health Service (USPHS) had 
begun using Metropolitan Life’s predictions in reports to Congress, warning of an 
estimated five hundred thousand or more diabetics in the United States.
70
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Conclusion 
In 1921, a discovery in a Toronto laboratory forever changed the trajectory of 
diabetes for millions.  Insulin lifted the death sentence and, subsequently, transformed 
long-held scientific and medical ideas about the disease.  The new diabetes treatment also 
became the foundation of an expansive new healthcare market, quickly shaping public 
ideas about diabetes and diabetic patients in ways that science and medicine had not.  
Changes in social perceptions of diabetics, as well as the more tangible changes in the 
daily lives of these patients-turned-healthcare consumers, were intimately connected to 
the emergence of this consumer market.   
As diabetes became a chronic disease of debilitating health issues and of the 
potential for great public expense, ideas about responsible health behaviors emerged.  
Physicians, businesses, and policy makers informed Americans about growing fiscal 
concerns with diabetes, and diabetic patients were increasingly seen as personally 
accountable for managing their diabetes.  With insulin therapy, diabetics began to live 
into adulthood but those longer lifespans allowed the complications of chronic diabetes to 
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emerge.  Complications mounted:  heart disease, nerve damage, and kidney disease, to 
name a few.
71
   
The transformed disease experience for diabetics has been a story of healthcare 
consumerism, constantly shaped by accommodations to the vagaries of insulin therapy 
and by the duty of responsible disease management.  That “duty” of the diabetic patient-
consumer had in fact become an integral part of physicians’ discussions by the 1940s.  
Elliott Joslin told an audience in 1943 that “responsibility” was essential for diabetics, 
and elaborated that “if a diabetic is not imbued with the necessity, the desire, and the duty 
to maintain his health, there is little that a doctor can do for him.”
72
  Despite the 
complexities of living with diabetes, physicians and patients strove for “happiness and 
normality in those added years.”
73
  However, as insulin changed diabetes from a fatal 
illness to a chronic and costly disease, diabetic consumers shouldered a new 
responsibility in striving for normality:  managing their disease and preventing 
complications for the public good.   
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CHAPTER IV 
“I HAD TO LEARN HOW TO TAKE CARE OF THEM”
1
 
PRISCILLA WHITE AND DIABETIC PREGNANCY 
 
In December of 1932, Boston physician Elliott Joslin received a letter from Dr. 
Edward Johns of Ohio about a mutual patient, Susan Thompson, a nineteen-year-old 
woman with diabetes who had recently eloped.  Undeterred by “the danger of pregnancy 
in her condition,” Susan had become pregnant, and Dr. Johns wrote to ask Joslin for his 
opinion on a “therapeutic abortion.”  Considering “youth and irresponsibility” 
insufficient grounds for abortion, Joslin emphatically disagreed.  But the pregnancy was 
aborted anyway.  Two years later, Susan Thompson wrote to Dr. Joslin herself.  She was 
pregnant again and she asked him to recommend a different physician in Ohio.  With the 
help of an obstetrician who kept in contact with the Joslin Clinic during the pregnancy, 
Susan gave birth to a healthy baby by cesarean section delivery in September of 1934.
2
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Over the next twenty years, thousands of diabetic women like Susan Thompson 
refused to acquiesce to the medical advice that they avoid pregnancy or that they end 
their pregnancies.  These women dismissed the course of treatment prescribed by 
physicians who opposed diabetic pregnancy and instead sought out doctors who would 
support their desire to have children.  Their rejection of that medical advice forced the 
creation of the specialty field of obstetrical diabetes.  While many scholars have assumed 
that specialization reflects an internal mechanism of the medical profession in response to 
scientific discoveries and advances, this history suggests that the impetus for 
specialization has also resulted when physicians ceded to social forces, in this case the 
pressure of women patients with diabetes who wanted to have children in spite of the 
potential risks.
3
   
Scholars have described the trajectory for obstetrical diabetes as a process in 
which medical professionals carved out a specialty field based on their increasing 
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expertise with specialized therapies for treating diabetes.
4
  Such interpretations miss the 
way in which a significant push for the emergence of obstetrical diabetes came from the 
patients.  When diabetic women ignored the advice of their physicians, became pregnant, 
and refused to terminate their pregnancies, the medical profession was forced to respond.  
Instead of continuing with strategies to preempt or even halt diabetic pregnancies, 
physicians were forced to think instead about ways to make such pregnancies successful.   
The history of obstetrical diabetes runs counter to the accepted scholarship that 
portrays specialization as a strictly medical development.
5
  Despite the conception of 
medical specialization as a uniquely scientific process, social forces played a significant 
role in its emergence.  The pervasive refusal of diabetic women to avoid pregnancy once 
insulin restored their fertility brought a range of reactions from the medical community, 
and these women’s continued efforts to conceive played a central role in forcing a change 
in medical approach.   
In addition, this history contradicts the wider historiography on women’s 
relationship to the medical community and on their struggles regarding access to 
healthcare.  It offers an expanded chronology and a broader definition of women’s 
agency in this area.  Historians have typically assigned a much later date for the changes 
in healthcare access for women.  Dubbed the women’s health movement, scholars have 
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situated its origins as an integral part of second-wave feminism during the mid-1970s.
6
  
Diabetic women’s actions during the 1930s and 1940s, though rarely recognized as social 
or political catalysts for such changes, likely had a significant impact on the trajectory of 
those events because their actions created a profound shift in the way medical 
professionals conceptualized their identities as women patients.  Moreover, diabetic 
women formed a collective force even without any visible, structured organization.  The 
diabetic women in this story rarely knew each other, except perhaps for the chance 
encounter in a clinic setting, and probably had limited awareness of the size and scope of 
their efforts, yet they pursued pregnancy en masse in the face of intense opposition.  
Their actions brought attention to the specific health concerns of women in the same 
fashion – though arguably less visibly – with which second-wave feminist groups like the 
Boston Women’s Health Collective would be credited nearly four decades later.
7
 
The key figure in the creation of the field of obstetrical diabetes was Priscilla 
White, a physician at the Joslin Diabetes Clinic in Boston, Massachusetts, from 1924 to 
1974.  White responded to her women patients’ desires to have children by trying to 
make their pregnancies successful.  Her approach came to include strict management of 
                                                 
6
 Ruth Rosen, The World Split Open:  How the Modern Women’s Movement Changed America 
(New York:  Viking, 2000), 175-181. 
7
 Boston Women’s Health Collective, Our Bodies, Ourselves (New York:  Simon and Schuster, 
1973); Barbara Ehrenreich and Deirdre English, Witches, Midwives, and Nurses (New York:  Feminist 
Press, 1971); idem, Complaints and Disorders:  The Sexual Politics of Illness New (York: Feminist Press, 
1977); and Sheryl Burt Ruzek, The Women’s Health Movement (New York:  Praeger, 1978).  The idea of 
female agency in the medical encounter gained momentum during the 1970s as historians trained in 
feminist theory began to pen health narratives.  Ehrenreich and English detailed a history of bias and 
oppression for women, emanating in large part from how women had been defined by their reproductive 
capacity.  Although many of these initial narratives have since been criticized as creating a victimization 
model for women, such revisionist scholars have not yet set the stage so much earlier. 
71 
 
the pregnant woman’s diabetes, intensive fetal monitoring, and early delivery to avoid 
late-term complications.  White’s approach dramatically decreased maternal deaths and 
fetal losses at the Joslin Clinic during the 1930s and 1940s.  Under White’s direction, 
maternal deaths dropped by over 90 percent in two decades, and fetal losses were cut in 
half during the same time frame.
8
   
White began to take on increasingly difficult cases during her career because even 
women with serious diabetic complications refused to be dissuaded from trying to have 
children.  Instead of discouraging them or insisting on ending their pregnancies, White 
tried to fashion successful treatment strategies for those cases as well.  Her efforts 
legitimated the field of obstetrical diabetes despite a lack of formal recognition from the 
American Medical Association (AMA).  So successful was White’s therapeutic approach 
that the White Classification System, as her methods became known, remains the 
foundation for the field today.   
 
Pregnancy and the Gendering of Diabetes 
Before diabetes physicians could embrace the idea of a medical field that focused 
exclusively on their women patients, they had to recognize the ways in which the 
introduction of insulin therapy had exposed significant differences between their men and 
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women patients.  Prior to the advent of insulin therapy in the early 1920s, differences 
between men and women with diabetes commanded little attention.  However, as the new 
treatment changed the disease and reconfigured the lives of those living with it, 
physicians began to shape their medical approaches and disease management strategies 
around the social gender roles that diabetic patients acquired as they survived longer and 
longer with insulin.   
Early twentieth century medical approaches to diabetic patients had rarely 
accounted for these issues of adult life because diabetic children seldom lived beyond 
those childhood years.  Although adults with the mild form of diabetes (now known as 
adult-onset or Type 2) actually comprised a sizeable portion of the diabetic population 
before the discovery of insulin, diabetic children were the most visible patients during the 
pre-insulin era.  The face of diabetes remained so young during the pre-insulin era, and 
for the first few years after the introduction of insulin, partly because the severity with 
which the disease struck children kept their plight in the public eye.  Also adding to the 
perception of diabetes as more a disease of youth, physicians had a less sensitive 
threshold for diagnosing adults with diabetes during that same time frame.  Adults were 
not diagnosed nearly as often then because the disease usually presented more slowly and 
with less visible symptoms than in children, and because urinalysis was generally the 
diagnostic test used, rather than the more sensitive blood testing used today.   
With the introduction of insulin therapy, diabetic children finally began to survive 
the diagnosis.  The boys grew into young men, the girls became women, and both became 
patients living with a chronic, costly disease that had the potential for serious and 
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debilitating complications.  Scholars have examined how insulin changed the lives of 
those first generations of insulin patients.  The new treatment turned the once acute and 
fatal diagnosis into a chronic malady; even though insulin saved lives, it left diabetics 
with a life-long regimen that was difficult to follow and that held no guarantee of a return 
to good health.  Missing from the literature on insulin’s impact, though, is how this 
transformation of diabetes brought physicians to consider gender in the care of their 
diabetic patients.
9
   
After the discovery of insulin, pregnancy became the overarching concern with 
female diabetic patients.  During the pre-insulin era, pregnancy had been nearly 
impossible “due to the inhibitive influence of the disease upon the function of 
reproduction.”
10
  Between the impact of the disease and the deleterious side effects of the 
only treatment that showed success in prolonging life at that time – a starvation diet – 
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young girls with diabetes rarely survived into adulthood and those who did found that 
they became infertile.  As one physician explained, “Prior to the discovery of insulin the 
vast majority of diabetic women were sterile.”
11
     
In a most ironic twist, when insulin allowed young girls like U.S. Secretary of 
State Charles Evans Hughes’s daughter Elizabeth to reach adulthood, to live a full life, 
and to become pregnant, both physicians and the general public began to conceptualize 
such women as more rife with problems after insulin than before.
12
  The paradox of 
insulin returning women’s health and fertility, only to expose them to the dangers of a 
pregnancy in the context of diabetes, created incredible anxiety among physicians.  In 
spite of being warned about the dangers of pregnancy, many diabetic women who were 
saved by the new insulin treatment attempted pregnancy as soon as they regained their 
fertility.   
Pregnancy quickly became one of the most contentious issues in diabetes care 
during the early decades of the insulin era.  The medical community responded to 
diabetic women’s attempts at pregnancy with increasingly dogmatic directives.
13
  
Reflecting the intransigent reactions of some physicians, a 1923 editorial letter in the 
British Medical Journal promoted the free dispersal of insulin to diabetic women in 
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return for an agreement to permanent sterilization.
14
  On occasion, diabetic women had 
actually faced the prospect of pregnancy prior to insulin because those who were 
diagnosed with the severe form of diabetes in adulthood, or those who had developed the 
mild form of the disease, may not have lost their fertility immediately.  Such cases, 
however, were extremely rare.  While the sick and dying child-patient identity of the 
young Elizabeth Hughes may have been the classic image of diabetes before 1921, the 
eventual mother of three children and several grandchildren that she became most 
certainly was not.   
Even as insulin became increasingly available and the results of insulin therapy 
were hailed as remarkable, many physicians would continue to recommend that 
“pregnancy should be avoided in women who are suffering from diabetes.”
15
  Warning 
that “we believe that diabetics should not have numerous pregnancies,” physicians at the 
Joslin Clinic in Boston reported that toxemia and preeclampsia were still as much as fifty 
times more likely in diabetic pregnancies, and they lamented the only slight drop in 
stillbirths.
16
  At Johns Hopkins Hospital in Baltimore the stance was more emphatic, 
“From the viewpoint of cold logic, diabetic women should not become pregnant.”
17
 
The obstetrician on the faculty of the Joslin Diabetes Clinic, Raymond S. Titus, 
endorsed caution when encountering pregnancy in a diabetic woman.  Throughout his 
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career, Titus would discuss one of his earliest cases in which a twenty-one-year-old 
diabetic patient went into labor after a seemingly uneventful pregnancy and quickly 
developed diabetic ketoacidosis, nearly died, and delivered a stillborn infant after twelve 
hours of labor.  The case, Titus said, affected him so greatly that he then began a standard 
procedure of delivering the baby by cesarean section as soon as medically feasible.  
Former colleagues have said that Titus also sterilized many of those diabetic women at 
the time of surgery, statements that cannot be verified.  Nevertheless, repeated references 
by Titus and his colleagues to early delivery and to limiting future pregnancies speaks to 
the prominence of the belief among physicians that pregnancy was contraindicated in 
diabetic women and to the increasingly forceful reactions by physicians to diabetic 
women’s pregnancies.
18
 
Throughout the 1920s and 1930s, in spite of all the obstacles they faced, 
increasing numbers of diabetic women insisted on trying to become pregnant.  Although 
larger diabetes care centers like the Joslin Clinic in Boston would try to develop some 
level of expertise in working with these new pregnant diabetics, most physicians 
remained ill-equipped to manage such cases and were all too aware of the history of 
dreadful outcomes.  The growing divide between diabetic women’s desires and 
physicians’ fears resulted in progressively public struggles between doctors and their 
women patients.  The nature of these struggles, and the extent to which they spilled over 
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into other parts of diabetic women’s lives, were reflected in a series of healthcare 
encounters for one of Dr. Joslin’s earliest insulin patients, a young woman named Sally 
for whom life became a constant battle to control personal choices:  for dating, marriage, 
and pregnancy.  Sally’s local doctors debated among themselves about the young 
woman’s maturity, her decisions about marriage, and her adherence to their medical 
advice.  And when she became pregnant, they discussed “[whether] she should be 
aborted.”  With Sally’s first pregnancy, by the time she was referred to be seen by 
physicians at the Joslin Clinic, she was no longer pregnant or perhaps had not been 
pregnant at all.  With her second pregnancy, Sally refused to abort the pregnancy but the 
infant was delivered dead.  Sally’s third pregnancy ended with a therapeutic abortion 
recommended by a local physician.  Sally never became pregnant again.
19
 
In the 1920s and 1930s, continued fears over a history of tragic failures in diabetic 
pregnancies shaped physicians’ approaches to their female patients.  Yet most physicians 
found that they could not dissuade diabetic women from becoming pregnant.  While 
expressing great hesitancy, physicians at the Joslin Diabetes Clinic responded to that 
realization by following the lead of their colleague, Priscilla White.  White tried to 
increase the success rates for the pregnancies of her patients through plans for nurse 
chaperons, lengthy hospitalizations for direct oversight of the women’s diabetic regimen, 
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and early delivery so that “good results will accrue.”
20
  As White’s colleague Dr. Donna 
Younger remembered, the issue of pregnancy created a deep divide between physicians, 
patients, and even families.  When the girls and young women were diagnosed with 
diabetes, Younger explained, the first concern of the parents was whether their daughter 
would grow up and be able to have children, “It was amazing, you know, … on the first 
day you’re learning insulin and on the second day, ‘is she going to be able to have 
children?’”
21
   
In contrast to the approach of the Joslin Clinic, many physicians elsewhere lacked 
the same level of expertise, and their patients lacked the financial means to seek out such 
a high level of care.  Some physicians readily promoted therapeutic abortions because 
they saw no other reasonable options.  Joseph DeLee, author of the most commonly cited 
textbook on obstetrical care for that era, advised that in diabetic pregnancies, “it is best to 
terminate the pregnancy at once.”
22
  It was a stance that DeLee would firmly maintain for 
almost a decade after the introduction of insulin therapy, when he conceded that “the 
treatment of diabetes complicating pregnancy has undergone a complete revolution.”  
However, while he toned down his emphasis on therapeutic abortion in diabetic 
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pregnancies, he still ardently recommended against attempting pregnancy in diabetic 
women – a view which he never relented on.
23
   
The issues that diabetes physicians connected with their male patients differed 
rather remarkably.  In stark contrast to Sally’s experience with the doctors she 
encountered, John was a twenty-seven-year-old patient who had a much more pragmatic 
dialogue with his physicians.  In letters to his physicians, John asked questions such as 
whether his lifespan with diabetes warranted further graduate education, and he discussed 
the employment difficulties that having diabetes had created for him.  In one letter, John 
explained that during a pre-employment physical he was told that company policy 
forbade the hiring of diabetics.  He asked Dr. White to write on his behalf so as to “make 
it possible for capable and intelligent diabetics [like himself] to secure jobs in the future.”  
He included a newspaper article as well, which discussed the possibility of denying 
diabetics a driver’s license.
24
   
Similarly, as Jim Havens continued to work as a print artist and do volunteer work 
in a parachute factory during World War II, the centrality of work defined both his life 
and the focus of his clinical care.  That focus shaped the way in which his physicians 
conceptualized his life as a diabetic, determining for example the structure of his diabetes 
regimen and diet to account for such issues as his “fear of having insulin shock while on 
the job.”
25
  For Sally, however, the life portrayed in her letters, and later in the letters her 
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mother wrote as Sally’s health deteriorated, the focus continued to be her struggle “to feel 
as well as most normal people” while negotiating with her physicians for personal control 
over her choices in life – from whether to get a chest x-ray for tuberculosis screening to 
deciding on changes in her insulin regimen when, with her current regimen, she believed 
that she was “getting along all right.”
26
 
Men diagnosed with diabetes did not completely escape the struggles over 
personal control such as those that women patients like Sally experienced.  Gerald 
Cleveland, for example, explained that when he was diagnosed with diabetes in 1932, he 
“felt that the world kind of dumped in on me.”  The strict regimen of shots, diet, and 
urine testing was rigorous enough even with the help of family, but the societal reactions 
he experienced were extremely difficult as well.  In trying to avoid being “separated out” 
in school and work whenever his diagnosis was discovered, he felt compelled to hide the 
disease as much as possible.  Likewise, his brother Bob, who had been diagnosed in 
1925, said that he hid the diagnosis from his fiancé for fear “she’d back off … just like 
employers did.”
27
   
Although diabetic men occasionally experienced some of the same social 
constraints and reactions that women did, a preoccupation with the dangers of diabetic 
pregnancies continually defined the therapeutic approach to diabetic women.  That 
central focus resulted in a markedly different approach to women’s diabetes treatments.  
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Physicians even portrayed their women patients differently when discussing the 
progression of the disease.  For example, unpredictable swings in blood sugars affected 
all diabetics who began insulin, but investigations into the causes of those variations 
focused almost exclusively on women.  What would become known as “brittle diabetes” 
took on a distinctively female image.  Use of the term “brittle” began with physician 
Rollin Woodyatt in the early 1930s.  In his original description, he called his patients 
with extreme swings between high blood sugars and low blood sugars, who were almost 
all women, “fragile diabetics.”  Later, Woodyatt changed the term to “brittle diabetics.”  
Brittle diabetes is a term that is still commonly utilized today.  Used almost exclusively to 
describe women with diabetes who have blood sugar patterns that are seemingly difficult 
to control, it is particularly applied to those women with a history of dangerously low 
blood sugars.  Both then and now, the term also implies a connection between poor 
diabetic control and mental or emotional instability.  In studies to determine if an 
underlying physiological cause for such poor diabetic control could be identified, women 
have consistently made up at least three quarters of those subjects given a diagnostic code 
of “brittle diabetes.”
28
  While Woodyatt called the low blood sugar patterns in his women 
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patients “brittle diabetes,” the same issue in Jim Havens had been discussed as “insulin 
shock while on the job.”
29
 
Because of difficulties with diabetic regimens such as strict diets and 
unpredictable reactions to insulin, both women and men found that their social 
experiences became inextricably entwined with their medical encounters.  But physician 
Priscilla White found that women and men described distinctly different experiences with 
their disease.  White received hundreds if not thousands of letters, notes, and cards from 
her patients.  Many of her women patients described a disease experience more personal 
and more connected to issues of the home and family, and expressed such personal 
concerns as “My greatest hope is that I don [sic] pass this [disease] to my daughter … 
maybe she won’t have to worry about this problem” and “I try to behave for the sake of 
my family now.”
30
   
Many of White’s academic and clinical notes from the 1930s and 1940s also 
demonstrate distinctions in her treatment approaches to men and women patients.  
Beyond the obvious reproductive differences, she noted other physiological variations 
and ruminated on the resulting social products.  For example, White believed that the 
stunted growth of diabetics, so pronounced during the early years of the insulin era, took 
a larger emotional toll on her young male patients, even though the weight gain her 
female patients often experienced resulted in a host of maladaptive and dangerous 
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behaviors in her young girls.
31
  By the end of her career, White completely shifted the 
focus of her practice by creating the Youth Division of the Joslin Diabetes Foundation so 
that she could concentrate entirely on what she believed were the contrasting emotional 
problems of male and female diabetics, including issues of body image and adult social 
gender roles.
32
   
 
Deterring Diabetic Pregnancy 
By the 1930s, medical care for pregnancy had improved significantly here in the 
United States as well as throughout most of the Western world.  Yet diabetic women’s 
experiences with that care differed remarkably from their non-diabetic counterparts.  
Rather than the range of medical care regimens and monitoring strategies that non-
diabetic women were offered as the century progressed, most diabetic women were 
discouraged from pursuing pregnancy, and therapeutic abortion was a common 
recommendation if they presented pregnant.   
Pregnancy quickly became a polarizing issue in the medical care of diabetic 
women who had seen their health improve dramatically with the introduction of insulin 
therapy.  Young girls with diabetes had begun to survive into adulthood with the miracle 
of insulin.  Many of these women found they were finally healthy enough to become 
pregnant, but most physicians were adamantly opposed to pregnancy in a diabetic 
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woman.  Non-diabetic women were offered an array of new approaches in pregnancy 
care, but those were usually withheld from diabetic women.  Moreover, as diabetic 
pregnancies increased, physicians responded by intensifying their efforts to dissuade 
these women from becoming pregnant, or to terminate a pregnancy as soon as it was 
discovered.   
Despite such widespread opposition to pregnancy in diabetic women, Priscilla 
White of the Joslin Diabetes Clinic in Boston took a different approach.  Instead, White 
accepted and embraced diabetic women’s desires to have children, and she worked to 
find ways to make their pregnancies successful.  White’s efforts would factor 
significantly into the rise of a medical specialty field concerned exclusively with diabetic 
pregnancies, obstetrical diabetes.  By mid-century, her work would convince physicians 
around the world to work toward successful diabetic pregnancies, even if many of them 
still tried to discourage diabetic women from trying to conceive.   
The concept of prenatal care, a type of preventive medical care to detect early 
signs of problems during a pregnancy, offered many of the guiding principles that 
undergirded White’s approach.  The basic tenets of prenatal care had emerged from the 
early twentieth-century writings of obstetrician John William Ballantyne.
33
  In his widely 
acclaimed textbook, Ballantyne posited that “the successful treatment of the unborn 
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infant must [include the] successful treatment of the pregnant mother.”
34
  White 
recognized the applicability of prenatal care to diabetic pregnancies, though she was 
actually not the first to see the connection.  Johns Hopkins’ obstetrician J. Whitridge 
Williams had written in 1915 that Ballantyne’s approach offered “great possibilities for 
the diminution in the number of deaths” in diabetic pregnancies.
35
  White, however, was 
the first to fashion a therapeutic approach to diabetic pregnancies by applying the 
principles of prenatal care. 
By the middle of the twentieth century, prenatal care was widely espoused as the 
most important step toward avoiding potentially serious problems with pregnancies, like 
death of the mother or baby, birthing injuries, and low birth weight.  Likewise, White 
presented prenatal care as an important facet of medical monitoring to those few 
physicians who would take on a pregnant diabetic and to the women who came to the 
Joslin Clinic.  In the waiting rooms at Joslin, women found a pamphlet that lauded the 
benefit of prenatal care and suggested that the avoidance of such care was negligent.  The 
pamphlet authoritatively stated that prenatal care protected the unborn child from danger 
by enlightening women about the “harm which a mother may do to her child in the 
uterus.”
36
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Statements in the Children’s Bureau pamphlet that health behaviors like diet were 
“quite within [a woman’s] control” made it seem an appropriate addition to a waiting 
room for diabetic women.
37
  Diet had been an essential treatment for diabetes in the years 
leading up to the insulin era and it remained a fundamental piece of the management 
strategy for diabetic women who wanted to have children in the 1930s.  The pamphlet 
stayed in production for more than a decade and revisions to it over the years increasingly 
highlighted the role of prenatal care and the role of obstetricians in that care.  By 1942, 
the pamphlet defined prenatal care as “the complete supervision of the pregnant woman 
[by a doctor] until the baby is born.”
38
  
 
                                                                                                                                                 
Maternal and Child Health Library of Georgetown University at 
http://www.mchlibrary.info/history/chbu/parents.html (accessed January 10, 2012).  A 1942 version of the 
pamphlet was in the files of Dr. Priscilla White and marked “Do Not Take” suggesting that the pamphlet 
was part of the reading material for waiting patients; see “Prenatal Care,” Carton 2, Folder 9, Priscilla 
White Papers. 
37
 Ibid. 
38
 Ibid., 4 and 5.   
87 
 
 
 
Figure 2.  Pamphlet, Prenatal Care, Children’s Bureau 
 
 
Even though it was certainly not a conversation limited to diabetic pregnancies, 
the dialectic that women could harm their unborn children through bad health behaviors 
and poor food choices had been a growing message in the United States.  That message 
had found its way into the waiting room of the Joslin Clinic through the Children’s 
Bureau pamphlet.  Throughout the first half of the twentieth century, physicians utilized a 
range of venues, like the Children’s Bureau pamphlet, to convey their recommendations 
to women patients.  Yet obstetricians still struggled to convince pregnant women to 
follow those recommendations.  Physicians from the New York Midwifery Dispensary, 
for instance, left a trail of comments about such discussions in the medical records that 
they penned.  They expressed their frustration when a “patient refused to obey” or 
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commented that their “patient [was] dismissed for insubordination.”
39
  They lamented 
that their efforts were often rejected by the very same pregnant women who had asked 
them for assistance.  Hence, it is important to remember that the struggle over medical 
authority in pregnancy care was not a new battle for physicians as a whole, or for 
physicians dealing with diabetic women.   
Adding to the difficulties these physicians faced, obstetrical physicians had 
struggled for credibility since the beginning of the century.  Even though technological 
advances in medicine had significantly decreased maternal mortality by the 1930s, which 
would bring some level of authority to the field of obstetrics, the congressionally-
mandated Flexner Report had dubbed obstetrical practice and education in the United 
States as “utterly worthless” and even labeled the field a danger to women’s health.
40
  By 
the 1930s, that view had tempered somewhat and nearly every hospital, even those that 
specialized in diabetes, actually had an obstetrician on faculty.   
Throughout the 1930s and 1940s, diabetes physicians would become more public 
and more fervent in their efforts to convince diabetic women to heed their advice and 
refrain from trying to have children.  They insisted that “pregnancy should be avoided in 
women who are suffering from diabetes” and their efforts to intercede took many routes, 
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some preemptive and some responsive.
41
  After the new insulin therapy had so 
dramatically returned diabetic women’s fertility, physicians openly worried that the new 
treatment would enable diabetic women to become pregnant “as readily as the non-
diabetic,” and others cautioned that because of insulin diabetic women would be “less 
likely to avoid pregnancy” despite being advised about the dangers.
42
  Diabetic 
pregnancies did increase with the advent of insulin therapy, but the overall rate of 
pregnancy actually remained lower for diabetic women than for their non-diabetic 
counterparts.  Even so, the mere idea that women with diabetes might choose to become 
pregnant fueled physicians’ anxieties.
43
  They responded with a slew of articles in 
professional journals highlighting the dangers of diabetic pregnancies.
44
   
Physicians shaped a compelling language to dissuade diabetic women from 
attempting pregnancy by focusing on the potential dangers for the woman with 
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diabetes.
45
  So forceful was the language in fact that Dr. Boyd Metzger, a physician-
researcher from Northwestern University, recalled, “It should be surprising – no, 
unbelievable – to think that any woman with diabetes even attempted something 
portrayed as so dangerous.”
46
  Childbirth, in fact, carried significant risks for women well 
into the twentieth century, not just for women with diabetes but for all women, and 
maternal mortality also became one of the targets of obstetricians who promoted prenatal 
care.  Even when maternal death rates began to decrease for women in general, both 
obstetricians and diabetes physicians would continue to talk about the hazards of 
pregnancy for diabetic women.
47
   
Almost a decade after insulin was discovered, Dr. Sam Davis, a local medical 
doctor from northern Massachusetts, wrote Elliott Joslin about a young diabetic patient of 
his who had presented two months pregnant.  Referencing an obstetrical textbook, Dr. 
Davis said that he favored a therapeutic abortion because of the “startling statistics in 
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regard to [maternal] mortality” reported in the text.
48
  The text advised physicians to 
intercede as soon as pregnancy was discovered in a diabetic woman.  Interceding meant a 
“therapeutic abortion.”
49
   
Davis had written Joslin for a second opinion on his patient’s pregnancy, but 
based on his assertion that he favored a therapeutic abortion, it would seem that he had 
already decided on the matter.  The need for a second opinion suggests that the woman 
under his care was not in agreement.  The pervasive refusal of diabetic women like 
Davis’s patient to acquiesce to recommendations for interventions such as therapeutic 
abortions and sterilizations morphed into a powerful force, with scenarios like this one 
becoming increasingly common during the 1930s and 1940s.  Even without a centralized, 
collective organization, diabetic women forced the medical profession to seek ways to 
help them have children safely – simply by refusing to stop trying.    
An intense focus on maternal mortality as a reason to discourage diabetic 
pregnancy became a staple argument for obstetricians during this time period.  Such an 
argument allowed for the prescription of abortion or sterilization as a therapeutic 
intervention rather than as eugenics.  In his late 1920s manual for diabetic patients and 
general practice doctors, London physician Robin D. Lawrence said that diabetic 
pregnancies were unadvisable and should be terminated because they could threaten 
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women’s lives.  He lamented, however, that he had “to leave the choice to the patient as 
there are no laws of national eugenics.”
50
  Though prescient, Lawrence’s statement only 
lasted for one edition of his manual.   
Many physicians also began to use a language that combined science and memory 
in their attempts to portray the dangers that women with diabetes could face with 
pregnancy.  Hence, as the language of maternal mortality gained momentum, the 
discourse came to include “memories” of maternal deaths.  Physicians called upon such 
memories, mostly from the decades before insulin, of tragic deaths and of unsuccessful 
efforts to prevent “accidents.”
51
  For example, Elliott Joslin described a case from the 
days before insulin in which a pregnant diabetic patient of his, who “had eluded [his] 
observation,” became sick and was subsequently admitted to the hospital for an 
emergency delivery.  Nearly forty years after the incident, Joslin evoked the memory of 
that case for his audience, “She died, the baby died, and the husband climbed the hill 
behind the hospital and shot himself.”
52
   
Complications with diabetic pregnancies before insulin thus became an important 
facet of the language of memory used to discourage such pregnancies after insulin.  An 
1882 article by London physician J. Matthews Duncan also became an oft-cited example 
of the potential dangers.  Of the fifteen diabetic women that Duncan found in his review 
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of medical records and anecdotal accounts, he reported that eleven died during 
pregnancy, delivery, or shortly thereafter.  Those fifteen women, however, represented 
twenty-two pregnancies and perhaps as many as twenty more pregnancies prior to the 
time frame of his review.  The women that Duncan included in his review had apparently 
been undeterred by the danger of pregnancy espoused by their doctors.  Even though 
Duncan’s report was perhaps less dramatic, his findings resonated with physicians for 
decades to come.  Many twentieth century physicians called upon the memory of those 
eleven nineteenth-century women who died during or after a diabetic pregnancy to 
discourage their patients from trying to conceive.
53
   
Not all physicians chose to propagate alarm without clarification, however.  J. 
Whitridge Williams tried to allay the fears of his colleagues who discovered sugar in the 
urine of their pregnant patients by distinguishing between “true diabetes” and what he 
considered a bevy of insignificant findings, such as lactose (breast milk sugar) or 
glycosuria (sugar in the urine) limited to the period of pregnancy only.  But in his 
retrospective analysis, when Williams reported that for the cases of so-called true 
diabetes, 27 percent of the mothers died immediately and 23 percent more died within 
two years, he had hardly calmed fears.
54
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Enter Priscilla White  
Priscilla White began her career at the Joslin Diabetes Clinic in Boston within the 
controversial atmosphere surrounding diabetes and pregnancy.  Instead of pursuing ways 
to intercede in those pregnancies like many of her colleagues who preceded her, White 
immediately began to seek ways to make pregnancy possible for the diabetic women who 
came under her care.  During the 1930s and 1940s, while many physicians continued to 
oppose such pregnancies and to debate whether diabetes and pregnancy were completely 
incompatible, White began documenting the methods and strategies she was employing 
to achieve successful pregnancies for her patients.   
White was born in 1900 and was raised by her single mother, as her physician 
father left the family when she was young.  White would never marry and never have any 
children of her own.  She attended Radcliffe College and then Tufts Medical School, 
where she graduated at the top of her class.  Harvard Medical School did not accept 
women at the time and, since no hospitals in the greater Boston area accepted women into 
their residency programs at that time, she did her residency training at Worcester 
Memorial Hospital about fifty miles west of Boston.  She worked as a lab assistant for 
Elliott Joslin one summer while she was a medical student and then accepted an 
invitation to join Joslin’s faculty in 1924.  She was immediately assigned to work with 
children and women at the clinic in the early years after the discovery of insulin.  As 
insulin was dramatically changing the course of diabetes, her career unfolded in 
unexpected ways, and she soon found herself managing diabetic pregnancies with no 
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precedent from which to plan.
55
  “She started at a time,” explained Dr. John Hare, a 
junior colleague and student of White’s, “when you shouldn’t let a [diabetic] woman get 
pregnant at all because she might die.”
56
   
While many of her contemporaries in the 1930s focused on the dangers of 
diabetic pregnancies, White quickly set about laying the groundwork for decreasing those 
dangers.  The first principle of therapeutic management espoused by White was that 
“controlled diabetes is essential to fetal welfare.”
57
  She quickly followed by noting that 
while diabetes did have an impact on pregnancy, that impact was due mainly to changes 
in insulin sensitivity created by pregnancy hormones.  The metabolic changes created by 
pregnancy hormones, she said, could be managed with modifications in the therapeutic 
approach to diabetes for each trimester of a woman’s pregnancy.  And finally, she made 
the connection that the duration of a woman’s diabetes adversely affected the outcome of 
her pregnancy because of the host of diabetes-related complications – mostly vascular 
lesions – that might have accrued for the woman.  That connection became the basis of a 
classification system for evaluating the risks of and for shaping the approach to a diabetic 
pregnancy.   
 White recognized that although insulin quickly eliminated many of the problems 
of diabetes, it did not immediately solve the complications associated with pregnancy in 
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the context of diabetes.
58
  She systematically evaluated what would amount to more than 
twenty-three hundred pregnancies over her fifty year career, and she adapted her 
treatment strategies accordingly.  By 1928, only seven years after the discovery of insulin 
and only three years into her career, she already asserted that for her patients “diabetes is 
no longer a contraindication to pregnancy.”
59
   
The rapid increase in the numbers of patients that Dr. White took on, in the face 
of an ample number of detractors, reflected the intensity of diabetic women’s desires to 
have children and of the collective power of their continued efforts.  During the first two 
decades of the twentieth century, before White came on staff, the Joslin Clinic recorded 
only 10 diabetic pregnancies.  Between 1924 and 1938, White managed the care of 128 
pregnancies, and from 1938 to 1958, the numbers surged even higher as White and her 
staff worked with 900 diabetic pregnancies.
60
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Figure 3.  Pregnancies in Diabetes Mellitus, Joslin Clinic, 1898-1977.
61
   
 
 
In stark contrast to the predominant contemporary opinion that pregnancy and 
diabetes were incompatible, Priscilla White’s increasing successes with such pregnancies 
told a different story to women, and they sought out her care in droves.  As Donna 
Younger explained, the pregnancy clinic at Joslin expanded rapidly because women 
would come from great distances to see White.  Physicians would refer their more 
difficult cases as well, “but there was some resistance to referring their patients … 
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because they felt they weren’t getting them back … the women wanted to stay with Dr. 
White.”
62
  In the days before insulin became available, roughly one third of the Joslin 
Clinic’s pregnant diabetics died.  During White’s tenure, maternal mortality fell to almost 
zero.  Fetal loss dropped quickly as well.  Before 1924, the baby died in more than half of 
the pregnancies.  By mid-century, though, 86 percent of Dr. White’s patients gave birth to 
live infants, and that number rose to 97 percent over the next twenty-five years of 
White’s career. 
From the beginning, Priscilla White’s medical career included roles as both 
clinician and researcher, and that dichotomy afforded her a unique perspective on the 
complications of diabetes in pregnancy.  Through her research on the make-up of 
placental blood in diabetic pregnancies, for example, White discovered that the fetus in a 
diabetic pregnancy was exposed to high concentrations of sugar in the placenta when the 
mother’s blood sugar was high.  In non-diabetic pregnancies, she found, that was not the 
case.  Her immediate response was to translate that finding into clinical practice such 
that, for her patients, “the treatment of diabetes in pregnancy is along the very same lines 
as the treatment of diabetes apart from pregnancy,” which meant keeping blood sugars 
safely as low as possible all the time.  To meet that goal, she managed her pregnant 
patients with smaller doses of insulin given more frequently in order to keep their blood 
sugar profiles as similar as possible to those of a non-diabetic.  That strategy was an 
incredibly novel approach for the time because the usual approach was a single shot of 
insulin each day.  The purpose of her strategy was to avoid the extremes of high or low 
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blood sugars.  In another break with traditional recommendations, White encouraged her 
patients to check urine specimens for sugar frequently, which during the final weeks of 
pregnancy and especially during labor would be as often as every four hours.
63
   
 White’s dedication to the women who sought her care played an important role in 
convincing them to adhere to such difficult diabetes regimens during pregnancy.  Other 
physicians often claimed that women patients could not be convinced to take more than 
one shot of insulin per day and that they could not be made to check their urine regularly.  
Colleague Donna Younger recalled, however, that because many of White’s patients 
came to her with an intense desire to have children, they often made great efforts to 
follow her advice.  While “doctors argued … about whether pregnant women would 
follow directions,” Younger recalled, “Dr. White’s women, they would take as many 
injections a day as she told them to.”  Extremely dedicated to her patients, White would 
also often remain with them throughout their labor and delivery.
64
   
 By the mid-1930s, White believed she had essentially solved the problem of 
maternal mortality, and she began to challenge the use of that language to dissuade 
diabetic women from pursuing pregnancy.  In an article requested of her by the Canadian 
Medical Association, she declared that maternal mortality “is fortunately very low” 
because intensive management of diabetes had allowed her patients to avoid many of the 
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complications associated with pregnancy.
65
  Miscarriage, she said, was three times more 
frequent in the pregnancy cases of other physicians who tolerated poorly controlled blood 
sugars as compared to control cases selected from her own patients.  Toxemia and 
eclampsia, two dangerous complications for pregnancy, had a fifty times higher incidence 
in diabetics with consistently high blood sugars.  White said that stillbirth of an 
“overdeveloped, macerated fetus” occurred when persistently high blood sugars caused 
what she called the “overnutrition” of the fetus.  And White theorized that hormonal 
imbalances contributed to complications, a theory which she would pursue for another 
three decades but which she was never able to establish with certainty.
66
 
 White increasingly published articles which declared that maternal mortality was 
a non-issue in diabetic pregnancies.  She authoritatively stated that complications in 
diabetic pregnancies “do not concern the welfare of the mother.”
67
  Instead, she said, the 
real issue that needed to be addressed was the death of the unborn child, emphasizing 
that, “the treatment of diabetes is the simplest part of our problem.”
68
  Even as late as 
1949, White would still find it necessary to confront the language of maternal mortality 
by physicians opposed to diabetic pregnancies.  She declared such language to be an 
inappropriate defense for avoiding or ending a diabetic pregnancy, repeatedly explaining 
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that “fetal not maternal survival constitutes the problem when pregnancy complicates 
diabetes.”
69
 
 White’s systematic approach to diabetic pregnancy was also based on her belief 
that pregnancy was in its own right a “diabetogenic” process.  Pregnancy, White felt, 
could alter any woman’s metabolism in a way that mimicked diabetes.  She was aware of 
the phenomenon in which a pregnant woman with no prior history of diabetes suddenly 
spilled sugar into her urine and often had a corresponding raised level of sugar in her 
blood.  Although she did not consider the condition at that time to be a true form of 
diabetes, she said that its appearance – which, in her words, was subtotal, asymptomatic, 
and transient – helped her to understand the impact that pregnancy had on a woman’s 
metabolism.  Pregnancy itself, she believed, created some of the same metabolic stresses 
that diabetes created. 
                                                 
69
 Priscilla White, “Pregnancy Complicating Diabetes,” American Journal of Medicine 7, 5 
(November 1949):  609.  
102 
 
 
 
Figure 4.  White’s notes on the metabolic impact of pregnancy.
70
 
 
 
 As early as the end of the 1930s, White believed that the threat of maternal 
mortality was no longer significant, and she designed a systematic program to help other 
physicians assist diabetic women in pursuing pregnancy.  Believing that pregnancy 
placed an increased stress on a woman’s metabolism, she posited that it could also 
intensify problems with the control of a pregnant woman’s diabetes.  And since the 
hormonal profile changed with each trimester, the influence of pregnancy on a diabetic 
woman’s metabolism likewise changed with each trimester.  As she explained, “The 
management of the diabetes during pregnancy varies with the problems of each 
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trimester.”
71
  During the first trimester, she focused on the problem of nausea, which 
could be a significant issue in the patient on insulin who must be able to take in food to 
prevent low blood sugars.  She also used that time to prepare her patients to make 
significant changes in their diabetic regimens over the remaining months.  The second 
trimester involved watching for changes in kidney function, which could cause blood 
sugars to rise, and monitoring the need for increased food intake.  Both issues required 
increases in the dosing of insulin.  During the second trimester, though, White advised 
that “changes in insulin must be made on blood sugar estimations only” because urinary 
sugar did not necessarily correlate directly with blood sugar during that phase of 
pregnancy, since all pregnant women experienced a change in how their kidneys filtered 
sugar and other metabolites after reaching the second trimester.
72
   
 For the third trimester of pregnancy, White’s main concern was watching for the 
development of acidosis.  Acidosis is a potentially lethal condition in diabetics where 
blood pH can drop due to a relative insulin deficiency, relative being the operative word 
here because the same amount of insulin used prior to pregnancy may not be adequate to 
account for insulin resistance from the influence of pregnancy hormones in the third 
trimester.  Factors that White identified as either contributing to the problem, or 
increasing the severity of it, were the mother’s increased metabolism, rising carbohydrate 
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intolerance, and loss of glycogen stores because of several months of pregnancy, as well 
as the developing baby’s increasing caloric requirements.
73
   
 
Evaluating Risk:  The White Classification System 
In 1949, Priscilla White published her classic essay that connected the level of 
risk for the fetus in a diabetic pregnancy to the length of time that the woman had 
diabetes.  The beginnings of her concept could be seen as early as 1937 in a paper that 
she and Elliott Joslin wrote along with a husband and wife research team who had 
partnered with the Joslin Clinic to investigate hormone profiles in pregnancy.  Although 
the focus of the 1937 article was hormone imbalances in diabetic pregnancies, White also 
presented her theory that the longer the duration of diabetes in a woman the higher the 
chance of fetal loss in pregnancy.
74
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White connected a diabetic woman’s health status going into pregnancy with the 
level of intervention needed to protect the unborn child during the pregnancy.  Such a 
therapeutic approach demonstrated that, unlike many of her contemporaries, she had 
shifted her clinical focus to a concern for the baby.  Because many obstetricians and 
diabetes physicians of the same era maintained their focus on the pregnant woman, 
treatment strategies often included terminating the pregnancy in order to protect the life 
and health of the diabetic woman.  For White, however, a successful pregnancy resulted 
in a healthy baby.  She explained that when her women patients refused to relinquish the 
idea of having children, “I had to learn how to take care of them.”
75
   
In a stack of her personal papers was a note that White had written about a patient 
who committed suicide after two pregnancies “were interrupted.”  She wrote, “This 
suicide answers the question asked so frequently today, ‘Why permit or encourage young 
women with diabetes to bear children?’  To many, to nearly all, life lacks meaning – may 
even be unendurable – without successful childbearing.”
76
  That note, likely part of a talk 
or paper that White was preparing, illustrates two very important forces that guided her 
work during that era.  First, although opposition to diabetic pregnancy was still pervasive, 
women’s rejection of that opposition was just as pervasive.  Second, White’s 
classification system was shaped by what her patients asked of her:  help in having a 
baby.  In response, Priscilla White shifted the medical focus in her clinic to protecting the 
life and health of the baby in a diabetic pregnancy.   
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 Many scholars, particularly historians examining abortion and reproductive rights, 
have suggested that there was similarly a broad, generalized shift in medical focus from 
the pregnant woman to the fetus during the mid-twentieth century.  However, they have 
typically presented that shift as a detrimental development to women’s control over their 
bodies and their medical decisions and suggested that this more public focus on the 
unborn child became a tool for criminalizing pregnant women’s health behaviors.  For 
example, terminating a pregnancy became portrayed as criminal, even as murder, by 
those who began to imagine the fetus as a vulnerable person who needed to be protected.  
Physicians did not escape such indictments either.  Medical advances have often 
influenced political debates about abortion by shaping “the popular understanding of the 
relationship between a woman and the fetus.”
77
  Historians have characterized this 
twentieth century shift in medical focus from woman to fetus as the landscape within 
which women lost a substantial amount of control in decision-making about pregnancy 
issues.  Yet, ironically, Priscilla White encouraged just such a shift in medical attention to 
the fetus because, for diabetic women, she viewed the focus on women as the restricting 
influence over personal choice.   
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In her now-famous 1949 article, published in the American Journal of Medicine, 
White presented her system for classifying risk in diabetic pregnancies.  Her original 
classification scheme contained six levels of risk, Class A through Class F.  The 
categories were based on a combination of factors such as how long the woman had 
diabetes and whether she had vascular complications like calcification (hardening) of the 
arteries, eye and kidney damage, or high blood pressure.  Class A had no complications 
and only required diet treatment; Class F included serious kidney damage.  In the lettered 
taxonomy, she connected the length of time that a woman had diabetes, and any 
associated vascular complications, with the risk of losing the baby.  As the letter for each 
class increased, the risk to the fetus increased, with one exception – Class F.  Of the six 
classes, the sixth (F) was concerned instead with the risk to the pregnant diabetic 
woman.
78
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Table 1.  The original White Classification System adapted from her 1949 article.
79
 
 
Class Diabetes Diagnosis Vascular Complications % of Study 
Population 
Class A Abnormal glucose tolerance test 
Diagnosed as adult 
No vascular disease 5% 
Class B Diagnosed as adult 
Less than 10 years duration 
No vascular disease 29% 
Class C Diagnosed 10 – 19 years of age 
Less than 10 years duration 
Minimal vascular disease 
(retinal arteriosclerosis, leg vessel 
calcification) 
44% 
Class D Diagnosed under 10 years of age 
Greater than 20 years duration 
More vascular disease (retinitis, 
transitory albuminuria, transitory 
hypertension) 
14% 
Class E Diagnosed under 10 years of age 
Greater than 20 years duration 
Calcification of pelvic arteries 7% 
Class F Diagnosed under 10 years of age 
Greater than 20 years duration 
Nephritis 1% 
 
 
Rather than including only cases with the potential for a successful outcome, 
White included all types of pregnancies regardless of how severe the diabetes-related 
health problems.  She never recommended terminating pregnancies with poor prognoses.  
As her protégé Donna Younger explained, physicians who claimed to have better 
outcomes in their clinics had been accepting only cases that would have fit into White’s 
classes of A or B.  Those clinicians had been terminating more risky pregnancies or 
referring them to facilities like the Joslin Diabetes Clinic.  White developed her 
classification system, Younger explained, “to challenge the idea of terminating a 
pregnancy … but also to ensure that they were comparing similar patients.”
80
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Although the classification system encountered some revisions over the next 
decade, mainly to accommodate new treatment and assessment tools like newer types of 
insulin and specialized lab tests, the basic premise always remained that a woman’s pre-
existing, diabetes-related complications dictated a specific treatment plan, one that did 
not include terminating the pregnancy.  White developed her system to classify risk in 
diabetic pregnancies and to spell out the best therapeutic approaches to decrease the risk 
to the fetus.  The White Classification System was not designed to determine if ending 
the pregnancy was justifiable.  Her inclusion of the entire spectrum of patients was 
essential in defining the field of obstetrical diabetes with the specific purpose of making 
diabetic pregnancies safe and successful.   
In spite of Priscilla White’s achievements in diabetic pregnancy, the topic of 
therapeutic abortion in such pregnancies endured well into the 1950s.  At a joint meeting 
of the British, Canadian, and Ontario Medical Associations, a substantial amount of time 
was spent on discussing contraindications to diabetic pregnancy and on enumerating 
indications for terminating such pregnancies.
81
  The conference panel on diabetic 
pregnancy proposed a list of indications for therapeutic abortion such as family history of 
diabetes and the presence of vascular complications.  By that time, some physicians 
adamantly opposed the concept of therapeutic abortion and when the panel included “the 
co-operativeness of the patient” and “the size of the family” in its indications for ending a 
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diabetic pregnancy, it drew intense criticism from physicians who disagreed with the very 
premise of therapeutic abortion.   
The conversation that ensued over the panel’s recommendations quickly turned 
into a firestorm.
82
  In the panel’s effort to communicate the danger of diabetic pregnancy 
to a wide audience – one that included both physicians and patients – they had used a 
language that was authoritative yet personal by including both medicine and memory.  
They maintained that their stance was medically-informed and that their indications for 
therapeutic abortion were based on scientific evidence from “recollections” of several 
hundred cases of troublesome diabetic pregnancies over several decades.  They 
maintained that many other physicians concurred with their indications for discouraging 
pregnancy in diabetics.  Detractors, however, pointed out that their several hundred 
troublesome diabetics who had presented pregnant, despite being told not to, obviously 
did not concur with their logic.
83
   
The debate continued for six issues of the journal.  Within a few weeks of the 
initial article, Dr. Ivo Drury began the rebuttal by stating bluntly that “there is no medical 
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case for therapeutic abortion in diabetics.”
84
  In their retort, Drs. Peel and Oakley called 
on such professional language as the “purely medical aspects of the problem.”  The final 
comment on the matter verbalized what had become by mid-century the collective 
struggle for women with diabetes, “Were their indications for therapeutic abortions to be 
applied, the diabetic anxious to have children would be much more limited by her 
physicians than by her disease.”
85
  
By the end of the 1950s, Priscilla White was “undeniably the doyenne of diabetic 
pregnancy,” a status that allowed her to challenge the opposing views of her mostly male 
colleagues.
86
  Although she was not a part of the debate that had played out in the pages 
of the British Medical Journal, she frequently found herself in the midst of similar 
challenges.  At the 1954 annual meeting of the American Diabetes Association (ADA) in 
San Francisco, she had been asked to serve on the Diabetes and Pregnancy panel.  The 
moderator for the panel discussion was Garfield Duncan of Pennsylvania.  Duncan’s 
expertise was in obesity as it related to diabetic management, but he had been asked to 
serve as moderator for the Diabetes and Pregnancy panel because he had engaged in 
several well-publicized debates about diabetic pregnancy over the years.
87
  Duncan made 
clear his trepidation about diabetic women pursuing pregnancy, citing a range of dangers 
for women from coma and death to an increased risk of insulin resistance that could lead 
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to “brittle diabetes.”  Duncan also commented on the poor outcomes of such pregnancies, 
with maternal and fetal mortality at one end of the spectrum and increased birth weight 
that could predispose the child to diabetes as an adult at the other end of the spectrum.  
When Duncan pressed White to admit that diabetic pregnancy should be avoided in many 
women, she adamantly disagreed.  Dr. White countered that there was only one 
complication that would make her hesitate about pregnancy in a diabetic woman and that 
was complete kidney failure.
88
 
  
Conclusion 
By the end of the 1950s, physicians world-wide were citing Priscilla White’s 
work when discussing diabetic pregnancy.  The broad recognition of White’s 
classification system reflected her internationally acclaimed expertise in the management 
of diabetic pregnancy.
89
  But White never achieved the same professional honors and 
appointments as her colleagues.  Even junior associates gained prominent roles over the 
years, while White was repeatedly passed over.
90
   
The specialty field that White built, the field of obstetrical diabetes, never became 
a formalized area of medical specialization.  Despite the fact that the specialty of 
Obstetrics and Gynecology was a founding field of the American Medical Association’s 
Advisory Board of Medical Specialties (ABMS) in the early 1930s, the Board did not add 
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subspecialties for obstetrics training and certification programs until the 1970s, when 
three subspecialties were added:  gynecologic oncology, maternal-fetal medicine, and 
reproductive endocrinology and infertility.  Later, a fourth subspecialty was added:  
female pelvic medicine and reconstructive surgery.
91
  Obstetrical diabetes has never 
gained formal recognition as a specialty field of medicine, or even as a subspecialty field 
in Obstetrics and Gynecology, even though the medical literature has commonly referred 
to obstetrical diabetes as a field of expertise since the 1940s.  Actually, no aspect of 
diabetes health care has ever gained formal status as a medical specialty field despite 
multiple applications for official recognition by the American Board of Internal Medicine 
(ABIM).
92
   
Public and political concern about specific diseases stimulated the rise of medical 
specialty fields in the United States during the twentieth century, as evidenced by the 
reactions of governmental, and even private, philanthropic organizations for the funding 
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of research efforts and for increasing access to care from medical specialists.  The refusal 
to grant specialty status for obstetrical diabetes, in the context of much medical and 
public concern, supports the argument that this area of medical specialization was shaped 
by forces much less visible historically.  Scholars, particularly sociologists and 
economists, have characterized specialization as an inevitable trajectory emanating from 
advances in scientific knowledge and from the associated market segmentations in 
healthcare.
93
   
The depiction of specialization as a uniquely medical or scientific process does 
not fit for diabetes and pregnancy.  Rather, diabetic women increasingly refused to avoid 
pregnancy.  They began to reject recommendations for therapeutic abortions.  Diabetic 
women sought the care of doctors like Priscilla White for their diabetic pregnancies 
because they believed that she could offer them something better than the general 
practitioners who were opposed to such pregnancies.  The actions of diabetic women who 
pursued pregnancy forced physicians to develop special skills to assist them.   
Obstetrical diabetes developed alongside other important social events that 
created connections to healthcare for diabetic women, such as the medicalization of 
pregnancy, the move of birthing from home to hospital, and the increasing difference 
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between men’s and women’s experiences with diabetes healthcare.
94
  Moreover, new 
social and scientific ideas about pregnancy had merged with the increasing public 
attention being cast on the health behaviors of diabetics, and created a social perception, 
both within and without the medical community, that pregnancy was not simply a 
personal decision for a diabetic woman.  Although medical specialization has been 
depicted as the natural result of increased knowledge and scientific advances, such an 
interpretation for obstetrical diabetes dismisses the important push that came from the 
patients – from women who wanted to have children and who refused to be told that they 
could not.    
Priscilla White was the pivotal figure in the emergence of obstetrical diabetes.  
Instead of dissuading diabetic women from trying to have families, she chose to help 
them.  Even though the discovery of insulin did not improve diabetic women’s chances of 
surviving pregnancy at first, her approach reversed that trend.  In 1949, she published her 
methods for success with diabetic pregnancies of varying complexity, and legitimated in 
many ways the field of obstetrical diabetes by laying down its founding principles.  
Donald Barnett, who had been one of White’s physician residents, said that White 
“created the basic reformational question in obstetrical diabetes, at least one of them, 
which was, ‘How much control [of diabetes] do you need?’”
 95
  She began her career 
challenging the contemporary view that diabetes and pregnancy were incompatible.  In 
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defending her decision to reject that ideology, she insisted that her patients’ pursuit of 
children drove her to make diabetic pregnancies safe.  More than sixty years later, the 
White Classification System remains the foundation for the field.   
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CHAPTER V 
 ONLY WHEN PREGNANT 
 
In 1950, Obstetrical and Gynecological Survey published an article on a condition 
known at the time as glycosuria of pregnancy.  Not a normal condition in healthy 
individuals, glycosuria (sugar in the urine) was diagnostic of diabetes in 1950 – except in 
pregnant women.  Mid-twentieth century physicians generally believed that glycosuria of 
pregnancy was a temporary event and so did not consider it a true case of diabetes.  The 
idea that pregnancy stressed a woman’s body in a plethora of ways was a widely accepted 
notion by the end of the 1940s, and glycosuria of pregnancy was believed to be one 
example of that physiological stress.  Glycosuria would sometimes appear toward the end 
of a woman’s pregnancy, and the predominant theory at that time was that hormonal 
changes related to pregnancy had caused sugar to “spill over” into the woman’s urine.  
After giving birth, the urinary sugar disappeared, which relieved any lurking fear that the 
woman had actually developed diabetes during the course of her pregnancy.
1
  The article, 
however, foreshadowed a shift in scientific thought about glycosuria of pregnancy.  The 
author acknowledged the contemporary medical view on the transience of the condition 
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but countered that physicians should not dismiss the condition because, in fact, some 
women “manifest diabetes only when pregnant.”
2
   
The discovery of insulin in 1921 had transformed diabetes, and a cascade of 
associated shifts in scientific and social thought had created a new public identity for 
diabetics.  The almost certain death sentence was commuted, but diabetics were left to 
contend with a chronic and costly disease.  Diabetic children began to live into adulthood, 
but they faced a life that included a meticulous and demanding medical regimen.  
Surviving a diagnosis of diabetes also meant that, as adults, diabetics took on social 
gender roles.  Men became insulin-consumers who had to manage such social 
responsibilities as job pressures.  Women became impending obstetrical disasters, 
characterized as “brittle” and “fragile,” with pregnancy becoming the defining issue in 
their patient identities.  At the same time, adults began to be diagnosed with the mild 
form of the disease at an alarming rate as public health officials ramped up campaigns to 
identify the “million hidden diabetics.”
3
  As the mid-century mark approached, the 
general public heard about the hidden costs of diabetes, the multitude of unknown 
                                                 
2
 F.J. Basil-Jones, “Diabetes in Pregnancy:  Laboratory Assistance,” Obstetrical and 
Gynecological Survey 5, 4 (August 1950):  492.  The journal mistakenly printed Basil-Jones’ initials as F.J. 
instead of B.J.   
3
 In the 1950s and 1960s, programs endorsed by both the American Medical Association and the 
American Diabetes Association were begun to identify the suspected “million hidden diabetics” in the 
United States. See American Diabetes Association, The Journey and the Dream:  A History of the 
American Diabetes Association (Indianapolis:  American Diabetes Association, 1990), 40-44; “The Hunt 
for Hidden Diabetics,” The Saturday Evening Post (December 6, 1958):  20; Paul de Kruiff, “A Million 
Hidden Diabetics,” Today’s Health (November 1958):  22; and John B. O’Sullivan, Hugh L.C. Wilkerson, 
and Leo P. Krall, “The Prevalence of Diabetes Mellitus in Oxford and Related Epidemiological Problems,” 
American Journal of Public Health 56, 5 (May 1956):  742-754. 
119 
 
diabetics who posed a fiscal risk to society, and the complexities of a growing diabetes 
consumer market.   
In conjunction with this redefinition of diabetes, the emergence of risk factor 
ideology played a key role in sparking new research interest in glycosuria of pregnancy.
4
  
As the social understanding of diabetes had evolved, the perception of its women patients 
had changed as well.  Pregnancy, which was a rare occurrence in diabetics before insulin, 
became the over-arching concern of physicians.  Glycosuria of pregnancy, however, 
remained out of the purview of physicians and researchers at first.  The condition only 
came under increased scrutiny when the concept of identifying risk factors for disease 
entered the growing market mentality of the diabetes healthcare sector.   
Bolstered by advances in scientific knowledge and by developments in medical 
technology, risk factor ideology created a conceptual framework that would change the 
medical definition of the condition within the short span of two decades.  Risk factor 
ideology was a postwar concept which posited that the early detection of chronic diseases 
like diabetes could allow for medical interventions before such diseases could wreak 
havoc.  This new approach to public health emanated from efforts by insurance 
companies to reduce fiscal risk by identifying who was most likely to get sick (or die) 
                                                 
4
 For more on the rise of risk factor ideology in chronic disease research, see William G. 
Rothstein, Public Health and the Risk Factor:  A History of an Uneven Revolution (Rochester:  University 
of Rochester Press, 2003).  And for an excellent study that includes an assessment of risk factor ideology in 
diabetes drug marketing, see Jeremy A. Greene, Prescribing by Numbers:  Drugs and the Definition of 
Disease (Baltimore:  The Johns Hopkins University Press, 2007). 
120 
 
and from attempts by pharmaceutical firms to identify potentially treatable – and hence 
marketable – precursors to disease.   
Risk factor ideology undergirded the massive growth and expansion of the 
American healthcare industry during the postwar years, and it also fashioned an 
innovative approach to medical research on diabetes and pregnancy.  Rather than 
focusing solely on the laboratory-based research on the biochemical and molecular 
components of disease, postwar medical researchers were heavily influenced by the 
inherent challenge of risk factor ideology to search for and identify the early warning 
signs of chronic illnesses, to stop disease before it even started.  They sought to connect 
information on predictors of disease to the development of interventions that could limit 
or preempt the disabling results of chronic disease and to therapeutics that could improve 
patients’ lived experiences with chronic disease.   
Within the context of a heightened sensitivity to diabetic pregnancy, risk factor 
ideology suggested a new way to frame the condition of glycosuria of pregnancy.  Up 
until the 1950s, the appearance of sugar in the urine of non-diabetic, pregnant women had 
generally been discussed in the medical literature as an aberration.  Maybe it resulted 
from the stress of pregnancy hormones.  Maybe the stress of increased blood pressure 
during pregnancy caused a woman’s kidneys to filter sugar differently.  Within the 
framework of risk factor ideology, however, glycosuria of pregnancy would quickly 
become an indicator of a woman’s potential to develop diabetes later in life.  “The 
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woman destined to develop diabetes,” general medicine physician William P. U. Jackson 
declared in 1953, “divulges her future fate [when she becomes pregnant].”
5
   
 
Reframing Glycosuria of Pregnancy 
As the mid-century mark approached, research interest in diabetic pregnancies 
grew at a rapid pace.  Insulin had been available for almost three decades, and as 
physicians realized greater success in controlling diabetes with the new treatment, 
scientists’ interests grew in the lingering problems associated with diabetic pregnancies.  
As well, diabetic women increasingly pursued pregnancy despite warnings to the 
contrary, and they voiced their own concerns and experiences to their physicians.  With 
more attention to these pregnancies and with more feedback from their women patients, 
physicians and scientists began to take more note of glycosuria of pregnancy.  Over the 
course of the next two decades, the condition would become seen as less benign and 
physicians would begin, instead, to describe it as an event that potentially unmasked a 
hidden disease state.  Suggesting that it was something akin to a precursor of the mild, 
adult form of diabetes, the research that informed these shifting views essentially 
reframed the medical definition of glycosuria of pregnancy.  The naming changes that 
followed reflected the developing ideas on the condition.   
Deciding if glycosuria of pregnancy was a hidden form of diabetes, unmasked by 
the stress of pregnancy, encompassed much more than science in a laboratory 
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somewhere.  Moreover, the shift in thought about glycosuria of pregnancy actually 
exposed an unexpected divide within the medical community because labeling someone 
with a diagnosis of diabetes was not a simple matter.  Diabetes had, by the 1950s, 
become a disease of significant social stigma and of personal challenges for those who 
encountered it.  Even though there were substantial differences between the thin, juvenile 
diabetics and the older, overweight, mild diabetics, all diabetics faced employment 
discrimination, difficulty getting insurance, and the constant worry associated with 
testing urine, measuring food and, of course, the potential for debilitating complications 
like kidney failure and blindness.
6
   
The stage had been set during the 1940s for the changes in the medical and social 
meanings of glycosuria of pregnancy that would emerge during the 1950s.  For 
researchers who began to work on glycosuria of pregnancy, the issues included both 
scientific and social matters.  Investigators had been wrestling with how to classify, or 
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whether to dismiss, glycosuria of pregnancy in their research cohorts, and no tidy 
consensus on that issue had emerged by the 1950s.  In addition, American and European 
researchers approached the condition from very different perspectives.  While American 
researchers focused on what the condition meant for the pregnant woman who presented 
with sugar in her urine, European scientists expended more of their efforts on 
investigating the potential impact of the condition on the developing baby.  Even with 
divergent scientific approaches, however, research work progressed at a rapid pace.
7
 
The new cadre of researchers who began to work on diabetic pregnancies in 
general, and on glycosuria of pregnancy more specifically, came from a variety of 
disciplines and from different medical specialties.  Their varied backgrounds brought new 
approaches to these studies.  For example, David Hurwitz, a general medicine physician 
who had also completed a fellowship in obstetrics, teamed up with pediatrician Herbert 
Miller to investigate why a significant number of diabetic pregnancies still resulted in the 
death of the baby despite insulin therapy.  Indeed, they found that as many as 30 percent 
of those pregnancies resulted in stillbirths or the death of the newborn shortly after birth.  
Meanwhile, for non-diabetic women, the fetal and neonatal death rates stood at a much 
lower 2 percent.  In a somewhat novel approach for the time, the pair of researchers took 
medical histories directly from their older women patients and reviewed earlier events in 
their medical charts.  To their surprise, they discovered that when older women were 
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diagnosed with adult-onset (or mild) diabetes, more than 8 percent of them reported that 
they had lost an infant during a pregnancy before they became diabetic.  In addition, the 
research duo was told by many of those women that they had experienced glycosuria 
during at least one of their pregnancies.
8
   
Another 1940s-era doctor, New York diabetes physician Herman Mosenthal, 
posited that multiple pregnancies had a cumulative, negative impact on a woman’s 
metabolism.  That cumulative stress, he theorized, might explain why a woman who had 
experienced glycosuria of pregnancy earlier in her life developed diabetes later in life.  In 
his studies on the impact of pregnancy on a woman’s metabolism, Mosenthal 
collaborated with obstetricians, pediatricians, pathologists, and even with a handful of 
epidemiologists who were compiling reports for insurance companies and congressional 
task forces.  To offer support for his theory, he pointed to similar death rates from 
diabetes for both single men and single women over forty-five years of age, but not for 
married or widowed women.  His assumption was that single women, like the single men 
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he studied, had not been pregnant.  He pointed out that for married or widowed women 
over forty-five, however, the rate of diabetes was “far greater than that of males.”  
Although his theory was flawed on many levels, Mosenthal suggested that the impact of 
pregnancy on a woman’s body, particularly multiple pregnancies, accounted for that 
difference.
9
   
Glycosuria of pregnancy did not go completely unnoticed before the 1950s, but 
neither did it garner a huge amount of attention up to that point.  While physicians like 
Herbert Miller, David Hurwitz, and Herbert Mosenthal pursued questions about 
glycosuria of pregnancy with their new research formats, many scientists simply 
continued to exclude non-diabetic pregnancies with glycosuria from their research 
cohorts.  They justified the exclusion by defining the condition as a temporary and 
benign, almost normal, effect of pregnancy for some women.  Ivo Drury, an obstetrician 
in Dublin, recalled that when his team began collecting data in the late 1940s for their 
thirteen-year research project, they adhered to the belief expressed by other researchers 
that “cases of this type should be clearly separated because they are benign when 
recognized and their inclusion in the general series weights results rather favorably.”
10
  
As well, Priscilla White, a leading physician-researcher in diabetic pregnancy from 
Boston, noted that simple glycosuria was insignificant and agreed that it should not be 
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included in any study results.  It required no treatment, she said, because it would recede 
spontaneously after the woman gave birth.  She went on to espouse several theories on 
why the condition was not a true case of diabetes, such as the possible spilling of breast 
milk sugars into the woman’s urine.
11
   
Before mid-century, researchers and physicians alike routinely dismissed the 
condition.  Johns Hopkins obstetrician Nicholson J. Eastman called the temporary 
condition, which he termed “renal glycosuria,” a false case of diabetes.  Many women, 
Eastman said, presented with the condition and, he elaborated, a “load” of sugar could 
bring it on, certain medicines often caused it, and all pregnant women’s blood sugars rose 
enough that sugar might overflow the kidneys for any of them.
12
   Moreover, even though 
a few physicians suggested that glycosuria might be the result of a “diabetogenic” effect 
of pregnancy, meaning that the pregnancy itself might cause the diabetic-like symptoms, 
many dismissed even that idea.
13
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With such an entrenched view of glycosuria of pregnancy as temporary, benign, 
and self-contained, the sudden interest in the condition at mid-century leaves the 
historical perception that a remarkable scientific discovery must have catalyzed the new 
research efforts.  The era was indeed rife with changes in the medical approach to 
diabetes brought about by the introduction of insulin therapy.  And the scientific 
understanding of diabetes physiology certainly underwent enormous changes after the 
discovery of the new treatment in 1921.  In addition, the medicalization of pregnancy had 
brought birthing inside the hospital under the purview of physicians and, hence, 
physician-researchers.  Diabetic pregnancy had evolved into a subspecialty of its own.  
And advances in laboratory medicine allowed for greater accuracy in bodily 
measurements, beginning a shift toward diagnosing diseases with numerical thresholds 
derived from laboratory tests instead of relying on a patient’s reported symptoms and 
appearance.
14
   
While these changes in healthcare – increased medical knowledge about diabetes 
and pregnancy as well as advances in laboratory medicine – played an important role in 
the shift in thought on glycosuria of pregnancy, women patients likely had a significant 
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impact as well.  Pregnant women have, of course, always worried about possible threats 
to their babies and have paid careful attention to the course of their pregnancies.  Looking 
at earlier studies, such as those from Herbert Miller and David Hurwitz, it seems that 
women patients have often told their doctors about experiences with glycosuria of 
pregnancy years, sometimes even decades, before being diagnosed with diabetes.
15
  
Women’s attention to their health and their conveyance of symptoms to their physicians 
undoubtedly brought greater attention to these possible connections between glycosuria 
of pregnancy and future health issues.  But ultimately, the business concept of risk factor 
ideology became the cohesive force in reshaping physicians’ understanding of glycosuria 
of pregnancy.  In the 1950s, risk factor ideology would guide the design and direction of 
the largest research study ever on the condition.  What would become known as the 
Boston Study began in 1954 at the Boston City Hospital and continued for ten years; the 
results became the basis for revising the way that blood sugar levels in pregnant women 
were assessed. 
 
Glycosuria of Pregnancy or Pre-diabetes? 
When a funding source materialized that could pay for an expanded study on 
glycosuria of pregnancy, it did not take long to find a young, new researcher willing to 
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129 
 
try to connect the dots.  With the assistance of a National Institutes of Health (NIH) 
research grant along with matching funding from the U.S. Public Health Service 
(USPHS), John B. O’Sullivan left his interest in arthritis behind and arrived in Boston in 
1954.  O’Sullivan began a long-range project to determine if the raised level of blood 
sugar that corresponded to the appearance of urinary sugar in glycosuria of pregnancy 
was a risk factor for women developing diabetes later in life.
16
  He collected data on low-
income, pregnant women who came to the “Free Clinic” of the Boston City Hospital for 
healthcare, and he used the newly developed laboratory test for measuring sugar levels in 
blood.
17
   
The Boston Study incorporated two important elements of modern research 
design.  First, the project was a prospective investigation rather than a retrospective 
observation and, second, women were enrolled in a consecutive manner in order to avoid 
selection bias.
18
  In contrast to retrospective research studies such as Herbert Miller’s that 
looked back in time, women enrolled in the Boston Study were currently pregnant, and 
the team planned to look forward, watching them prospectively for ten years to see what 
                                                 
16
 Physicians and researchers had known since before the discovery of insulin in 1921 that the 
presence of sugar in the urine corresponded directly to sugar in the patient’s blood stream.  But the 
difficulty of measuring blood sugar remained a limiting factor and forced physicians to rely instead on 
urine testing until mid-century when significant advances in laboratory chemistry made blood tests simpler, 
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 Robert H. Knopp, “John B. O’Sullivan:  A Pioneer in the Study of Gestational Diabetes,” 
Diabetes Care 25, 5 (May 2002):  943-944. 
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130 
 
happened without subjective interpretation.  Many of those older, retrospective studies 
had necessarily relied on anecdotal evidence:  personal stories about health experiences 
related informally by patients or clinicians, usually with no means of validation.  One 
previous physician-researcher who had based his findings on anecdotal evidence even 
acknowledged that his method of simply asking patients about their experiences was 
“admittedly subject to great inaccuracy,” but he justified his approach by claiming that 
“there is no reason to believe that diabetics are greater exaggerators.”
19
  The Medical 
Director at Boston City Hospital, Hugh Wilkerson, asserted that the Boston Study’s 
scientific design would revolutionize scientists’ understanding of women’s pre-diabetic 
experiences with pregnancy because “most current theories on ‘maternal prediabetes’ are 
based on retrospective studies among diabetic women past the childbearing years.”
20
   
The design of the Boston Study combined clinical observation with a 
sophisticated statistical analysis.  Pregnant women who came to the Free Clinic were 
given an initial blood test that involved drinking a small cup of liquid with fifty grams of 
sugar.  One hour later, blood was drawn and tested.  The blood sugar level was recorded 
as a baseline measurement.  The women were then scheduled for a more involved test 
called the Oral Glucose Tolerance Test (OGTT).  For that test, the women were given 
dietary instructions for the three days leading up to the test and were instructed to arrive 
at the clinic in the morning after an overnight fast.  They were given a liquid to drink 
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which contained one hundred grams of sugar.  Following the liquid, a series of blood 
tests were performed:  the first test was drawn immediately and then again at one hour, 
two hours, and three hours.  The women were given the test at several points during their 
pregnancies, and the test results were inserted into a formula that calculated a running 
average for the entirety of the study.
21
 
The main research question in the Boston Study was whether non-diabetic, 
pregnant women who experienced raised blood sugars during the OGTT developed 
diabetes later in their lives.  Even though the main research question was straightforward, 
the study team included a complex calculation of continuous averages for the blood sugar 
levels in their research participants.   They tried to compare study test results against the 
research subjects’ own laboratory values because they believed there was a potential 
problem in defining the normal range for blood sugar in pregnancy.  In 1954, the 
“normal” range for blood sugars was still based on calculations from thirty-something-
year-old, white, male soldiers.
22
  However, the research subjects in the Boston Study 
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were women who were pregnant, mostly non-white, and from a lower-income strata of 
the population.  O’Sullivan and his graduate student assistant, Clare Mahan, chose to 
calculate a new set of “normal” blood sugar values for the pregnant women enrolled in 
the study.  To create this set of average ranges for blood sugar measurements, they 
continually recalculated an average range throughout the study enrollment period and 
then set a statistical threshold to designate an abnormal blood sugar level specific to 
pregnancy.  It was one of the first times that research involving laboratory tests 
acknowledged real differences in physiology between men and women and considered 
the state of pregnancy as a factor in how a woman’s body responded to the food she ate, 
in this case a sugary liquid.
23
  Although the study’s design elucidated the problematic 
concept of the “standard male” in physiology, the study’s design arguably furthered the 
gendering of diabetes. 
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Figure 5.  Chart of blood sugar measurements.
24
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 “Oral Glucose Tolerance Test,” Carton 1, Folder 17, Priscilla White Papers.  This was a widely 
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Adding to the complexities of the research design, the women who were enrolled 
in the Boston Study presented for care at the Boston City Hospital at a time when 
prenatal care had become a standard recommendation by obstetricians but was not yet 
widely accepted as a valuable aspect of healthcare by other physician groups.
25
  Between 
the mid-1950s and the mid-1960s, many low-income, inner-city women rarely received 
what obstetricians deemed adequate prenatal care.  In fact, many of those women 
received no care at all during their pregnancies.  A number of women could not afford 
prenatal care or were not aware of doctors’ recommendations about what constituted 
adequate care.  However, other women simply chose to avoid it because they believed 
that the benefits did not outweigh the costs.  Those “costs” were not always counted in 
dollars.  Many low-income women, for example, were deterred by long waits in the 
crowded waiting rooms of public health clinics; by the struggle of balancing 
employment, child care, and difficult, or even erratic, appointment schedules; and by the 
lack of any tangible results of inconvenient visits, like valuable test results to reassure 
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them or education to assist them during their pregnancies.
26
  Recognizing the potential 
deterrents to the low-income women in their study seeking prenatal care at their clinic, 
the Boston Study team sought financial assistance from the Children’s Bureau to create 
“improved services for prenatal, postpartum, and well child care for the mothers and their 
children in this project.”
27
  The research team shaped the way that prenatal care was 
offered to encourage the study participants to seek care at their clinic and to encourage 
them to keep coming back for their follow-up appointments.  The need to offer adequate 
care for low-income, pregnant women was certainly a driver for restructuring the study’s 
design, but the desire to retain study participants undoubtedly ensured that the necessary 
changes would be made.  By the mid-century mark, research design included attention to 
“retention,” and a high rate of drop-out or “lost to follow-up” in a study limited the 
acceptability of its conclusions.
28
 
American pharmaceutical companies also played a role in bringing attention to 
glycosuria of pregnancy.  Companies like Merck, Upjohn, and Pfizer helped to acquaint a 
broader sector of the public to the concepts of risk factors for disease and early warning 
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signs of chronic disease states as they worked to develop treatments for debilitating 
illnesses like heart disease and diabetes.  Pfizer’s Chief of Operations, Charles Mottley, 
epitomized that effort when he told an audience at the American Drug Manufacturer’s 
annual meeting in 1957 that chronic, life-long illnesses were the next frontiers in 
sustainable markets for the drug industry.
29
  Since its discovery in 1921, insulin remained 
the only drug therapy available for treating either type of diabetes as the mid-century 
mark approached.  But insulin had to be injected with a needle.  Not only was the 
treatment hard – stabbing oneself with a sharp object is difficult at best – both the 
enormous cost of the treatment as well as the daily use of syringes added to the social 
stigma of diabetes.  And even though insulin did not work very well for the mild 
diabetics who were quickly beginning to comprise the majority of patients with the 
disease, there was no other alternative to offer to those diabetics for whom diet and 
activity failed to control their disease.   
With the possibility of pills to treat diabetes, the idea of expanding the definition 
of the disease to include an underlying condition, or even a risk factor for diabetes, into 
the realm of diagnostic and, hence, treatment possibilities became an easier pill to 
swallow.  The development of pills to treat diabetes was no less a miracle in the world of 
diabetic medicine than insulin had been some three decades earlier.
30
  In 1957, The 
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Saturday Evening Post enthusiastically presented a four-page spread on the new diabetes 
pills that could “free thousands of diabetics from their lifelong slavery to the hypodermic 
needle.”  In a telling note for researchers investigating glycosuria of pregnancy, the 
article even reported on “a young mother who was successfully carried through her 
pregnancy” with the new pills.
31
  Researchers investigating the condition certainly found 
their direction clearer.  Likewise, they found that the ethical dilemma of labeling a 
symptomless condition as a precursor to a disease that came with significant social 
problems was somewhat reduced if an easier treatment with less stigma existed.   
By the late 1950s, within this changing environment of medical care for diabetes, 
doctors stopped referring to the condition as glycosuria of pregnancy and began, instead, 
to call it pre-diabetes of pregnancy.  The name change certainly reflected how quickly the 
idea had taken hold that the condition was an indicator of a woman’s risk for developing 
diabetes.
32
  However, it is important to recognize that other factors fed into the name 
change as well.  For example, doctors during the 1950s began to rely more on blood tests 
for diagnosing diabetes when such tests became easier, more affordable, and quicker.  
                                                                                                                                                 
doses.  A group of German scientists discovered that the severe reactions were actually the result of 
dangerously low blood sugars caused by the sulfa drug.  American pharmaceutical firms like Upjohn raced 
to bring these drugs to the American market as quickly as possible, succeeding with Orinase by the late 
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Blood tests also afforded physicians the ability to select a numerical threshold for 
defining diabetes (or even for “early” diabetes) instead of waiting for an individual’s 
internally-regulated threshold for sugar to appear in the urine.  With the numerical 
specificity of a blood test, decisions about defining diabetes or pre-diabetes could 
potentially bypass any physiological regulatory systems within a person’s body, like 
urine production, allowing for earlier and earlier cut-off points to be established for 
defining abnormal pathology.
33
  Adding to the complexity, even though blood tests were 
available earlier in the decade and were already widely promoted as the new diagnostic 
standard, many physicians had resisted the switch from urinalysis because of the need for 
quick results.  As one physician explained, “If a patient came into the ER [emergency 
room], we would draw blood but it could be two hours before we would get a result; with 
a urine test, we dipped the stick and had the result.”
34
   
Adding to the impact of new laboratory tests and new medications to treat 
diabetes at earlier stages, the American Diabetes Association (ADA) and the American 
Medical Association (AMA) had begun disease detection campaigns to search for the 
“million hidden diabetics” that they believed stood to derail the fiscal stability of the 
fledgling American health insurance industry.  Year-round Diabetes Detection Drives 
began across the nation as results from the enormous, industry-supported Oxford 
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Diabetes Survey came out during the 1950s.  Researchers reported that the data suggested 
that as many as one million people in the United States actually had diabetes but did not 
know it yet.
35
  Popular news magazines like Time, Newsweek, The Saturday Evening 
Post, and Today’s Health, all picked up on the detection campaigns and connected those 
efforts to the language of risk factor ideology by stressing that “early discovery is 
vital.”
36
   
The general approval within the medical community of the new name pre-
diabetes of pregnancy was bound to the ever-expanding connections between risk factor 
ideology, a growing public concern with “the million hidden diabetics,” and American 
scientists’ belief that the physiological stress of pregnancy could unmask diabetes.  What 
had been at the beginning of the 1950s a “non-entity,” became by the end of the decade 
an early warning sign of a woman’s predisposition to develop diabetes.  Moreover, not 
only had glycosuria of pregnancy become a potential predictor of diabetes, but it had 
become as well an experimental window into how diabetes developed.  As physician-
researcher Hugh Wilkerson observed, “The ideal state for the investigation of 
‘prediabetes’ is to be found in the pregnant woman.”  John O’Sullivan, lead investigator 
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of the Boston Study, and a colleague researcher of his, Norbert Freinkel, reported that 
pre-diabetes of pregnancy was the ideal laboratory for studying diabetes because 
pregnancy taxed a woman’s ability to produce insulin so much that it “unmask[ed] 
chemical diabetes.”
37
   Another prominent obstetrician declared, “It is now well 
established that married women who develop diabetes in middle life give obstetric 
histories very similar to those of the long-established diabetic.”
38
   
 
Glycosuria of Pregnancy and the Baby  
While American researchers continued trying to clarify the link they saw between 
glycosuria of pregnancy and the development of diabetes later in a woman’s life, 
European scientists were examining the same condition from a different perspective.  
Beginning in the early 1950s, a line of research based mostly in European laboratories 
ran parallel to the efforts by American scientists.  Without the influence of the American 
healthcare market’s ideology of risk factor identification, European scientists looked at 
the effects of glycosuria of pregnancy on the fetus instead of on the pregnant woman.  A 
key figure in the European efforts was Jorgen Pedersen, a Danish physician trained in 
both internal medicine and obstetrics, who also had extensive research experience in the 
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laboratories of important chemistry and physiology scientists such as Nobel Laureate 
Hans Christian Hagedorn, who had developed the first long-acting insulin.
39
 
In his doctoral research dissertation in 1952, Pedersen proposed a theory that he 
called “the hyperglycemia-hyperinsulinism hypothesis.”  The basic premise was that 
when a pregnant woman – diabetic or not – experienced a high blood sugar, the fetus 
experienced it as well.  Pedersen suggested that the mechanism which allowed the fetus 
to experience the mother’s blood sugar was the permeability of the placenta.  
Additionally, Pedersen theorized that the fetus actually tried to compensate by producing 
more insulin in order to bring down the high blood sugar.  He claimed that this 
experience before birth, where the placenta failed to block sugar from the mother’s blood 
and the fetus tried to respond, produced specific problems for the newborn infant such as 
breathing difficulties immediately after birth.  More importantly, Pedersen said, the 
experience shaped the baby’s developing organ systems in a way that likely determined 
aspects of its adult health.
40
  Pedersen’s theory ran contrary to the predominant belief of 
the time that the placenta protected the baby by acting like a filter and, as such, his theory 
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undermined a basic premise that had guided American obstetrical thought for over a 
century.  His work would also open the door for American researchers to conceive of the 
womb as an environment vulnerable to a variety of influences.   
Even though research scientists often work in isolation, Pedersen’s studies were 
intimately connected to the work of other scientists of his era.  The work which 
undergirded Pedersen’s hyperglycemia-hyperinsulinism theory began in the physiology 
lab of the Steno Memorial Hospital in Copenhagen during the 1940s.  There, Pedersen 
used a technique for sampling amniotic fluid that a British obstetrician, Douglas Bevis, 
had perfected in a nearby research laboratory – a technique that would later become part 
of the widely used amniocentesis testing.
41
  Amniocentesis involves the collection of 
cells from the fluid that surrounds the fetus by inserting a needle through a pregnant 
woman’s abdomen into her uterus.  The actual needle insertion procedure was not new at 
all, but a discovery in 1949 had drawn more attention to the procedure.  A Canadian 
neuroanatomist, Murray Barr, had discovered that the cells in the amniotic fluid of 
research animals differed between males and females.  The cells of females contained a 
                                                 
41
 Jorgen Pedersen, “Diabetes and Pregnancy:  Blood Sugars of Newborn Infants during Fasting 
and Glucose Administration,” Nordisk Medicin 47, 30 (July 25, 1952):  1049; idem, “Glucose Content of 
the Amniotic Fluid in Diabetic Pregnancies,” Acta Endocrinologica 15 (April 1, 1954):  342-350; and 
idem, “Diabetes without or with Slight, Intermittent Glucosuria,” Acta Medica Scandinavica 163, 6 (1959):  
477-482.  Douglas Bevis’s work on determining the blood typing of the fetus in pregnancies in which the 
woman was Rh-negative (a potentially fatal issue for the fetus because of a complicated immune system 
rejection that could occur) was first published in 1952 and gained interest throughout Europe.  However, 
very little commentary on his work transpired in American medical journals.  In the mid-1970s, Bevis 
would become famous for his success with in-vitro fertilization.  See Douglas C.A. Bevis, “The Antenatal 
Prediction of Haemolytic Disease of the Newborn,” Lancet 259, 6704 (February 23, 1952):  395-398.  Also 
see A.C. Crompton, “Obituary:  Professor Douglas Bevis,” The Independent (July 30, 1994); and Lars 
Molsted-Pedersen, “The Pedersen Legacy,” 23-25. 
143 
 
small, extra structure.  By the early 1950s, Barr had proven that the extra structure also 
existed in the cells of human females.
42
  In 1956, based on Barr’s discovery, 
amniocentesis was used for the first time to determine a baby’s gender because of the 
possibility that the baby had hemophilia, a sex-linked blood disorder.  Researchers 
immediately embraced the new technology for its potential in “the detection of [other] 
antenatal hereditary disorders.”
43
  The belief was that procedures like amniocentesis 
could help physicians identify, or diagnose, inherited diseases before the baby was born.       
Pedersen’s theory on the fetal environment gained momentum through the work 
of other European researchers and through the studies of scientists working on issues in 
diabetes and pregnancy.  A contemporary of Pedersen’s, Belgian researcher Joseph Pierre 
Hoet, also began investigating the idea that glucose crossed the placenta in pregnancies 
complicated by glycosuria.  Because many of his older, diabetic women patients reported 
previous “disturbances during pregnancy,” Hoet had turned his attention toward studying 
glycosuria of pregnancy.  Many of the women that Hoet reported on had histories of 
miscarriages and stillbirths as long as twenty years before being diagnosed with diabetes.  
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In addition to their generally problematic obstetric histories, many of his diabetic women 
patients reported specifically that they had experienced glycosuria of pregnancy.  Medical 
chart reviews that his research team performed confirmed those reports.
44
   
Another European obstetrician whose work increased the attention paid to the 
impact of glycosuria on the fetal environment was London physician Sir John Peel.  By 
the late 1940s, Peel had become increasingly concerned with the problems he saw in 
babies born to diabetic and “pre-diabetic” women.  He added research staff to his clinic 
team to study the “relatively small group of patients” with glycosuria of pregnancy.  His 
scientific interest in the condition emanated, he said, from a concern for fetal size, 
congenital abnormalities, and intrauterine death in pregnancies that had been affected by 
the supposedly benign event of transient glycosuria.  His research focused on placental 
function to determine if the temporary condition had somehow “touched” the unborn 
baby.
45
  Peel’s research career, however, followed an interesting tract in the European 
scientific community.  By the end of the 1950s, he was tapped to become the Surgeon-
Gynaecologist to Queen Elizabeth II, a position that afforded him great sway in political 
decisions about pregnancy-related healthcare.  With the influence bestowed by such an 
important appointment, he also became chairman of the legislative committee that drafted 
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Great Britain’s 1967 Abortion Act, which legalized the medical termination of 
pregnancy.
46
   
Peel’s work on the 1967 abortion legislation was doubtless influenced by the 
social environment that had intruded into his research laboratory as well as into those of 
his colleagues.  Debates over British physicians’ authority to use therapeutic abortion as a 
medical treatment preceded similar issues that would dominate headlines in the United 
States during the 1960s and 1970s.  Much like in the United States, the Catholic Church 
figured prominently in those European struggles, although church officials in Europe 
tended to take the issue straight to the public rather than through the court system.  On 
October 29, 1952, Pope Pius issued a statement to European media outlets that derided 
the work of medical researchers in pregnancy.  Specifically indicting researchers who 
studied the impact of diabetes and other metabolic disturbances, he criticized any 
research that expressed primary concern for the welfare of the mother.  Physician-
researchers across Europe were incensed as they widely interpreted the papal statement as 
“valuing the life of the unborn child above that of the mother and as making it obligatory 
upon doctors to ‘kill’ the mother if they could thereby save the child.”  Even though the 
Vatican released a follow-up statement saying that the Pope was trying only to put the 
issue into perspective by bringing an important ethical question to the forefront, 
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European physician-researchers viewed the statement as infringing on their medical 
authority and reacted to protect their medical practices.
47
     
By the 1960s, the attention to the fetal environment that had been raised by 
diabetic pregnancy researchers undoubtedly influenced other pregnancy-related studies, 
such as scientific work on the impact of thalidomide, the effects of maternal rubella 
infection, and the recognition of Fetal Alcohol Syndrome (FAS).
48
  A new vocabulary 
appeared in obstetrical medicine, and it actually came in large part from the world of 
diabetic pregnancy research.  Alcohol, the rubella virus, and thalidomide became 
teratogens, substances capable of altering the environment inside the womb.  Researchers 
reported, and then the media subsequently warned the public, that there were potentially 
dozens of teratogens that could cross the placental barrier and harm the growing baby.
49
   
During the 1960s, the idea that outside forces could harm the fetus also became an 
over-arching principle in public health efforts and, subsequently, brought significant 
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changes in the social understanding of women’s private health choices during pregnancy.  
For example, reaction to the threat of the rubella virus (German measles) in the United 
States, which could cause serious birth defects if a woman was exposed while pregnant, 
reconfigured public perceptions about disabilities, abortion, and even personal medical 
choices.  The mass public health efforts at immunization in the wake of the rubella virus 
scare embedded state policy in the social understanding of personal medical decisions.  In 
targeting children as potential carriers of the virus, immunization campaigns cut across 
lines of race, class, and gender but created a new idea that it was okay for the state to 
impose medical interventions on one person in order to protect the health of another 
person, even if that other “person” had not been born yet.
50
 
In the wake of an ever-increasing scientific and social concern for the fetus, the 
media began to report on a slew of drugs, chemicals, foods, x-rays, and even noises that 
could potentially injure a growing fetus.  A New York Times article quoted two 
Wisconsin pediatricians who had spent more than a decade studying potential injuries to 
the fetus, and they broadly posited that “everything you give a pregnant mother is 
suspect.”  The pair said that drugs, viruses, chemicals, and even vitamins and “enriched 
foods” could potentially harm the fetus because, as they explained, the placenta did not 
actually protect the fetus as well as doctors once believed.  In fact, they theorized, the 
placenta could “overload” the fetus with seemingly normal nutrients from the mother’s 
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blood – like iron, amino acids, and sugar – because not only was the placenta not a filter 
but it could even be a magnifier of the components on the fetal side.
51
 
 
One or Two Patients in Pre-diabetes of Pregnancy? 
The European research focus on the fetus gained such influence world-wide that 
the investigative team for the American-based Boston Study revised their research 
protocol to incorporate questions about the impact of blood sugar fluctuations on the 
developing baby.  What had begun as a study to predict the future health of women 
changed mid-stream.  The study expanded to account for a new medical and 
technological focus that had crossed over the Atlantic:  the unborn baby.  By the late 
1950s, the Boston Study’s preliminary results and reference ranges for women were 
already being cited in nearly every article on testing strategies for pre-diabetes in 
pregnancy.  In 1957, though, three new outcome measures were added, which addressed 
the growing concern for the fetus in these pregnancies:  (1) complications such as 
miscarriage, oversized (or premature) babies, and congenital anomalies; (2) blood sugar 
problems experienced by the newborn; and (3) the impact on the newborn’s health of 
giving insulin to pregnant women with the condition.
52
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For American scientists working on diabetes and pregnancy, the pregnant woman 
had been the main research target for decades, but the European focus expanded the 
research window.  Another young researcher who was influenced by ideas about a fetal 
environment was Dr. Norbert Freinkel.  Freinkel had arrived at the Boston City Hospital 
during the early years of the Boston Study and, in the late 1950s, after spending a decade 
in thyroid research, he began studying insulin metabolism in pregnancy when the Boston 
City Hospital received another major research grant from the National Institutes of 
Health.
53
  Within a year, his research also included changes in carbohydrate metabolism 
during pregnancy.  That new research focus became a natural segue for Freinkel to begin 
conducting studies on the temporary condition of pre-diabetes in pregnancy.  Freinkel’s 
wife, Ruth, actually became an informal research subject for his initial studies on 
pregnancy metabolism.  In order to test his theories, he jokingly explained that he drew 
blood tests on Ruth “from the fifth day following the conception of [daughter] Susie (I 
was a very confident young man in those days!).”
54
   
Over the next decade, Freinkel’s work evolved into an influential theory on how a 
woman’s health behaviors shaped the environment of the womb.  Interchangeably known 
as “fuel-mediated teratogenesis” or “the tissue culture experience of pregnancy,” he 
theorized that a pregnant woman’s diet created a unique and specific environment for the 
developing baby.  Suggesting that the food a pregnant woman ate became something 
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tantamount to the agar in a petri dish, Freinkel assigned to the pregnant woman “the role 
of an incubator and a supplier of incubation medium.”
55
  Freinkel’s emphasis on the way 
in which events during pregnancy influenced health cycles afterward fit nicely with the 
premise of risk factor ideology, making his work a natural bridge for incorporating the 
concept of a fetal environment into studies on diabetic pregnancy.    
Few scholars have recognized that the work of these researchers from the 1950s, 
like Jorgen Pedersen and Norbert Freinkel, actually laid the foundation for connecting a 
pregnant woman’s health behaviors to the trajectory of fetal development.  Looking 
instead to more recent works, scholars as well as advocates for fetal rights see the concept 
of a fetal environment as a newer development and have most often contextualized it as a 
reaction to Roe v. Wade.
56
  An important exception has been researcher Andreas 
Plageman, who has called Freinkel’s theory a “forerunner of today’s rapidly expanding 
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fields of ‘perinatal programming’ and ‘developmental origins of health and disease.’”
57
  
As well, Northwestern University’s Boyd Metzger has said that Freinkel was “the driving 
force [for demonstrating] the mutual interplay between mother and fetus.”  Freinkel and 
Pedersen were indeed the first scientists, Metzger said, who “provided convincing 
evidence that diabetes begets diabetes.”
58
   
More typically credited with creating the concept of a fetal environment is David 
J. Barker.  A British physician who, beginning in the late 1980s, popularized the idea that 
the nutritional make-up of the womb “programs” the developing fetus, Barker 
concentrated mostly on hypertension and Type 2 diabetes in his research, but he also held 
various consulting positions on privately- and federally-funded nutritional programs for 
pregnant women.
59
  Barker’s work often replicated the language used by researchers from 
the 1950s by discussing how “the growth of a fetus is influenced … by the nutrients and 
oxygen it receives,” explaining that “insulin has a central role,” and even focusing at 
length on the condition of raised blood sugars during pregnancy.  Yet, even Barker does 
not credit the work of his European forerunners, such as Jorgen Pedersen, Joseph Hoet, 
and Sir John Peel, or of their American counterparts, such as John O’Sullivan, Hugh 
                                                 
57
 Andreas Plagemann and Thomas Harder, “Fuel-Mediated Teratogenesis and Breast Feeding,” 
Diabetes Care 34 (March 2011):  779.  
58
 Boyd E. Metzger, “The Freinkel Legacy,” in Textbook of Diabetes and Pregnancy, 30-38; 
quotes on pages 35 and 36 respectively. 
59
 See Barker’s extensive Curriculum Vitae including a summary of his consulting roles at 
http://www.southampton.ac.uk/medicine/about/staff/djb2.page#background (accessed December 1, 2012). 
152 
 
Wilkerson, Norbert Freinkel, and Boyd Metzger.
60
  The result has been a historical 
inaccuracy which somewhat exclusively connects the concept of fetal rights to the social 
movements of the late 1960s and 1970s and that ignores the impact of research on 
diabetic pregnancy. 
Contemporaries of the diabetic pregnancy researchers from the 1950s have 
suggested that when the American and European research efforts on pre-diabetes of 
pregnancy merged, the result was that loosely connected scientific findings turned into 
coherent medical approaches and that popular ideas about the condition of pre-diabetes of 
pregnancy were formed.  In 1960, for example, South African obstetrician William 
Jackson remarked that the monumental research efforts from both sides of the Atlantic 
had transformed understandings of blood sugar fluctuations in pregnancy so dramatically 
that, “We [now] believe that most, and probably all, of the abnormalities which occur in 
the fetus of the diabetic may also occur in the fetus of the prediabetic.”
61
  In a 1962 
article on the increased prevalence of diabetes in the mid-twentieth century, geneticist 
James Neel proposed that the importance of pre-diabetes of pregnancy was not that it was 
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“an expression of the mother’s diabetes,” but rather that “this phenomenon is also in part 
an expression of the infant’s predisposition.”
62
   
In fact, Neel’s description of pre-diabetes in pregnancy as a health condition of 
the unborn child embodied the new ideas about a fetal environment, a focus which was 
gaining momentum in popular conceptions of pregnancy as well.  A mid-1970s article in 
the Journal of Perinatal Medicine reviewed the impact of research into glycosuria of 
pregnancy, or pre-diabetes of pregnancy, during the 1950s on the then-current approach 
to patients.  The authors reported on a trial of universal screening in their obstetrical 
clinic to “identify the patient at risk of obstetric problems.”  The problems that they 
investigated, however, (macrosomia, birthing injuries, malformations, fetal morbidity, 
neonatal deaths, and overgrowth or growth retardation of the baby) were health problems 
experienced by the fetus or newborn, not the pregnant woman.  In a complete reversal 
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from the obstetrical approach prior to the 1950s, the “patient at risk” for their obstetrical 
group was the unborn baby.
 63
  
 
Conclusion 
Risk factor ideology certainly brought increased interest to the condition of 
glycosuria of pregnancy.  The new concept began a process that integrated this interest 
into the massive medical research enterprise that emerged with the post-war 
transformation of American medicine.
64
  Yet, the role of risk factor ideology in creating 
interest in glycosuria of pregnancy remains a much more complicated picture.  
Throughout the 1950s, scientific interest in glycosuria of pregnancy indeed grew as 
physicians began to ask if it could be a harbinger of diabetes in later life.  They even 
examined the condition with the hope that it could illuminate some new understanding of 
how diabetes developed.   
Risk factor ideology alone, however, could not maintain the momentum.  Unlike 
other conditions that came under scrutiny mid-century as possible precursors to disease, 
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glycosuria of pregnancy held no potential for a pharmaceutical treatment and so its utility 
as a disease concept was limited.
65
  Even though glycosuria of pregnancy was swept up in 
the rush to identify and target indicators of future disease, clinicians and researchers had 
not developed any standard therapeutic intervention.  As historian Jeremy Greene has 
explained, the idea of identifying and reducing risks for diseases “naturally emphasized 
the importance of the asymptomatic patient” because of the potential for lucrative 
pharmaceutical interventions.  Risk factor ideology, Greene explained, has historically 
been connected to an assortment of therapeutics created by pharmaceutical companies to 
define and treat these new pre-disease patients.
66
   
Research interest in glycosuria of pregnancy did not emerge from the potential for 
new drug treatments or therapeutic interventions, even though American researchers 
spoke the language of risk factor ideology.  While the new oral diabetes medications that 
came out during the 1950s certainly spurred researchers to continue their work on a 
condition that many physicians were still calling temporary and benign, even the new 
therapeutics would not be applied to the condition.  The merging of risk factor ideology 
with the concept of a fetal environment became the force that propelled research on the 
condition forward.  Just how much of a driving force the connection between risk factor 
ideology and the concept of a fetal environment would be became clear during the 1970s 
                                                 
65
 For example, Belgian physician Jean Pirart criticized American researchers’ exclusive focus on 
the pregnant woman.  See Jean Pirart, “So-Called Prediabetes of Pregnancy,” Acta Endocrinologica 20 
(October 1, 1955):  192-208. 
66
 Greene, Prescribing by Numbers, 6.   
156 
 
and 1980s, when the engine of medical research in the United States transformed a 
condition with little to no investigational budget into a research enterprise with millions 
of dollars of state support.  
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CHAPTER VI 
PART II:  MAKING GESTATIONAL DIABETES  
 
John Hare, a retired physician from the Joslin Diabetes Center in Boston, told the 
story of a doctor who became his patient during her second pregnancy.  Her first 
pregnancy had gone well despite being complicated by gestational diabetes.  His mid-
thirties patient was once again diagnosed with gestational diabetes, but she was “very 
motivated and tested her blood sugars herself.”  After her pregnancy, however, she 
insisted on having an antibody test that, if positive, would change her diagnosis from 
gestational diabetes to Type 1 diabetes.  Much to Hare’s surprise, the test came back 
positive.  More surprising, he said, his patient was relieved, almost happy, to be 
diagnosed with a form of diabetes arguably much more serious than gestational diabetes, 
“She was a patient of mine, yes, and she was also a doctor, but she was determined not to 
have GDM [gestational diabetes] and, well, she was actually right, but she was so 
determined to have anything else.”
1
 
Part II of this dissertation argues that these social perceptions of gestational 
diabetes, like those of Hare’s physician-patient, were influenced by the way that the 
disease concept for gestational diabetes was framed within the bureaucratic channels of 
social welfare policy.  Officially, the disease was codified in 1980, with its inclusion in 
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the disease coding manual maintained by the World Health Organization (WHO).  But 
the process of defining the disease had been a task of creating policies that specified who 
was at risk and what fiscal and social problems could result from not identifying those at 
risk.  The language of Medicaid eligibility rules, for example, became intimately 
connected to treatment standards for this disease because many of the women who 
encountered the diagnosis came increasingly from lower-income groups.  And that 
connection tagged gestational diabetes with a certain set of pejorative social judgments.  
Gestational diabetes also became encumbered by the negative perception of diabetes that 
had developed.  Diabetics in general faced a problematic consumer identity by 1980 that 
portrayed them as personally responsible for the very public financial burden they might 
cause – through low-income status and through negligent health behaviors like inactivity, 
overeating, and rejecting medical advice.
2
   
The connections between medicine, business, and government that became more 
concrete after World War II resulted in state policies becoming embedded in the 
definition of this new disease.  Research and treatment guidelines for gestationally 
diabetic pregnancies were translated into healthcare practices through the channels of 
congressionally-mandated committees and legislative work groups.  During the 1970s 
and 1980s, the demographic picture of gestationally diabetic women became poorer and 
less white.  The low-income and minority women encountering the new diagnosis were 
marginalized consumers in the healthcare market, but they would gain access to prenatal 
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care for the condition when Medicaid eligibility policies began to reflect the medical 
recommendations on gestational diabetes.  Both risk factor ideology and the concept of a 
fetal environment had served as an impetus to improve pregnant women’s access to 
healthcare.  For gestational diabetes, that meant the condition would shift from being an 
interesting notation in a medical chart to part of the prenatal care package of national 
preventive health interventions.
3
 
As our governmental structure has grown enormously over the twentieth century, 
much of our social system has come under the control of a large federal bureaucracy, 
including facets such as electoral participation and healthcare.
4
  During the twentieth 
century, healthcare quickly became commodified through the interplay of the increasing 
role of the federal government, the rise of a pharmaceutical consumer market, and the 
birth of third-party payers as liaisons between healthcare providers and consumers.
5
   
Chapter VII in this section adds to the literature on the bureaucratization and 
commodification of healthcare by examining the conduit that bound those elements 
                                                 
3
 The Centers for Disease Control, “The National Diabetes Fact Sheets,” 
http://apps.nccd.cdc.gov/DDTSTRS/FactSheet.aspx.  Also, see Boyd E. Metzger, “The Global Increase in 
Diabetes: Unique Issues for Mothers and Children,” International Journal of Diabetes in Developing 
Countries 26 (2006):  57-62, online serial, http://www.ijddc.com/text.asp?2006/26/2/57/28274 (accessed 
November 4, 2009).  
4
 On the growth of the federal government in the U.S., see Nell Irvin Painter, Standing at 
Armageddon:  The United States, 1877-1919 (New York:  Norton, 1987); Thomas J. McCormick, 
America’s Half Century:  United States Foreign Policy in the Cold War (Baltimore:  Johns Hopkins 
University Press, 1989); and, with an emphasis on consumer identity, Lizabeth Cohen, A Consumer’s 
Republic:  The Politics of Mass Consumption in Postwar America (New York:  Knopf, 2003). 
5
 Colin Gordon, Dead on Arrival:  The Politics of Health Care in Twentieth-Century America 
(Princeton:  Princeton University Press, 2003), particularly “Chapter Two:  Bargaining for Health:  Private 
Health Insurance and Public Policy,” 46-89; Jeremy Alan Greene, “The Therapeutic Transition:  
Pharmaceuticals and the Marketing of Chronic Disease,” (Ph.D. diss., Harvard University, 2005); and John 
Patrick Swann, “Insulin:  A Case Study in Pharmacomedical Research,” Pharmacy in History 28, 1 (1986):  
3-13. 
160 
 
together:  the rapidly expanding enterprise of federally-funded medical research.
6
  The 
billions of dollars poured into the growth of research from mid-century on created and 
supported new career paths for physicians, built new businesses in the healthcare market, 
and gave new focus to many federal agencies.
7
  The system of grants and committees, of 
departments and centers, and of public policy positions that tapped physician-researchers, 
together played a significant role in the transformation of gestational diabetes because 
they formed a structure that connected medicine, business, and government.
8
   
Chapter VIII details the actual mechanics of how a condition that was once so 
thoroughly believed to be benign was transformed into a disease of such importance that 
every single pregnant woman had to be screened for it.  Physician-researchers utilized the 
power of government structures to frame their concept of gestational diabetes as a serious 
public health threat, even if an indirect one, into a more formally recognized disease 
diagnosis.  The World Health Organization (WHO), an alphabet soup of committees in 
the U.S. Congress, and a host of businesses with ties to legislators, all became part of the 
                                                 
6
 Gerald Grob, “New Wine in New Bottles:  The History of Health Policy,” Reviews in American 
History 15, 3 (September 1987):  365-373; and Charles E. Rosenberg, “Disease and Social Order in 
America:  Perceptions and Expectations,” Milbank Quarterly 64, suppl. 1 (1986):  34-35. 
7
 Daniel M. Fox, “The ‘Milbank Quarterly’ and Health Services Research, 1977-1990,” The 
Milbank Quarterly 69, 2, Health, Society, and the “Milbank Quarterly:”  Essays in Honor of David P. 
Willis’ Editorship (1991):  185-197; A. Hunter Dupree, “The Structure of the Government-University 
Partnership after World War II,” Bulletin of the History of Medicine 39 (1965):  245-251; and George 
Rosen, “Patterns of Health Research in the United States, 1900-1960,” Bulletin of the History of Medicine 
39 (1965):  201-221. 
8
 That triad of connections is referred to as the Medical-Industrial Complex (MIC).  The term 
originated in 1969 in a series of articles.  See Barbara Ehrenreich and John Ehrenreich, “The Medical 
Industrial Complex,” Health PAC Bulletin (November 1969):  1-9; Harold B. Meyers, “The Medical 
Industrial Complex,” Fortune 81 (January 1970):  9; and Barbara Ehrenreich and John Ehrenreich, 
American Health Empire:  Power, Profits, and Politics (New York:  Random House, 1970), 95-123.  For a 
slightly revised definition of the MIC, see Arnold S. Relman, “The New Medical-Industrial Complex,” 
New England Journal of Medicine 303, 17 (October 1980):  963-970.   
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machinery to codify the new diagnostic label.  The disease became the third “official” 
form of diabetes mellitus.  It became a priority item on the list of public health issues to 
be addressed by the National Institute of Child Health and Human Development 
(NICHD).  Several assessment programs in President Johnson’s War on Poverty, like 
Chicago’s Poverty Program, were convinced to list gestational diabetes as a program 
target.  Testing for gestational diabetes became a part of prenatal care covered by 
Medicaid for many newly diagnosed women.  Even though estimates suggested that 
gestational diabetes only affected about 3 percent of pregnancies, physicians and policy 
makers used these channels to push for the implementation of universal screening for the 
disease.   
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CHAPTER VII 
MEDICAL RESEARCH, DIABETIC PREGNANCY, AND DEFINING 
GESTATIONAL DIABETES 
 
In a 1948 article, Boston diabetes physician Priscilla White dismissed the 
significance of a laboratory finding of sugar in the urine of a pregnant woman.  Known at 
the time as glycosuria of pregnancy, the condition could appear suddenly toward the end 
of a woman’s pregnancy and then go away just as quickly after she gave birth.  Although 
glycosuria, or urinary sugar, was diagnostic of diabetes mid-century, White maintained 
that in pregnant women such a finding was not necessarily indicative of diabetes, or even 
of pre-diabetes.  Suggesting instead that pregnancy hormones could alter a woman’s 
kidney function and cause sugar to spill into her urine, White warned her colleagues 
about the “fallacy of basing a diagnosis of diabetes on sugar in the urine [of a pregnant 
woman].”1   
A little over a decade later, in 1960, one of White’s contemporaries wrote about 
the same condition but posited instead that any sign of glycosuria should be considered 
abnormal since “glucose tolerance is not impaired in a completely normal person during 
pregnancy.”2  Much had changed in a decade’s time.  Physicians had known about this
                                                 
1 Mary R. Petkauskos and Priscilla White, “Pregnancy Complicating Diabetes Mellitus,” The 
American Journal of Nursing 48, 5 (May 1948):  301. 
2 William Peter Uprichard Jackson, “Present Status of Prediabetes,” Diabetes 9, 5 (September-
October 1960):  373. 
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particular condition since at least the mid-1800s, but a widespread belief in its transience 
and questionable significance had persisted for a century.3  Why did medical opinion 
change so suddenly in the middle of the twentieth century?  Certainly, a better 
understanding of the physiology of diabetes and pregnancy had contributed.  Moreover, a 
small cadre of physicians and researchers in North America and Europe had been 
studying and writing about the condition for three decades, and kept the medical 
community at large informed of their findings.  But scientific knowledge was not the only 
factor.  The privileging of scientific discovery, or simply of the increased medical 
knowledge it brings, as the main impetus for changes in definitions of diseases has 
obscured the impact of factors like health policy and businesses in the healthcare market 
on transforming our perceptions about health and illness.  To understand how opinion on 
the significance of glycosuria of pregnancy changed so quickly, we must look at the 
institutional structures that have created shifts in the way health and illness are defined in 
public policy and in the healthcare consumer market.   
This chapter suggests that the sudden change in perspective on glycosuria of 
pregnancy was fostered by the large influx of money for medical research in the United 
States that grew out of new connections between medicine, business, and the state – what 
scholars have called the Medical-Industrial Complex (MIC).  In the mid-twentieth 
century, American medicine, a growing healthcare consumer market, and the federal 
                                                 
3 David R.  Hadden, “Diabetes in Pregnancy:  Past, Present, and Future,” Diabetes and Pregnancy:  
An International Approach to Diagnosis and Management, eds. Anne Dornhorst and David R. Hadden 
(New York:  John Wiley & Sons, 1996), 1-10; and idem, “History of Diabetic Pregnancy,” Textbook of 
Diabetes and Pregnancy, eds. Moshe Hod, Lois Jovanovic, Gian Carlo Di Renzo, Alberto de Leiva, and 
Oded Langer (London:  Informa Healthcare, 2003), 2-12. 
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government became intimately connected.  The ways in which those connections 
emerged, and how they have changed and grown, is a subject well-studied, but the history 
of the research industry embedded within the MIC has not been examined quite so well.4   
The condition of glycosuria of pregnancy had certainly not gone completely 
unnoticed in the medical and scientific communities but, until the 1950s, discussions 
about it were largely confined to a few specialized physicians and to a handful of under-
funded laboratories.  In the late 1950s and early 1960s, however, research on diabetic 
pregnancy became absolutely central to a growing diabetes industry, and by corollary, 
scientific interest in the condition of glycosuria of pregnancy grew in tandem.  With this 
new research enterprise, funded and supported by healthcare companies and by the U.S. 
government, physicians and scientists joined forces with businessmen and legislators to 
create fellowships, research centers, and lobbyist positions that brought money and 
attention to the issue of diabetes and pregnancy.  The result was the emergence of a 
massive diabetes research and healthcare industry that created and supported the careers 
of many new doctors and researchers.   
In the second half of the twentieth century, public health policies were 
fundamentally shaped by the research arm of the MIC and were instrumental in reframing 
glycosuria of pregnancy from a condition of low priority into a disease that required 
universal screening for early detection.  While scientific knowledge and technological 
                                                 
4 Harold B. Meyers, “The Medical Industrial Complex,” Fortune 81 (January 1970):  9; Arnold S. 
Relman, “The New Medical-Industrial Complex,” New England Journal of Medicine 303, 17 (October 
1980):  963-970; and Daniel M. Fox, “The ‘Milbank Quarterly’ and Health Services Research, 1977-1990,” 
The Milbank Quarterly 69, 2, Health, Society, and the “Milbank Quarterly”:  Essays in Honor of David P. 
Willis’ Editorship (1991):  185-197. 
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advances had indeed informed physicians’ medical understanding of the condition, it still 
had received limited attention for over a century.  The health outcomes research industry 
linked scientists, clinicians, pharmaceutical representatives, Senators, and Congressmen.  
The new connections allowed for health policy roles to be created for those studying the 
condition; for their research findings to be turned into clinical practice and public 
education; and for proposed initiatives on screening for the condition to be included in 
national preventive health measures.  Throughout the 1960s and 1970s, fiscal support 
from businesses and from government agencies buttressed research efforts in the diabetes 
healthcare market as a whole.  For glycosuria of pregnancy, that resulted in millions of 
dollars backing research grants, underwriting conferences, creating and financing 
investigative centers, and drafting and enacting legislation that helped to turn research on 
diabetes and pregnancy into a measure of national importance.   
Understanding the mechanics of how and why a condition that physicians once 
believed to be benign and insignificant was redefined into a disease that called for the 
systematic screening of all pregnant women in the United States adds a new dimension to 
our understanding of the process that historians of medicine call disease creation.  Several 
recent studies address the role of state policy and of the influence of business on the 
process of disease creation.  For the subset of studies that examine policy and business, 
“healers and sick people [are] seen within the actual context of their interaction (social 
and intellectual).”  But even this small group of scholars has largely continued to view 
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scientific discovery as the guiding principle in defining and “creating” disease.5  
Moreover, their narratives do not recognize the power of medical research in shaping 
those interactions.6  In the case of glycosuria of pregnancy, later called pre-diabetes of 
pregnancy and then renamed gestational diabetes, medical research became an essential 
interface between physicians, policy makers, and businesses.   
The specter of great public cost with diabetes helped to embed the postwar 
emphasis on finding risk factors and early precursors to disease into research on urinary 
sugar and raised blood sugars in pregnant women.  As such, many of the scientists 
working on the condition pushed for state assistance because they believed that 
government agencies should help this group of new patient-consumers by funding 
targeted research.   
While the postwar era in the United States saw reform-minded New Dealers 
broadly retreating from the statist programs that challenged the power of capitalism in the 
                                                 
5 Judith Walzer Leavitt, “Medicine in Context,” American Historical Review 95, 5 (December 
1990):  1473.  For examples of works that incorporate the influence of business and the state, see Jeremy A. 
Greene, Prescribing by Numbers:  Drugs and the Definition of Disease (Baltimore:  The Johns Hopkins 
University Press, 2007); Steven Peitzman, Dropsy, Dialysis, Transplant:  A Short History of Failing 
Kidneys, Biographies of Disease (Baltimore:  Johns Hopkins University Press, 2007); and Leslie J. Reagan, 
Dangerous Pregnancies:  Mothers, Disabilities, and Abortion in Modern America (Berkley:  University of 
California Press, 2010).  Greene examined the role of industry in redefining the asymptomatic states that 
often precede a diagnosis into disease entities themselves; in his work on kidney disease, Steven Peitzman 
explained the creation of the broad category of End Stage Renal Disease in Medicare policies to create a 
channel of access to dialysis treatment; and Reagan examined the legislative work that mandated a 
universal vaccination program for rubella.  
6 Daniel M. Fox, “History and Health Policy: An Autobiographical Note on the Decline of 
Historicism.”  Journal of Social History 18, 3 (Spring 1985):  349-364; M. Jefford, M.R. Stockler, and 
M.H.N. Tattersall, “Outcomes Research:  What is it and Why Does it Matter?” Internal Medicine Journal 
33 (2003):  110-118; and Stephanie J. Lee, Craig C. Earle, and Jane C. Weeks, “Outcomes Research in 
Oncology:  History, Conceptual Framework, and Trends in the Literature,” Journal of the National Cancer 
Institute 92, 3 (Feb 2000):  195-204. 
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U.S. economy, no such retreat took place in the arena of American healthcare.7  In fact, at 
a time when liberals had all but abandoned their efforts at consumer protection through 
the Office of Price Administration (OPA), they began to tackle those very issues in 
clinical research through the Food and Drug Administration’s (FDA) new Kefauver-
Harris Drug Amendments, which required manufacturers to prove a drug’s effectiveness 
before bringing it to market, and through the Consumer Bill of Rights, which proclaimed 
that patient-consumers had basic rights that government was bound to protect such as 
safety and informed decision-making.8     
In the realm of diabetes and pregnancy research, what began mid-century as a 
very small fraction of the federal and industry spending in healthcare would become a 
million dollar engine by the late 1970s.9  In 1950, the total research budget of the NIH 
was approximately fifty-two million dollars, but that allotment grew to over three billion 
                                                 
7 On the postwar retreat from the guiding principles of New Deal liberal reform crusades, see Alan 
Brinkley, The End of Reform:  New Deal Liberalism in Recession and War (New York:  Vintage Books, 
1996).  On the persistence of such reform-minded efforts in the healthcare market, see Daniel M. Fox, 
“History and Health Policy: An Autobiographical Note,” 349-364; and Nancy Tomes, “Merchants of 
Health:  Medicine and Consumer Culture in the United States, 1900-1940,” Journal of American History 
88, 2 (September 2001):  519-547. 
8 For a brief summary of FDA legislation on consumer protection, see 
http://www.fda.gov/AboutFDA/WhatWeDo/History/Milestones/ucm128305.htm (accessed June 29, 2012).  
For a more in-depth summary of the history of the FDA that focuses on the roles of business and research 
in the development of government regulation for this very unique consumer market, see Philip J. Hilts, 
Protecting America’s Health:  The FDA, Business, and One Hundred Years of Regulation (New York:  
Knopf, 2003). 
9 Victoria A. Harden, Inventing the NIH: Federal Biomedical Research Policy, 1887-1937 
(Baltimore: Johns Hopkins University Press, 1986); Stephen P. Strickland, The Story of the NIH Grants 
Program (Lanham, MD:  University Press of America, 1989); Fox, “The ‘Milbank Quarterly’ and Health 
Services Research, 1977-1990,” 186; Nancy Carol Erdey, “Armor of Patience: The National Cancer 
Institute and the Development of Medical Research Policy in the United States, 1937-1971,” (Ph.D. diss., 
Case Western Reserve University, 1995); Lee, et.al., “Outcomes Research in Oncology”; Jefford, et.al., 
“Outcomes Research:  What Is It and Why Does It Matter?”; and Harold Varmus, The Art and Politics of 
Science (New York:  W.W. Norton & Company, 2009), 140-147.  On the research budgets for agencies in 
the NIH, see the appropriations budgets in the NIH Almanac on-line at 
http://www.nih.gov/about/almanac/appropriations/part2.htm (accessed January 1, 2013).   
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dollars by 1979.  Throughout the 1960s and 1970s, research initiatives on diabetes and 
pregnancy in general, and glycosuria of pregnancy specifically, garnered increasing 
federal and private funding that supported – even created – the careers of new physicians 
and researchers.10  By the mid-1970s, the budgets for the new diabetes research and 
training centers, all of which had diabetic pregnancy as a top focus and nearly half 
focused on gestational diabetes, increased research efforts in diabetes alone by another 
forty million dollars.11  Research experience became a key component of physicians’ 
status as experts and allowed them to inform policy decisions and to support the growth 
of investigative initiatives and specialty fields.12  Congressionally-mandated committees 
and legislative work groups followed, and they translated research findings into 
healthcare practices and public education efforts.  Through that process, a condition in 
                                                 
10 Federally funded projects for diabetic pregnancies rarely focused on gestational diabetes 
specifically before 1975, but in the round of funding proposals that went through Congress in 1975, with 
projected completion and publication dates in the 1980s, five of the twelve studies on diabetes and 
pregnancy focused specifically on gestational diabetes; see National Commission on Diabetes, “Report of 
the Workgroup on Pregnancy of the Committee on Scope and Impact,” Report of the National Commission 
on Diabetes to the Congress of the United States, Vol. III, Reports of Committees, Subcommittees, and 
Workgroups, Part 2, Scope and Impact of Diabetes (11), U.S. Department of Health, Education, and 
Welfare, DHEW Publication No. (NIH) 76-1022 (Washington, D.C.:  Government Printing Office, 1976), 
177-258. 
11 Barbara C. Hansen and Marilyn D. Cohn, “Diabetes Research and Training Centers:  Science, 
Application, Training, and Translation,” Diabetes Care 3, 4 (July-August 1980):  548-553; Lois F. Lipsett, 
“Birth of a Clearinghouse,” Diabetes Care 1, 5 (September-October 1978):  308-309; and Miryam Frieder, 
Carolyn M. Hickey, Courtney H. Pieczynski, Amanda Drehobl Llorens, Sara Rubin, and Jon Glaudemans, 
“Case Study:  National Commission on Diabetes,” Focusing Federal Efforts:  A Review of Health-Related 
Offices, Commissions, Panels, and Conferences (Washington, D.C.:  Avalere Health LLC, 2008):  24-25. 
12 Daniel M. Fox, “The ‘Milbank Quarterly’,” 185-197.  Although dated, the discussions by A. 
Hunter Dupree and George Rosen on the postwar collaborations between government agencies and 
university-based researchers explains the origins of the complex network that researchers on diabetic 
pregnancy found themselves in.  See A. Hunter Dupree, “The Structure of the Government-University 
Partnership after World War II,” Bulletin of the History of Medicine 39 (1965):  245-251; and George 
Rosen, “Patterns of Health Research in the United States, 1900-1960,” Bulletin of the History of Medicine 
39 (1965):  201-221. 
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pregnancy that was once believed to be temporary and inconsequential would become a 
central tenet of the prenatal care package of preventive health interventions.13 
 
Building a Research Career 
“I chose internal medicine first and then I was looking at cardiology,” retired 
physician Donald Barnett remembered, “but there were NIH [National Institutes of 
Health] fellowships at the Joslin [Clinic] and when I got down here I realized it was a 
whole new world here because of the NIH.”  Dr. Barnett arrived at the Joslin Diabetes 
Clinic in 1960 and thus began a clinical and research career that would span more than 
four decades and would include work with children, pregnant women, and eventually 
with diabetics who had developed eye complications.14  Diabetic pregnancy very quickly 
became an important focus in the “new world” of medical research that had lured Barnett 
out of his original calling and led him instead into the profession of diabetes research.   
Along with heart disease and cancer, diabetes had become a top target of federal 
research funding.  The actuarial scientists hired by healthcare businesses had also 
impressed upon policy makers the value of identifying chronic disease early – before 
such illnesses could wreak havoc on the economy through missed work days and costly 
medical bills that many patients could not afford.  The risk factor ideology introduced by 
                                                 
13 The Centers for Disease Control maintains annual compilations of demographic trends; the 
National Diabetes Fact Sheets are available at:  http://apps.nccd.cdc.gov/DDTSTRS/FactSheet.aspx.  For a 
discussion of the current and historical understanding of diagnosis rates, see Boyd E. Metzger, “The Global 
Increase in Diabetes: Unique Issues for Mothers and Children,” International Journal of Diabetes in 
Developing Countries 26 (2006):  57-62, online serial, http://www.ijddc.com/text.asp?2006/26/2/57/28274 
(accessed November 4, 2009).  
14 Donald Barnett, interview with author, August 11, 2010, tape in author’s possession. 
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pharmaceutical companies and insurance agencies quickly guided much of the federal 
investment in research.15  
The emergence of a research funding apparatus of such magnitude during the 
postwar years brought attention to diabetic pregnancy when it built an entire new career 
path for many physicians.  The new physician-scientists followed the road paved by 
policy makers through government agencies like the National Institutes of Health (NIH).  
While many of these young physicians had certainly been interested in finding ways to 
improve patient care, a research career in health outcomes was not necessarily how they 
had envisioned that undertaking.  Norbert Freinkel, who would become the director of the 
Diabetes in Pregnancy Center (DPC) at Northwestern University in Chicago, had 
originally started his medical career working on thyroid regulation.16  Dr. Oscar Crofford, 
who became the chairman of the National Commission on Diabetes and the architect and 
principal investigator for the largest diabetes research study ever, the Diabetes 
Complications and Control Trial (DCCT), first began working on cell cultures in a 
pathology and physiology lab.17  Dr. John Hare, a protégé of one of the world’s most 
renowned diabetic pregnancy specialists Priscilla White, went to Chicago to study 
hematology “but the endocrine program was stronger because of Norbie Freinkel’s 
funding.”  After finishing his fellowship at Northwestern University, Hare said, he “went 
                                                 
15 Greene, Prescribing by Numbers; Harden, Inventing the NIH; Strickland, The Story of the NIH 
Grants Program; Jefford, et.al., “Outcomes Research”; and Varmus, The Art and Politics of Science. 
16 Freinkel memoir, 1-4; and Boyd Metzger, interview with author, October 26, 2009, tape in 
author’s possession. 
17 Bill Snyder, “Oscar Crofford:  On the Horns of a Revolution – Oscar Crofford and the 
Landmark Trial that Changed Diabetes Forever,” Lens, A New Way of Looking at Science (July 2003), 
http://www.mc.vanderbilt.edu/lens/article/?id=60&pg=999 (accessed July 27, 2010).   
171 
 
to Joslin because of the NIH pay and was assigned to pregnancy with Priscilla White.”18  
The funding opportunities that opened up in the 1960s and 1970s shaped obstetrician and 
diabetic pregnancy researcher Donald Coustan’s career as well.  He was recruited to 
Brown University in Providence, Rhode Island because “Brown had one of those diabetes 
center grants and was losing it because they didn’t have an obstetrician that was involved 
… and we got the center grant renewed after that.”19   
Examining how one researcher’s career took shape in the area of diabetic 
pregnancy illuminates the enormous impact of the rapid rise in government funding of 
medical research during this era.  Norbert Freinkel would become the key figure during 
the 1970s in redefining the temporary condition of glycosuria, or pre-diabetes, of 
pregnancy into the disease gestational diabetes.  The enormous growth of funding in 
medical research on diabetic pregnancy played a significant role in guiding his career in 
that direction.   
Freinkel’s academic profession in diabetic pregnancy research, and his influence 
with legislators and business interests in that realm, coalesced with his position as 
Director of the Diabetes in Pregnancy Center (DPC) at Northwestern University, but his 
road to Chicago began in the 1950s at the Boston City Hospital.20  While his colleague in 
Boston, John O’Sullivan, began the ten-year-long “Boston Study” on blood sugar profiles 
in the low-income, pregnant women who presented for care at the inner-city clinic there, 
Freinkel arrived to pursue a new career path that would take him into the world of 
                                                 
18 John Hare, interview with author, August 11, 2010, tape in author’s possession. 
19 Donald R. Coustan, interview with author, August 12, 2010, tape in author’s possession. 
20 Freinkel memoir, 12. 
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research on diabetic pregnancy metabolism.  In October 1952, he began a research 
position at the Thorndike Memorial Laboratory of Boston City Hospital on a $2,000 per 
year stipend that was funded through the Massachusetts State Department of Health and, 
later, through the Children’s Bureau of the U.S. Department of Health, Education, and 
Welfare.21  
Max Finland, a prominent scientist who was also a member of the advisory board 
of the National Academy of Sciences, recruited Freinkel to the Thorndike from Walter 
Reed Army Medical Center in Washington, D.C.  During the postwar years, the Academy 
was one of several institutions that were instrumental in maintaining collaborative 
connections established during World War II between American government agencies 
and academic research groups.  Those connections had originated through the funding of 
an American-based network of scientific research, a network which had been needed to 
replace German knowledge bases lost with the war.  In addition, U.S. policy makers had 
allocated wartime funds to enhance the American effort in biological and chemical 
warfare and were not ready to cease that initiative with the nominal end of the war.22  
                                                 
21 Freinkel memoir, 3.  Also, on the source of funding for the Thorndike Laboratory, see Hugh 
L.C. Wilkerson, “Maternal Pre-diabetes and Outcome of Pregnancy – A Preliminary Report,” American 
Journal of Public Health 49, 8 (August 1959):  1034.  
22 The American Chemical Society (ACS) also sought to preserve the connections made during the 
war by seeking increased government funding for research, by creating a partnership between the chemistry 
industry and the nascent medical research community, and by fostering relationships with businesses in the 
new and rapidly expanding pharmaceutical industry.  The ACS wrote a report for Congress titled, “The 
Future Independence and Progress of American Medicine in the Age of Chemistry.”  The report suggested 
that medical research in the United States was falling short because of a lack of funding for collaborative 
efforts.  For a summary of the report, see Van Buren Thorne, “Chemistry’s New War on Disease:  
Important Report on Need of Intensive Research in Co-operation with Medicine and Other Sciences,” New 
York Times, 19 February 1922, 89.  On the influence of German science centers on American endeavors in 
the early twentieth century, including the development of city infrastructures like sanitary sewer and the 
creation of research groups of chemists and physicians, see Paul Starr, The Social Transformation of 
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Freinkel was quite aware of the sources of his research funding at Walter Reed, 
occasionally joking that although his position was deemed medical work on kidney 
functioning and thyroid physiology, it was really to determine “where to duck and with 
whom ‘when they drop the Big One.’”23  
In 1956, the allocation of federal funds created a new division at the Thorndike – 
the Diabetes and Metabolism Division – and Freinkel was recruited to be the director.  
The funding for new researchers at the Thorndike came from a mixed bag of federal 
money that emerged with the creation of the Office of Research Grants within the NIH.  
Senator Lister Hill and Congressman John Fogarty, through their roles in appropriations 
sub-committees, helped to initiate and then increase the funding of projects within centers 
like the Thorndike Lab from eighty grants totaling about $780,000 in 1946 to 2,000 
funded grants totaling over twenty million dollars by 1953.24   
The funding of researcher-initiated grants and of collaborative centers that 
focused on specific diseases was an innovative step in the 1950s, and the Diabetes and 
Metabolism Division of the Thorndike Memorial Laboratory became a model for 
                                                                                                                                                 
American Medicine:  The Rise of a Sovereign Profession and the Making of a Vast Industry (New York:  
Basic Books, 1982), 338-344; and Daniel T. Rodgers, Atlantic Crossings:  Social Politics in a Progressive 
Age (Cambridge:  Harvard University Press, 2000), 209-266.  In his discussion on Workingman’s 
Insurance, Rodgers touched on medical/science networks and health insurance, and he explained that U.S. 
reformers often modeled their programs after the German “subsidarist” systems where the state subsidized 
local and voluntary organization programs, such as city planning, utilities construction, and workmen’s 
insurance.   
23 Freinkel memoir, 1; and Metzger interview.  
24 Ernest M. Allen, “Early Years of NIH Research Grants,” NIH Alumni Association Newsletter 2, 
2 (April 1980):  6-8. 
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programs to follow.25  The establishment of the program at Boston City Hospital, 
however, was not the result of objective evaluations of patients’ needs, nor even of 
community-based assessments.  Rather, an influential network of people brought in one 
of the first NIH training grants in diabetes through their connections to businesses and 
policy makers.  As one researcher explained, “There were a few congressman who had 
diabetes or who had people in their family with diabetes who pushed the NIH, and they 
convened this congressional task force which came up with goals for funding and areas to 
investigate for the next five or ten years, and that’s how stuff got accomplished in 
Washington.”26  One of Freinkel’s colleagues – David Hurwitz – had just started a 
diabetes clinic at Boston City Hospital.  For the sake of convenience in the busy schedule 
of a physician-researcher, Hurwitz began bringing his private patients in to the clinic at 
Boston City, many of whom were important figures in state and national politics, 
including the Lieutenant Governor of Massachusetts and several other wealthy clients.27  
                                                 
25 Fox, “History and Health Policy,” 350.  In a unique role as a historian and a health policy 
advisor, Daniel Fox explains that in looking at the rise of influence of health outcomes research during this 
period, historians continue to focus on the failure of compulsory health insurance.  But, Fox suggests that 
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26 Coustan interview.  Also, former Director of the NIH Harold Varmus has said that advocates for 
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for raising their mentally handicapped child at home in Massachusetts rather than seeking 
institutionalization for the child, which was quite a departure from the norm in the 1940s and 1950s.  See 
The Jewish Western Bulletin, 60, 44 (25 November 1993):  1-2 
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More the norm than the exception, connections often grew out of these casual and 
familiar links.   
Businesses in the diabetes marketplace also assisted with the creation and 
expansion of research programs and the funding of salaries for scientists at the Boston 
City Hospital.  With the development in the 1950s of oral hypoglycemic agents (pills for 
treating Type 2 diabetes), pharmaceutical companies expressed interest in supporting 
these new research centers as well because of the marketing opportunities that such 
tangible support could open up.  By the end of the 1950s, in fact, Medical Director Hugh 
Wilkerson had gained substantial “material assistance” for the research programs at 
Boston City Hospital from several big pharmaceutical firms such as the Ames Chemical 
Company, Eli Lilly and Company, and E.R. Squibb and Sons.28  Businesses like Ames, 
which developed test strips for the new devices being used to measure blood sugars, and 
both Lilly and Squibb, which produced insulin and diabetes pills, offered financial 
support in direct and indirect ways.  Sometimes funds came through the sanctioned and 
visible sponsorship of salaries for research assistants, support for conferences, or with 
small, focused research grants.  Company representatives often supported research 
centers in less visible ways as well, with the creation of on-site libraries or by supplying 
pharmaceutical samples and trial devices.29   
                                                 
28 Freinkel memoir, 6-8; and Wilkerson, “Maternal Prediabetes,” 1040. 
29 Coustan interview; and Metzger interview.  The supplying of “samples” and of non-monetary 
gifts by pharmaceutical sales representatives is strictly forbidden today, but was a common practice until 
the 1990s.  The Prescription Drug Marketing Act was enacted in 1987 and amended in 1992 to restrict the 
distribution of “gifts” by drug sales representatives.  For more information on the legislative history, see 
U.S. Department of Health and Human Services, Food and Drug Administration, Guidance for Industry:  
Prescription Drug Marketing Act (PDMA) Requirements, Questions and Answers (Rockville, MD:  Food 
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The Diabetes in Pregnancy Center at Northwestern University 
In 1966, Freinkel left his position as Director of the Diabetes and Metabolism 
Division at the Boston City Hospital to become the Chief of Endocrinology and 
Metabolism at Northwestern University in Chicago.  He brought with him to Chicago the 
knowledge of how to gain substantial funding for research and the connections to make it 
happen.  During his tenure at Northwestern, Freinkel would connect diabetes physicians 
and scientists in the field to other medical professionals, to businesses in the diabetes 
market, and to legislators who controlled healthcare financing.  In addition, Freinkel 
worked to make research results and developments in treatment strategies from 
Northwestern accessible to broad sectors of society:  areas of the medical community, 
government officials, popular media, patients, and the lay public.30   
Freinkel and his colleagues at Northwestern began a practice of “translating” their 
research findings into information and education for legislators and for the general public 
and, eventually, into clinical practice recommendations for women facing urinary sugar, 
or raised blood sugars, during pregnancy.  Although today we have become accustomed 
to popular media reports on how research advances have given us better healthcare 
services or improved medications, in the 1960s and even into the 1970s it was a novel 
concept for researchers to publicize that work.  That the Northwestern University 
researchers broke new ground with their efforts would become apparent during the 1970s 
                                                                                                                                                 
and Drug Administration, 2006), 
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM13439
9.pdf (accessed October 20, 2012). 
30 Freinkel memoir; Metzger interview; and Charles M. Clark, Jr., “President’s Address,” Diabetes 
38, 12 (December 1989):  1506-1507. 
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when their research findings were written into legislative acts like the 1974 Diabetes 
Research and Education Act and the 1979 reorganization of the World Health 
Organization’s classification rubric for diabetes.   
During the 1960s and 1970s, researchers at institutions like the Diabetes in 
Pregnancy Center (DPC) at Northwestern University in Chicago gained incredible 
influence in shaping public health policy.  The rapid growth in federal support for 
medical research built the DPC at Northwestern out of the Division of Endocrinology and 
Metabolism and allowed the center to become a driving force in formulating policies on 
pregnancy in diabetic and pre-diabetic women.  The connections to legislators that came 
with the funding of the DPC placed investigators like Norbert Freinkel on congressional 
planning committees, on task forces within federal agencies like the NIH, and on data 
review boards that made decisions on prioritizing the dispersal of federal money for 
medical research.     
Such connections allowed for greater sway with issues relating to diabetes and 
pregnancy, and such links were essential for reframing the condition of pre-diabetes of 
pregnancy into the disease gestational diabetes.  But these connections were not 
established in a social vacuum.  The climate of rising expectations for the promise of 
medical research developed alongside efforts to improve the state of healthcare in general 
and, more specifically, to combat the fear of a chronic disease epidemic in the United 
States.31  As part of what scholars have called the professionalization of American 
                                                 
31 The hallmark event in the “epidemiological transition” from infectious agents to chronic illness 
was the Framingham Study, which was designed to understand the “modern epidemic” of heart disease.  
See Thomas R. Dawber, Gilcin F. Meadors, and Felix Moore, “Epidemiological Approaches to Heart 
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medicine, the bevy of federally-funded initiatives to contain communicable disease had 
also helped to create the foundation for medical research on chronic diseases like 
diabetes.32  Three major federal efforts that set the groundwork had come in quick 
succession:  the Hill-Burton Act in 1945, the formation of the Center for Disease Control 
in 1946, and the expansion of the National Institutes of Health in 1948.  Hill-Burton 
poured millions of federal dollars into building a national hospital system that answered 
to government entities, which essentially wrested control of healthcare from voluntary 
organizations and local municipalities.  With urging from the American Medical 
Association (AMA), Surgeon General Thomas Parron then expanded the scope of Hill-
Burton by transforming the old Malaria Control in War Areas office and the venereal 
disease programs of the U.S. Public Health Service into the Center for Disease Control 
(CDC) in Atlanta and by giving the new agency a regulatory role over medical research.  
Over the next two years, the still relatively new National Institute of Health (NIH) was 
incorporated into the growing public health infrastructure and, by 1948, Congress 
mandated control of three major research institutes, and their private and state funds, into 
the umbrella of the NIH.33   
                                                                                                                                                 
Disease:  The Framingham Study,” American Journal of Public Health 41 (1951):  279-286; and Thomas 
R. Dawber, Felix Moore, and George V. Mann, “Coronary Heart Disease in the Framingham Study,” 
American Journal of Public Health 47 (1957):  3-24.  For a discussion of the shift in the ideological 
approach in medicine, see Abdul R. Omran, “The Epidemiological Transition:  A Theory of the 
Epidemiology of Population Change,” Millbank Quarterly 49, 4 (1971):  509-538.  
32 On federal funding for public health efforts to contain infectious diseases, see Starr, The Social 
Transformation of American Medicine, 145-179.     
33 For more detail on the birth of federal venues for research dollars and on the creation of 
federally-funded and federally-controlled medical facilities, see John Duffy, The Sanitarians:  A History of 
American Public Health (Chicago:  University of Illinois Press, 1990), 239-272; and Starr, The Social 
Transformation of American Medicine, 338-351 and 375-378.  At the same time, the International Health 
Conference was held in New York during the summer of 1946.  American physicians and policy makers 
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Those federal initiatives generated a significant level of financial support that 
would allow physicians to embrace the role of researcher.  Diabetes was one of the main 
targets in those first federally supported research grants, just as it had been with the 
private, philanthropic agencies like the Rockefeller Institute and the Duke Endowment.  
Also among those top targets were heart disease and cancer because those three had 
become the leading causes of death in postwar America, when infectious diseases were 
significantly ameliorated through antibiotics, vaccinations, and sanitary practices.34   
A growing belief in the power of medicine, and in the research that bolstered it, 
led to federal appropriations for many new programs and initiatives in diabetes care. 
Widespread public concerns about the rising numbers of “hidden” diabetics converged 
with the growing belief in medicine and research as the solution to all sorts of public 
health issues.35   By mid-century, Congress had endowed the U.S. Public Health Service 
with the budget and authority to fashion specific grants for medical research and 
education on a range of diabetes issues.36   
                                                                                                                                                 
proposed that the newly formed World Health Organization (WHO) be entrusted with the revision of 
international lists of causes of death and that they draft a list that would also track morbidity (or illness), 
essentially giving WHO the power to define patients.  See World Health Organization, Official Record of 
the World Health Organization (Geneva:  World Health Organization, 1948), parts 2, 11, 23, and 110, 
http://www.who.int/library/collections/historical/en/index3.html (accessed July 2, 2010).  On the idea that 
potential disruptions in commerce have made public health issues like communicable diseases a federal 
priority and, hence, have shaped policy, see Margaret Humphreys, Yellow Fever and the South (Baltimore:  
Johns Hopkins University Press, 1992).   
34 Greene, Prescribing by Numbers, 1-17; and Daniel M. Fox, “The Public Health Service and the 
Nation’s Health Care in the Post-World War II Era,” Public Health Reports 109, 6 (November-December 
1994):  725-727. 
35 The Public Health Service Act of 1944 resulted in one of the first in a string of larger 
government commitments to funding medical research, and it designated medical research as a major 
priority in national policy.  See Starr, The Social Transformation of American Medicine, 342-344. 
36 In the 1940s, the American Diabetes Association teamed up with the American Medical 
Association to implement a program to detect the suspected mass of people who had the mild form of 
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Along with those early moves toward the creation of federal research budgets, 
physician groups like the American Medical Association (AMA) and the American 
Diabetes Association (ADA) introduced national campaigns to combat the effects of 
chronic disease by trying to identify debilitating illnesses before the diseases could take a 
toll on individuals and on the U.S. economy as well.37  However, those programs did not 
always turn out the way that the enthusiastic proponents of risk factor identification 
hoped for.  In 1963, for example, the Diabetes Association of Greater Cleveland (DAGC) 
implemented a program endorsed by both the AMA and the ADA to identify the “million 
hidden diabetics” in the United States.38  By the mid-1970s, that program would result in 
the DAGC having screened over six hundred thousand people for diabetes by setting up 
booths in shopping malls, sites at businesses, and testing centers at community events 
throughout the Greater Cleveland area.39  However, even before the project in Cleveland 
was scrapped in the 1970s, it had been deemed a failure.  The costs had overwhelmed the 
                                                                                                                                                 
diabetes but did not know it because they were not having health problems severe enough yet to send them 
to a doctor’s office.  Suspicions on the large numbers of people with undiagnosed, and therefore untreated, 
diabetes was a result of the landmark Oxford Study that had found nearly twice as many people with lab 
tests conclusive of diabetes than the number of people reporting that they had diabetes.  See American 
Diabetes Association, The Journey and the Dream:  A History of the American Diabetes Association 
(Indianapolis:  American Diabetes Association, 1990), 40-44. 
37 The ADA began in 1941 as a strictly professional organization open only to physicians but 
began to allow other medical professionals such as nurses and nutritionists to join the organization during 
the 1960s.  In 1970, ADA members voted to restructure the organization’s constitution to change it into a 
voluntary organization open to the public that was primarily concerned with funding research, detection 
drives, and education.  See Journey and the Dream, 151-160. 
38 Irwin R. Merkatz, Method A. Duchon, Toyoko S. Yamashita, and Harold H. Houser, “A Pilot 
Community-Based Screening Program for Gestational Diabetes,” Diabetes Care 3, 3 (May-June 1980):  
453-457.  On the search for the “million hidden diabetics,” see Journey and the Dream, 40-44; “The Hunt 
for Hidden Diabetics,” The Saturday Evening Post, 6 December 1958, 20; Paul de Kruiff, “A Million 
Hidden Diabetics,” Today’s Health 36, 11 (November 1958):  22; and John B. O’Sullivan, Hugh L.C. 
Wilkerson, and Leo P. Krall, “The Prevalence of Diabetes Mellitus in Oxford and Related Epidemiological 
Problems,” American Journal of Public Health 56, 5 (May 1956):  742-754. 
39 Merkatz, et.al. “Screening Program,” 454.  
181 
 
DGAC and the local city council.  Moreover, any analyses on data amassed from the 
efforts to identify Greater Cleveland’s “hidden diabetics” created heated debates.  Local 
physicians often dismissed the diagnostic results in their patients that had been obtained 
from the screening drives.  They argued over whether the screening was done correctly 
and belied what they saw as arbitrary recommendations from outsiders for medications 
for their asymptomatic patients.40   
The fallout from failed programs like the DGAC would spill over into other 
initiatives.  Almost a decade later, because of the history of controversy over the mass 
screening events by the DAGC, a group of obstetricians working in a low-income, inner-
city clinic in East Cleveland would recommend smaller-scale, targeted, “discriminate 
screening” for raised blood sugars in the pregnant women at their clinic.  Because of the 
financial fiasco from those earlier screening efforts, and the bureaucratic arguments that 
erupted, the obstetrical group would suggest focused screening on specific at-risk women 
to find “a compromise between specificity and sensitivity in order to provide maximum 
clinical utility and cost effectiveness.”41  Debates like the one at the inner-city clinic in 
Cleveland, Ohio were not unique, and they had emerged from the same climate within 
which research centers like the DPC at Northwestern struggled to operate during the 
1960s.  Such arguments reflected the serious fiscal challenges and the delicate nature of 
                                                 
40 Harold B. Houser, Wilma Mackay, Narendra Verma, and Saul M. Genuth, “A Three Year 
Controlled Follow-Up Study of Persons Identified in a Mass Screening Program for Diabetes,” Diabetes 
26, 7 (July 1977):  619-627; and Saul M. Genuth, Harold B. Houser, James R. Carter, Jr., Irwin R. Merkatz, 
J. Wade Price, O. Peter  Schumacher, and Ralph G. Wieland, “Observations on the Value of Mass 
Indiscriminate Screening for Diabetes Mellitus Based on a Five Year Follow-Up,” Diabetes 27 (April 
1978):  377-383. 
41 Merkatz, et.al. “Screening Program,” 456. 
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political collaborations faced by physicians starting their new careers in research on 
diabetic pregnancy.   
In that complex social, political, and scientific environment surrounding diabetes 
and diabetic pregnancy, Norbert Freinkel arrived at Northwestern.  Freinkel became 
Director of the new Diabetes in Pregnancy Center on the heels of the creation of the 
National Institute of Child Health and Human Development (NICHD) by President 
Kennedy.  Under Freinkel’s direction, the new center at Northwestern secured one of four 
initial grants from the NICHD, which had been slated to create Major Research Programs 
(MRPs) across the country.  And the recruitment of a highly respected young researcher 
in diabetic pregnancy metabolism became, of course, instrumental in securing 
Northwestern University’s designation as a Major Research Program of the NICHD.42   
The first four MRPs were specifically entrusted with combatting the high infant 
mortality and morbidity seen in diabetic pregnancies by educating pregnant women on 
the need for good diet, exercise, and regular doctor visits.  The President’s sister, Eunice 
Kennedy Shriver, and her politician husband, Robert Sargent Shriver, were instrumental 
in the creation of the NICHD and, more important, in the substantial research funding 
that the agency would garner for investigating birth defects.  That focus meshed well with 
Freinkel’s research work and with the connections he had cultivated before coming to 
Chicago.  The other three programs were established at Cleveland Metropolitan Hospital, 
                                                 
42 Metzger interview; and Barbara C. Hansen and Marilyn D. Cohn, “Diabetes Research and 
Training Centers:  Science, Application, Training, and Translation,” Diabetes Care 3, 4 (July-August 
1980):  548. 
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the University of New Mexico in Albuquerque, and Brown University in Providence, 
Rhode Island.43   
The complex set of variables that brought the MRP to Northwestern illustrates 
how the glycosuria and transient high blood sugars seen in pre-diabetes of pregnancy, or 
as some researchers were starting to call it by then gestational diabetes, were becoming 
viewed as something more than simply a temporary condition.44  American investigators 
had originally studied the condition as an indicator of potential risk for the pregnant 
woman to develop diabetes later in life, but by the 1960s that line of research had begun 
to merge with European investigations that focused instead on the impact of raised blood 
sugars for the fetus in those pregnancies.  The funding protocols for the MRPs connected 
both research foci by emphasizing the impact of a pregnant woman’s health behaviors on 
the fetus.  The MRP protocols required researchers to use their findings to design and 
                                                 
43 Hansen and Cohn, “Diabetes Research and Training Centers”; and The National Commission on 
Diabetes, “Long Range Plan to Combat Diabetes,” U.S. Department of Health, Education and Welfare, 
DHEW publication no. (NIH) 76-1018-1024, 76-1031-1033, and 77-1229.  These reports do not contain the 
agency budgets but the creation of the National Commission on Diabetes and the authority for the NCD to 
set research budgets came out of the National Diabetes Research and Education Act of 1974, PL 93-354.  
The National Commission on Diabetes was the brainchild of Lee Ducat, a Pennsylvania mother who had a 
son with diabetes, and Senator Richard Schweiker (R-PA), an influential friend of Ducat’s.   
44 Two European researchers, Joseph Hoet and Jorgen Pedersen, are both credited with introducing 
a new name for the condition:  metagestational diabetes.  Pedersen is said to have eventually shortened the 
term to gestational diabetes.  It is difficult to tell who coined the term “metagestational diabetes” first and 
exactly when it came into use.  It is entirely possible that Jorgen Pedersen began using the term gestational 
diabetes before Hoet coined the term metagestational diabetes.  In several short historical synopses in 
medical textbooks, two articles by J.P. Hoet are usually referenced, but instead of using the exact term, 
both of Hoet’s articles mention metagestational influences or factors and he uses the term diabetes in 
discussing the condition in pregnancy.  Confounding the problem is that both researchers wrote in at least 
three different languages each.  The references in textbooks, though, seem to have taken on a life of their 
own and became the standard citation.  See, Joseph P. Hoet, “Carbohydrate Metabolism in Pregnancy,” 
Diabetes 3 (1954):  1-12 and Joseph P. Hoet, J.J. Hoet, and A. Gommers, “Endocrine Disturbances of 
Pregnancy and Foetal Pathology,” Proceedings of the Royal Society of Medicine 52, 10 (October, 1959):  
813-816.  It seems that the article in which the words were combined and the term was used was an article 
by Hoet’s physician son.  See J.J. Hoet, “Le Diabete de la Gestation,” Bulletin et Memoires de l’Acadamie 
Royale de Medecine de Belgique 7 (1969):  118. 
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implement educational programs to teach women good health behaviors that could 
protect the health of their unborn babies.45   
At the same time that Freinkel was pursuing the MRP funding, Northwestern 
University had also begun to establish a new link to maternal and infant welfare programs 
among indigent clients in the Chicago area.  Presaging the allocation of MRP funding, 
but aligning with the intention of NICHD protocols, the dean of the Medical School at 
Northwestern, Richard Young, sent a letter to the coordinator of a congressional study on 
indigent health care in urban centers, expressing the medical center’s interest in 
participating in the proposed “Poverty Program” in Chicago.  The program was part of 
President Johnson’s “War on Poverty,” funded and coordinated by the new Office of 
Economic Opportunity (OEO).46  The Chicago Board of Health had just completed a 
large-scale study on health problems in the low-income neighborhoods in and around 
Chicago and had submitted their report to the OEO.  The report noted that zero percent of 
pregnant, indigent clients were seen for care at Northwestern University, and as part of 
their proposal to develop a medical program for Chicago’s low-income residents, the 
Board recommended that a new center for healthcare and research should be “attached to 
or affiliated with a medical school, teaching hospital, [and] community hospital.”  The 
Board of Health did not specifically name Northwestern in their recommendations, but 
Northwestern University’s medical center was the only institution in Chicago that fit that 
description:  healthcare and research, teaching hospital, and medical school.  The 
                                                 
45 Hansen and Cohn, “Diabetes Research and Training Centers.” 
46 Richard H. Young, MD to Dr. Mark Lepper, October 12, 1965, letter in files of Dr. Boyd 
Metzger, Feinberg School of Medicine, Northwestern University. 
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proposal specifically requested funding both for the “support of the infant welfare and 
prenatal clinics” as well as for high caliber research to guide medical care in diabetes and 
pregnancy.47   
Compatible funding for research on diabetic and pre-diabetic pregnancies, and on 
healthcare for indigent pregnant women, greatly expanded the work of Freinkel’s group 
at Northwestern.  Such complementary funding, like the grant support from the OEO and 
the monies from the NICHD, resulted in an impressive amount of fiscal support for 
research on diabetes and pregnancy at Northwestern’s Diabetes in Pregnancy Center.  By 
the time that the NIHCD issued its first annual report to the Director’s Office of the NIH, 
the Diabetes Mellitus Coordinating Committee (the precursor to the congressionally-
mandated National Commission on Diabetes) listed eighteen federal grants through the 
NICHD that focused specifically on issues of diabetic pregnancies and that totaled over 
three-quarters of a million dollars for the fiscal year.48  The funded projects focused on 
“diabetes in pregnancy and the influence of this disorder on the mother, the fetus and the 
newborn, and with the influence of age on carbohydrate metabolism.”  The addition of 
                                                 
47 Chicago Board of Health, “Preliminary Report on Patterns of Medical and Health Care in 
Poverty Areas of Chicago and Proposed Health Programs for the Medically Indigent,” Chicago, July 1965, 
copy available from Records of the Southern Christian Leadership Conference, 1954-1970, Part 2:  Records 
of the Executive Director and Treasurer, Subgroup II, Executive Director, Series IV, Andrew Young, 
Subseries 3, Administrative Files, http://web.lexis-nexis.com/histvault?q=001565-011-0174 (accessed 
February 22, 2012).  On the utilization of health services by indigent patients, see Table 8 (no page number, 
inserted between pp. 46-47); on the proposal for health care delivery to indigent populations, see pp. 150-
151.  I have to thank Dr. Tom Jackson for alerting me to the online archive of SCLC documents that led to 
finding the report from the Chicago Board of Health, which I knew existed but for which it seemed that no 
copy had survived.  The report included a copy of the letter in Dr. Boyd Metzger’s files from Dean Young 
of Northwestern University, confirming that the letter indeed referred to the Poverty Program under 
Johnson’s War on Poverty and that the report referenced in the letter indeed existed. 
48 Diabetes Mellitus Coordinating Committee, “First Annual Report to the Director of the National 
Institutes of Health, Fiscal Year 1974, DHEW Publication No. (NIH) 76-1017, 172-174. 
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“carbohydrate metabolism” to the research agenda was a direct nod to the condition of 
pre-diabetes of pregnancy, as that was language used specifically in medical discussions 
about the condition.49   
 
The National Diabetes Research and Education Act  
As much as the resources of President Kennedy’s National Institute of Child 
Health and Human Development (NICHD), Johnson’s War on Poverty programs, the 
grants from the Office of Economic Opportunity (OEO), and the fiscal support from 
diabetes healthcare companies like Ames, Squibb, and Eli Lilly helped to support and 
expand Northwestern University’s DPC, researchers there still faced the problem of 
turning their findings into recommendations for clinical practice.  Increased scientific 
knowledge and technological advances could not alone change the therapeutic approach 
to the condition known variously as glycosuria of pregnancy or pre-diabetes of 
pregnancy.   
In the mid-1970s, one of the most far-reaching pieces of legislation for diabetes 
research ever would open a channel for researchers in diabetic and pre-diabetic 
pregnancies to affect the clinical approach to such pregnancies by substantially increasing 
the financial support of their work – through individual grants and through the creation of 
collaborative research centers – and by bringing researchers into health policy roles in 
congressional committees.  In one of his last actions as President of the United States, 
Richard Nixon signed into law the National Diabetes Mellitus Research and Education 
                                                 
49 Ibid., 172. 
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Act (DRE Act) on July 23, 1974.  Nearly glossed over due to the enormous amount of 
time spent on the energy crisis that session, the vote came at the last hour but passed 
overwhelmingly.  President Nixon resigned two weeks later.  The law codified the 
National Commission on Diabetes, created the National Diabetes Data Group (NDDG), 
specified that the Commission and the NDDG would report directly to Congress, and 
mandated the creation and federal support of research centers with $40 million of 
financing through several NIH institutes as well as with continued financing through the 
NICHD.  The NICHD was, of course, already a major funding agency for the MRP at 
Northwestern and an important liaison agency for Chicago’s Poverty Program.  Under the 
DRE Act, though, the budgets at places like Northwestern expanded tremendously and 
fell under the management of the House and Senate Committees on Appropriations, as 
well as the Committee on Labor and Public Welfare of the Senate and the Committee on 
Interstate and Foreign Commerce of the House.  The connections were elaborate and the 
funding scheme was complex because diabetes and pregnancy research initiatives had 
developed piecemeal within the intricate web of ties connecting medicine, business, and 
government.50 
The 1974 DRE Act created a substantial source of research funding and built a 
firm foundation for the DPC at Northwestern to translate research on pre-diabetic 
pregnancies into medical interventions.  Less recognized, however, was how the DRE 
Act embedded the interest of the state in matters of diabetic pregnancy.  The creation of 
                                                 
50 National Diabetes Mellitus Research and Education Act, 1974, Pub. L. No. 93-354, 93rd 
Congress (July 24, 1974).  On the amounts of financing and for a very brief chronology of committee 
reports, congressional votes, and actions of sponsors and co-sponsors of the bill, see American Diabetes 
Association, Journey and the Dream, 160-167. 
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committee roles for health services researchers with the National Commission on 
Diabetes and of lobbyist roles inside the House and Senate Committees on 
Appropriations had finally opened a channel for prominent researchers like Norbert 
Freinkel to advise government officials on healthcare policy.  The process that Freinkel 
would follow to turn medical research findings into clinical practice for pre-diabetes of 
pregnancy had been written into the structure of government agencies.  As spelled out by 
more than half of the text of the DRE Act, the function of the National Commission on 
Diabetes was controlled by Congress, but its committee members also gained advisory 
roles in subcommittees within the Senate Committee on Labor and Public Welfare and 
the House Committee on Interstate and Foreign Commerce.  Research needed to be 
translated into healthcare practices and with the DRE Act that process of translation 
would go through the United States Senate and the House of Representatives.51   
The channels for researchers created by the DRE Act were actually foreshadowed 
in the flurry of near-frantic activities that led up to the passage of the bill.  In March of 
1974, for instance, a private memo circulated at the Joslin Diabetes Clinic about the 
possibility of increased money for diabetes research through a congressional bill that was 
in jeopardy of being buried in a “political graveyard.”52  The memo discussed the 
proposed bill “calling for the expenditure of a considerable amount of funds for research 
and related activities [concerning diabetes]” and noted that one of the bill’s sponsors, 
Congressman William A. Steiger, was a member of the Board of Directors at the Joslin 
                                                 
51 National Diabetes Mellitus Research and Education Act, 1974, Pub. L. No. 93-354, 93rd 
Congress (July 24, 1974), Section 3.  
52 American Diabetes Association, Journey and the Dream, 162. 
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Diabetes Foundation.  The memo was typed on a small note-sized piece of paper with the 
list of individuals who were to read it, check their name, and pass it on privately to the 
next person on the list.  Although Congressman Steiger was on the Board of Directors, 
his name was conveniently left off of the memo’s circulation list.53   
Those types of information chains, formal and informal, existed in places like 
Northwestern as well, evidenced by the bevy of letters sent to Congress from researchers 
in support of the proposed bill.  The DPC faculty from Northwestern sent letters to 
Congress in order to call attention to their research priorities.  In 1974, Dr. Boyd 
Metzger, who had joined Norbert Freinkel at Northwestern, wrote “to lend support to the 
Diabetes Commission in formulating recommendations to Congress.”  His letter 
delineated the current research progress at Northwestern.  Metzger stressed the 
importance of the research program at Northwestern for connecting their research and 
medical interventions to the prevention of birth defects by asking, “Can quality of 
diabetic control be implicated here?”  And, when he connected gestationally diabetic 
pregnancies to “congenital anomalies,” he engaged legislators who had so strongly 
supported the goals of Eunice Kennedy Shriver’s work in the NIHCD by using familiar 
language.  Because of the work of the NIHCD on such public health issues as the 
thalidomide scare and the vaccination program for rubella, the linking of “congenital 
anomalies” with “diabetic control” had a resounding impact.54 
                                                 
53 Richard L. Dowling, Ph.D. to Members of the Youth Committee, “Congressional Legislation” 
March 22, 1974, Carton 1, Folder 25, Priscilla White Papers, Schlesinger Library.   
54 Dr. Boyd Metzger to The National Commission on Diabetes, undated, in “The Long-Range Plan 
to Combat Diabetes,” Report of the National Commission on Diabetes to the Congress of the United States, 
vol. 1, DHEW Publication No. (NIH) 76-1018, 23-26, quotes on pages 23, 25, and 26 respectively.  On the 
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Figure 6.  Section 1 of the National Diabetes Mellitus Research and 
Education Act, PL 93-354, signed into law on July 23, 1974. 
                                                                                                                                                 
work of agencies like the NIHCD on creating a mandatory, universal vaccination program for rubella, or 
German measles, see Reagan, Dangerous Pregnancies. 
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 Immediately following the passage of the Diabetes Research and Education Act, 
Freinkel and his colleagues at Northwestern applied to become one of the new Diabetes 
Research and Training Centers (DRTC) mandated by the legislation.  The program at 
Northwestern was not converted to a DRTC in that first round of funding, but a 
collaborator of Freinkel, Arthur Rubenstein of the University of Chicago, managed to 
secure one of the first eight centers.  Those first eight sites all had important connections 
to policy makers and government agencies, connections that ultimately gave greater 
standing to their applications for a DRTC and that had been created through the web of 
new relationships in the research arena of diabetes and pregnancy.  Norman Fleischer, 
who became director of the DRTC awarded to Albert Einstein College of Medicine in 
New York, started his career with a research fellowship under Oscar Crofford of 
Vanderbilt (another of the initial eight centers), who because of his earlier work as a 
lobbyist became the first chairman of the National Commission on Diabetes and the lead 
investigator for the landmark, multi-center Diabetes Control and Complications Trial 
(DCCT) mandated through the DRE Act.  Fleischer had also worked with Charles Clark 
of Indiana University (also one of the eight new DRTCs), who would become president 
of the American Diabetes Association (ADA).  And Indiana undoubtedly received higher 
priority for one of the DRTCs because of Clark’s Robert Wood Johnson Fellowship that 
had placed him in Washington in a health policy role under Senator Dale Bumpers (D-
AR), a role that also connected Clark to Senator Richard Schweiker, the main architect of 
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the Diabetes Research and Education Act.  Suffice it to say that the connections and 
relationships ran deep.55 
Pregnancy had become absolutely central to government-funded diabetes research 
by the 1970s because it accounted for a majority of the funded studies on diabetes issues 
and because the clinical investigators who were taking on policy roles came from that 
area of diabetes research.  Of those first eight DRTCs, half identified diabetic pregnancy 
as the area of priority and the other four also had main projects that focused on diabetic 
pregnancy.56  In 1977, with an additional five million dollars, Congress approved five 
more DRTCs.  The Major Research Program (MRP) at Northwestern was converted to a 
DRTC and became a fully funded research center in 1977.  As Dr. Boyd Metzger 
explained, the work at Northwestern was mostly in animal models at first because of 
limited funding.  In order to turn their research work into healthcare practices for 
pregnant diabetic women, they needed the fiscal support that came from DRTC status.  
Once Northwestern University’s Diabetes in Pregnancy Center received the NIH-
controlled funds, “the clinical arm expanded and people and patients came in.”57  
Even with the funding and influence that investigators in the field had garnered, 
the social milieu surrounding diabetes contributed to an on-going lack of widespread 
acceptance of their research findings.  Many clinic-based physicians remained reticent 
                                                 
55 Many of these connections were pieced together by examining online Curriculum Vitae and 
then asking interviewees to discuss the connections.  See also Freinkel memoir; Moshe Hod, interview by 
Mark Perloe, October, 1999, http://www.obgyn.net/avtranscripts/perloe_hod.htm (accessed October 12, 
2009); Metzger interview; Coustan interview; Hare interview; and Snyder, “Oscar Crofford.” 
56 Hansen and Cohn, “Diabetes Research and Training Centers,” 550-552. 
57 Metzger interview; and Snyder, “Oscar Crofford.”   
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about diagnosing a woman with any form of diabetes, regardless of whether it was called 
glycosuria of pregnancy, pre-diabetes of pregnancy, or gestational diabetes.  The negative 
public perception of diabetic patients, which was especially difficult for diabetic women, 
made many physicians hesitant to accept lower thresholds for diagnosis.  Women with 
diabetes could become pregnant women with diabetes, a possibility that conjured a sense 
of immediacy, but the diagnosis was not a benign label.  Moreover, in the shadow of the 
new “perinatal movement” that focused on the well-being of the baby in high-risk 
pregnancies, pregnant women diagnosed with diabetes – of any form – were responsible 
as well for a second patient:  the unborn child.  And when the unborn child became the 
focus of concern, what diabetic or pre-diabetic women did during their pregnancies was 
no longer a private matter.58  Boyd Metzger explained, “The diagnosis [of gestational 
diabetes] was not given lightly … [instead] we wanted to capture people who were so at 
risk that the pejorative baggage was outweighed by the potential problems for the 
baby.”59   
Diabetes itself acquired a significant social stigma shortly after the discovery of 
insulin, when the perception of the disease shifted from being seen as an acute and deadly 
                                                 
58 Merkatz, et.al. “Screening Program,” 453.  Also, a review article that discussed the impact of 
the perinatal movement, or what legal analysts were calling the fetal rights movement, on medical care for 
pregnant women and on depictions of culpability for pregnant women appeared in 1986; see Dawn E. 
Johnsen, “The Creation of Fetal Rights:  Conflicts with Women’s Constitutional Rights to Liberty, Privacy, 
and Equal Protection,” The Yale Law Journal 95, 3 (January 1986):  599-625.  The issue finally came to a 
head within the AMA by the late 1980s when a subcommittee within the AMA drafted a position statement 
on physician responsibility in identifying, defining, and confronting negligent and dangerous health 
behaviors in pregnant women; see American Medical Association Board of Trustees Report, “Legal 
Interventions during Pregnancy:  Court Ordered Medical Treatment and Legal Penalties for Potentially 
Harmful Behavior by Pregnant Women,” Journal of the American Medical Association 264, 20 (November 
28, 1990):  2663-2670. 
59 Metzger interview. 
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illness of mostly children from higher-income families, to one of a chronic and costly 
illness of adults from a more diverse and less wealthy sector of society.60  Diabetes 
detection drives had continued across the nation during the 1960s, and those drives also 
increased the public awareness of racial differences in the prevalence of diabetes.   
Diabetes physicians and researchers often avoided addressing the issue of race 
directly in professional journals, but the uncomfortable issue of race and diabetes made 
headlines in 1963 with an accidental discovery on a remote Indian reservation in the 
Sonoran Desert of southern Arizona.  A federally-commissioned study on rheumatoid 
arthritis among the Pima Indians of the Gila River Community discovered that over two-
thirds of adult Pima Indians on the reservation had “hidden” diabetes and at least one-
third of pregnancies on the Gila River Indian Community were pre-diabetic.61   
Researchers and physicians could no longer tiptoe around the issue that certain 
racial and ethnic groups – Asians, Hispanics, Native Americans, and to a lesser extent 
African Americans – exhibited both a higher incidence and a greater degree of blood 
                                                 
60 For a more thorough discussion on the emergence of a pejorative popular image of diabetes, see 
Chapter 1of this dissertation; and Chris Feudtner, Bittersweet:  Diabetes, Insulin, and the Transformation of 
Illness (Chapel Hill:  University of North Carolina Press, 2003). 
61 Researchers from the National Institute of Diabetes, Digestive, and Kidney Diseases (NIDDK) 
had gone to the Gila River Reservation in 1963 to begin a longitudinal study on rheumatoid arthritis among 
residents of the community.  Because of the strong government-funded push to identify the multitude of 
“hidden diabetics,” large blood testing collection efforts for any purpose routinely included blood sugar 
testing as well, which resulted in the discovery of the incredibly high prevalence of diabetes in the Gila 
River community; see Carolynn M. Smith-Morris, “Diagnostic Controversy:  Gestational Diabetes and the 
Meaning of Risk for Pima Indian Women,” Medical Anthropology 24, 2 (April 2005):  145-177; Meda E. 
Pavkov, et. al., “Changing Patterns of Type 2 Diabetes Incidence among Pima Indians,” Diabetes Care 30, 
7 (July 2007):  1758-1763; and M. Miller, P. H. Bennett, and T. A. Burch, “Hyperglycemia in Pima 
Indians:  A Preliminary Appraisal of its Significance,” Biomedical Challenges Presented by the American 
Indian, Scientific Publication 165 (Washington, D.C.:  Pan American Health Organization, 1968).  Also, 
for a summary of the Pima Indian studies, see the online booklet by the NIDDK, 
http://diabetes.niddk.nih.gov/dm/pubs/pima/index.htm (accessed July 29, 2012).   
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sugar increases, especially affecting women during pregnancy.  But women in minority 
groups found that the recommended educational programs and interventions were 
stymied by “payment denials” for the more intensive prenatal care.  As John Hare 
explained, “Without a recognized diagnosis, women couldn’t pay extra … and those at 
the lower end of the threshold were money drains with little gain.”62  Although the engine 
of medical research was growing, investigators had to convince physicians to follow 
proposed policies for which no valid statistical data existed, while answering to policy 
makers concerned with growing concerns about the uneven rates of the condition in non-
white groups of women – women who generally lacked private insurance.63  In the midst 
of the growing controversy, Norbert Freinkel and Boyd Metzger learned that the World 
Health Organization (WHO) planned to revise the diagnostic category for Diabetes 
Mellitus in an update to the International Classification of Diseases (ICD).  The pair 
began to organize a conference, and they invited colleagues in the field to Chicago in 
order to draft a recommendation for gestational diabetes to be added to the category of 
diabetes as a separate form of the disease. 
 
  
                                                 
62 Hare interview. 
63 Ibid. 
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The First International Workshop-Conference on Gestational Diabetes Mellitus 
 By the late 1970s, researchers and clinicians working on the disorder realized that 
in order to implement standardized screening for raised blood sugars during pregnancy 
and to convince medical practitioners to take seriously the potential problems with the 
condition, they would have to find a way to transform the condition of pre-diabetes of 
pregnancy into the disease gestational diabetes.  Reporting research findings, publishing 
articles and position statements, and crafting detailed recommendations had not sufficed.  
The DRE Act had taken researchers like Norbert Freinkel a long way toward bringing 
attention to the problems faced by pregnant women who presented with glycosuria or a 
raised blood sugar, but research findings still needed to be put into clinical practice.   
Freinkel and his colleagues organized the First International Workshop 
Conference on Gestational Diabetes to detail the potential harm to the fetus from the 
condition, to establish the best methods for detecting it, to explore the possibility of 
testing all pregnant women, and to decide what therapeutic interventions were justified.  
The conference was held November 9 and 10, 1979 at the Northwestern University 
Medical School in Chicago, Illinois, and was financed by the American Diabetes 
Association (ADA), the American College of Obstetrics and Gynecology (ACOG), the 
NIH, the CDC, and McNeil Laboratories.  McNeil Laboratories was a diagnostics and 
pharmaceutical company that had been acquired two years prior by Johnson & Johnson, 
an acquisition that placed Robert Wood Johnson in the position of CEO and united the 
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company with political lobbyists through the Robert Wood Johnson fellowships that had 
been established for physician-researchers to learn healthcare policy roles in Congress.64   
 With over three million live births in the United States each year, at least 3 
percent of which Freinkel believed could be diagnosed as pre-diabetes of pregnancy, the 
increasing national attention paid to preventive healthcare, he claimed, should include as 
well the nine months of a pre-diabetic pregnancy’s impact on the fetus.65  The conference 
summary defined the condition as “glucose intolerance with recognition of onset during 
pregnancy” and recommended diagnosis with the testing criteria established nearly two 
decades earlier in John O’Sullivan’s study at the Boston City Hospital.66  Freinkel 
formally submitted the findings and recommendations of the conference to the National 
Diabetes Data Group and requested that the submission be forwarded to the World Health 
Organization for use in the upcoming revision of the terminology and classification of 
Diabetes Mellitus in its international compendium of diseases.67   
In 1980, the World Health Organization published the ninth revision of its manual 
for disease classifications, the ICD-9.  Under the category of Diabetes Mellitus, three 
distinct forms were listed:  Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus, and 
                                                 
64 The entire issue of Diabetes Care for May-June 1980 was devoted to the workshop-conference 
in Chicago; see Diabetes Care 3, 3 (May-June 1980).  On McNeil Laboratories, see Robert L. McNeil, Jr., 
interview with Arnold Thackray and Mary Ellen Bowden, August 13, 2001, August 30, 2001, and August 
15, 2002, available through the online archives for the Chemical Heritage Foundation, 
http://www.chemheritage.org/discover/collections/oral-histories/details/mcneil-jr.-robert-l.aspx (accessed 
January 20, 2011).   
65 Norbert Freinkel, “Gestational Diabetes 1979:  Philosophical and Practical Aspects of a Major 
Public Health Problem,” Diabetes Care 3, 3 (May-June 1980):  400.  
66 Freinkel, “Summary and Recommendations,” Diabetes Care 3, 3 (May-June 1980):  500.  
67 Freinkel, “Summary and Recommendations,” 501; and Metzger interview. 
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Gestational Diabetes Mellitus.  The process of creating and defining this “new” disease, 
designated as 648.8 in the international disease compendium, involved as much 
bureaucratic as scientific labor.68  Its creation had essentially occurred in a series of 
policy meetings, illustrating the extent to which medical research had become an 
interface between physicians, policy makers, and businesses.  The research that 
established a link between raised blood sugars during pregnancy and potential problems 
for the pregnant woman and her unborn child was translated into healthcare practices 
through the channels of congressionally-mandated committees and legislative work 
groups. 
Once Gestational Diabetes Mellitus (GDM) was added to the International 
Classification of Diseases, Ninth Revision (ICD-9) in 1980, Freinkel and many of his 
colleagues felt they had cleared the proverbial hurdle.  After decades of work, they had 
finally gained influence in policy decisions regarding pregnant women at risk for 
gestational diabetes.  The decade that followed, though, would be filled with controversy 
over diagnosing the new disease.  With many physicians questioning why the disease 
should be identified at all, arguments about screening for it had just begun to take center 
stage.  There would be technical problems with changes in diagnostic chemistry – some 
                                                 
68 For the full list of diseases under the numerical heading of 648, see:  
http://www.icd9data.com/2012/Volume1/630-679/640-649/648/default.htm (accessed November 1, 2012); 
and for the full list of numerical codes for the disease category of diabetes, see:  
http://www.icd9data.com/2012/Volume1/240-279/249-259/250/default.htm (accessed November 1, 2012).  
The numerical category of 648 includes “Other Current Conditions in the Mother Classifiable Elsewhere 
but Complicating Pregnancy, Childbirth, or the Puerperium.”  The numerical category of 250 includes all 
categories of “Diabetes Mellitus.”  For a brief summary of references to gestational diabetes as a non-entity 
in the discussions that led up to that first conference in Chicago, see R.J. Jarrett, “Gestational Diabetes:  A 
Non-entity?” British Medical Journal 306 (January 2, 1993):  37.  
199 
 
laboratories, for instance, used whole blood for testing while others used plasma.  There 
was a lack of up-to-date epidemiological data.  Results from the Boston Study that were 
used to define the disease were questioned because of a series of rounding errors.69   
Don Coustan explained, “It had been a Tower of Babylon for all these years” 
because a convoluted system for implementing policies had taken shape within the 
intricate funding system that had developed over a period of decades.  Recommendations 
funneled first through workgroups funded by agencies like the NIHCD and the OEO; 
then through the congressionally-mandated oversight committee, the National Diabetes 
Data Group; then through the National Commission on Diabetes, a subcommittee that fell 
under the control of the U.S. House Committee on Interstate and Foreign Commerce; and 
then through physician review boards in the American Medical Association (AMA).  
Committee members at all these levels came from a wide range of backgrounds as well – 
congressional liaisons, physicians, businessmen, the general public – and most “didn’t 
take all that into account … it was all like ‘sitting in a chair with a slide rule’ kind of 
thing.”70   
 
  
                                                 
69 Coustan interview.  Twenty years earlier, John O’Sullivan had rounded his data points from the 
Boston Study to make the results and conclusions more accessible to physicians, and later, congressional 
committees had placed their own rounding estimates on top of that data.  Then, the World Health 
Organization created a new formula for converting those lab results to make the data more accessible to 
policy makers. 
70 Ibid.     
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Conclusion 
In 1984, a group of physician-researchers met on the campus of Northwestern 
University in Chicago for the Second International Workshop-Conference on Gestational 
Diabetes Mellitus.  The first conference, in 1979, had resulted in the recognition of 
gestational diabetes as a third, distinct form of diabetes when the World Health 
Organization (WHO) responded to the conference committee’s recommendations by 
adding the new classification to its compendium of diseases, the International 
Classification of Diseases, Ninth Revision (ICD-9).  Officially defined as “glucose 
intolerance with recognition of onset during pregnancy,” the addition of GDM to the 
disease manual seemed a straightforward product of increased medical knowledge.71   
The summary from the second conference hinted at controversy over the “new” 
disease.  The committee stressed the potential risks to both the fetus and the pregnant 
woman and discussed the need to convince women and their healthcare providers of the 
seriousness of GDM.  The use of more benign terms that avoided the word “diabetes,” 
they said, was counter-productive to that goal.  The physicians and researchers who had 
worked to codify GDM were well aware that a large number of the women facing the 
new diagnosis had inadequate access to healthcare, and in their summary, the committee 
members said that a diagnosis of GDM “communicates the need for ‘high risk’ 
                                                 
71 World Health Organization, WHO Expert Committee on Diabetes Mellitus:  Second Report 
Technical Report Series, No. 646 (Geneva:  World Health Organization, 1980); Freinkel, “Summary and 
Recommendations,” 499.  The disease compendium maintained by the World Health Organization is the 
International Classification of Diseases, Ninth Revision (ICD-9), available online at:  
http://www.cdc.gov/nchs/icd/icd9.htm (accessed 10 January 2012).  
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surveillance to providers of third-party payments or others responsible for the financing 
of health care delivery.”72   
Researchers understood the need to craft policies that opened access to care for 
the growing numbers of women who received their healthcare through government-
subsidized programs.  Their recognition of and concern for that issue could be seen in the 
language used to define the new disease label – language that mirrored eligibility criteria 
to government-funded programs for lower-income women.  But the use of those 
bureaucratic channels also shaped women’s personal and public experience of the new 
disease because of the public perceptions already attached to such social welfare 
programs.  Even though debates about Gestational Diabetes Mellitus were structured 
around the language of science and medicine, the new disease would be defined within 
the framework of social welfare policy.  Federal policy was embedded in the disease, 
which would be evidenced by the influence of AFDC, Medicaid, private health insurance, 
ICD-9 codes, and CPT codes on medical policies about the disease.   
Because of the relationship between the medical meaning of GDM, the social 
understandings of the disease, and the federal policies that shaped its creation, struggles 
over medical care regarding GDM were shaped by policies outside the healthcare market 
that could control approaches inside the healthcare market – what economist Kenneth 
Arrow had famously dubbed “the welfare economics of medical care.”73  Florence Brown 
explained that intense debates over the influence of federal policy created a challenge for 
                                                 
72 Organizing Committee, “Summary and Recommendations,” 123.  
73 Arrow, “Uncertainty,” 141-149. 
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clinicians but those debates also even derailed programs.  “This is where we really 
missed the boat,” she said, “because we lose them to follow-up after their pregnancies are 
over.”  Policies for financing medical care have forced the use of outdated diagnostic 
criteria, but newer research, Brown predicted, “will at least double the number of women 
diagnosed with gestational diabetes and we’re not ready for that.”74   
In the post-World War II era, the research industry embedded within the Medical-
Industrial Complex substantially influenced healthcare policy in the United States.  The 
network of scientists in the new industry of health outcomes research became linked to 
clinicians, pharmaceutical representatives, Senators, and Congressmen.  The roles they 
gained in health policy allowed their research findings to be turned into clinical practice 
and national preventive health measures.  The millions of dollars that supported grants, 
research centers, and legislative initiatives created new career paths for physicians-
turned-researchers and turned their work on diabetes and pregnancy into a measure of 
national importance.  The classic history of disease creation has suggested that new 
concepts of disease emerge from changing social perceptions, but that formula does not 
fit for gestational diabetes.  Scientific advances shaped medical understanding, but the 
reframing of glycosuria of pregnancy from a condition of low priority into a disease that 
required universal testing came out of the work of unlikely partnerships, and the public 
perception of the women diagnosed was a consequence, not a cause.   
                                                 
74 Florence Brown, interview with author, August 11, 2010, tape in author’s possession. 
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CHAPTER VIII 
GESTATIONAL DIABETES MELLITUS: 
MEDICINE, CULTURE, POLICY, AND BUSINESS 
 
In 1980, the World Health Organization (WHO) added a new form of diabetes to 
its disease compendium:  Gestational Diabetes Mellitus (GDM).  Inclusion in the 
classification system granted a sort of officialdom to an illness because by then the 
manual was being used throughout the Western world to create consensus in diagnostic 
standards; to compile consistent epidemiological data for statistical analyses; to construct 
reimbursement strategies for third-party payer systems; and to develop comparable 
language in medical circles.  The new addition was defined as “carbohydrate intolerance 
of variable severity with onset or first recognition during pregnancy.”1   
As the 1980s progressed, however, it would become clear that the definition of 
gestational diabetes was not a matter of medical certainty.  Most clinicians did “not view 
gestational diabetes as a disease but rather as a risk factor.”2  Women of the Pima Indian 
tribe in the Sonoran Desert of southern Arizona, who were being diagnosed with the new 
disease at an alarming rate, found themselves unsure about the diagnosis.  One Pima 
                                                 
1 World Health Organization, WHO Expert Committee on Diabetes Mellitus:  Second Report 
Technical Report Series, No. 646 (Geneva:  World Health Organization, 1980); and Boyd E. Metzger and 
The Organizing Committee, “Summary and Recommendations of the Third International Workshop-
Conference on Gestational Diabetes Mellitus,” Diabetes 40, suppl. 2 (December 1991):  197.  
2 Donald R. Coustan, “Diagnosis of Gestational Diabetes:  What Are Our Objectives?” Diabetes 
40, suppl. 2 (December 1991):  15.  
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woman summed up the collective confusion, “After they told me [I had it], I didn’t have 
it.”3  The Washington Post told its readers that gestational diabetes was just “a reversible 
diabetic state” that would go away for women who practiced good health habits.4  
According to a pamphlet produced by the pharmaceutical firm Becton Dickinson, 
gestational diabetes was “different than other types of diabetes” because it only happened 
during pregnancy and then went away.5  A major study at Mount Sinai Medical Center in 
New York said that pregnancies complicated by gestational diabetes were mostly in 
women who were non-white and poor.6   
 This chapter argues that the process of creating gestational diabetes fundamentally 
shaped how the new disease and its patients became understood.  The public confusion 
about gestational diabetes was in many ways a reflection of the complexity of redefining 
a biological phenomenon from acceptable to adverse.  However, with gestational diabetes 
the complexity also arose from the impact of elements not typically recognized in studies 
of disease creation.  Gestational diabetes was created within the bifurcated system of 
social welfare policy, and examining the process that reframed the condition elucidates 
the role that the state has gained in defining health and illness.  Historians of medicine 
                                                 
3 Carolyn M. Smith-Morris, “Diagnostic Controversy:  Gestational Diabetes and the Meaning of 
Risk for Pima Indian Women,” Medical Anthropology 24, 2(April 2005):  157.  
4 Richard C. Eastman and Joseph V. Collea, “Gestational Diabetes,” Washington Post, 11 
November 1984, 15. 
5 BD Consumer Healthcare, “’My Doctor Says I Have Gestational Diabetes …’ What Do I Do 
Now?” (Franklin Lakes, NJ:  Becton, Dickinson and Company, 1991), 4.  This was the first printing of the 
pamphlet; two more versions were printed, the second in 1998 and the third in 2001. 
6 Gertrude S. Berkowitz, Robert H. Lapinski, Rosemary Wein, and Deborah Lee, “Race/Ethnicity 
and Other Risk Factors for Gestational Diabetes,” American Journal of Epidemiology 135, 9 (1992):  965-
973.  
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have demonstrated how social context influences the need to define or redefine health 
and illness, but rarely have they focused on how the mechanics of creating a disease has 
shaped the social meaning of the disease.   
Gestational diabetes quickly began to take on a negative image after being added 
to the classification rubric for diabetes because it became entangled with the broader 
view of diabetes as a disease of great public cost, and because many of the lower-income 
women encountering the diagnosis were defined by the way they accessed their 
healthcare.  Florence Brown, Director of the Diabetes and Pregnancy Program at the 
Joslin Diabetes Institute in Boston, lamented that women diagnosed with gestational 
diabetes were often portrayed as culpable, as responsible for their diagnosis through some 
measure of personal negligence, a view similar to the media portrayal of diabetics in 
general as bringing the disease on themselves through negligent lifestyles and health 
behaviors.  Even doctors, she noted, would sometimes suggest “that the person who has 
come to me with gestational diabetes … ate too much, that they’re gluttonous or 
hedonistic.”7   
Boyd Metzger, a physician and Professor Emeritus in Endocrinology at 
Northwestern University, explained that the focus on behavioral interventions with 
gestational diabetes resulted, to a great degree, in “the policing of lifestyles.”  While 
research showed that lifestyle could influence the timing and the progression of both 
Type 2 diabetes and gestational diabetes, Metzger said, the connection between behavior 
and health outcomes was not necessarily so clear-cut for this condition.  For Metzger’s 
                                                 
7 Florence Brown, interview with author, August 11, 2010, tape in author’s possession. 
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overweight patients who came to the Diabetes in Pregnancy Center at Northwestern, for 
example, “weight [was] a modifiable variable, but in some ways not.”  In fact, one only 
need look at the number of overweight and inactive people who do not have diabetes to 
understand the fallacy of equating lifestyle with causation.8   
In the reframing of gestational diabetes, from a condition of little notice to a 
disease that required testing every pregnant woman, the process of creating the disease 
was itself a significant factor in shaping our social understanding of the disorder and the 
women being diagnosed with it.  Prior to 1980, diagnosing a woman with gestational 
diabetes was counterproductive:  it simply placed a label of diabetes without opening up 
medical interventions because it did not create a tract for reimbursement.  But creating 
gestational diabetes in an operative sense – adding it to the international compendium of 
diseases – did not solve the problem of treatment in a functional sense.  That solution 
would depend on proof that detection and intervention reduced health problems for 
women and their babies in a measurable and cost-effective way.   
The process of “creating” gestational diabetes occurred within a bifurcated system 
of social welfare policy, and that mattered for how the disease and its patients became 
understood.  The number of women being diagnosed with the “new” disease who 
received their healthcare through government-subsidized programs for the poor grew 
dramatically during the 1980s.9  Social welfare programs like Medicaid had become seen 
                                                 
8 Boyd E. Metzger, interview with author, October 26, 2009, tape in author’s possession. 
9 Ian D. Smedley, Adrienne Y. Stith, and Alan R. Nelson, eds., Unequal Treatment:  Confronting 
Racial and Ethnic Disparities in Health Care (Washington, D.C.:  National Academies Press, 2003); and 
Luca Cavalli-Sforza, Pablo Menozzi, and Alberto Piazza, The History and Geography of Human Genes 
(Princeton:  Princeton University Press, 1994). 
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as fostering a “culture of poverty,” and women who sought assistance through such 
programs were often viewed as lazy and burdensome.10  Yet in order to diagnose and 
treat gestational diabetes effectively, it became necessary to craft policies that opened 
access to care for the substantial number of women who utilized public assistance 
programs.  And that resulted in the language of federal policy from programs like 
Medicaid becoming embedded in definitions of the disease.  For example, the wording 
for medical recommendations to diagnose and treat gestational diabetes would eventually 
mirror the eligibility text of federally-supported programs for the poor like Medicaid and 
Aid to Families of Dependent Children (AFDC).  
Examining the actual process that reframed the condition also clarifies the role 
that the state has gained in defining health and illness.  Historians debate the extent to 
which disease is socially constructed, and explain, for instance, that definitions of illness 
and health depend on such elements as time and place.  For the purists of social 
construction, disease does not even exist until we name it.  But many historians of 
medicine are medically trained, and the world of medicine privileges the reductive side of 
science – never completely dismissing social forces but viewing scientific knowledge and 
technological advances as the fundamental sources for defining illness.11  Certainly, for 
gestational diabetes, social constructs like time and place mattered; the condition had for 
over a century prior been viewed as temporary and mostly benign.  Likewise, increased 
                                                 
10 Linda Gordon, Pitied but not Entitled: Single Mothers and the History of Welfare, 1890-1935 
(Cambridge:  Harvard University Press, 1994). 
11 Charles E. Rosenberg, “Disease in History:  Frames and Framers,” Millbank Quarterly 67, 
supplement 1 (1989):  1-15; Georges Canguilhem, The Normal and the Pathological, trans. Carolyn R. 
Fawcett (Brooklyn, NY:  Zone Books, 1989); and Ian Hacking, The Social Construction of What? 
(Cambridge:  Harvard University Press, 2000). 
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medical knowledge and technological developments had changed physicians’ 
understanding of blood sugar variation and its consequences in very meaningful ways.12   
Diabetes had already become a popular topic in the news by the 1980s, and as 
attention to “the obesity epidemic” grew, the assumption followed that obesity and 
diabetes went hand-in-hand.13  Such publicity also emphasized the increasingly 
disproportionate incidence of diabetes in minority populations.  The Centers for Disease 
Control reports that, as a whole, diabetes affects over eight percent of the U.S. 
population, and non-white racial and ethnic groups experience prevalence rates as much 
as twice that of whites.14  Indeed, minority and low-income populations have long been 
known to have poorer health in almost all measures of healthcare and to have less access 
to everything, from preventive medicine to treatments for acute illnesses.15   
                                                 
12 David R. Hadden, “Diabetes in Pregnancy:  Past, Present, and Future,” Diabetes and 
Pregnancy:  An International Approach to Diagnosis and Management, eds. Anne Dornhorst and David R. 
Hadden (New York:  John Wiley & Sons, 1996). 
13 Amanda Shaffer, “Diabetes,” New York Times, Health Guide, 
http://health.nytimes.com/health/guides/disease/diabetes/overview.html (accessed April 1, 2008). 
14 Although the terms “prevalence” and “incidence” are often used interchangeably by the lay 
public, each is a different measure of a disease’s occurrence.  Prevalence refers to the total number of 
individuals who are affected by a condition at a specific point in time; incidence refers to the number of 
new cases in a particular time period, usually a calendar year.  The distinction is important when examining 
rates of chronic illness in populations because prevalence gives us an understanding of the cumulative 
impact of a disease while incidence gives us an understanding of variations in diagnosis from one year to 
the next. These statistics are from the “National Diabetes Fact Sheet, United States, 2011” published by the 
Centers for Disease Control, http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2011.pdf (accessed November 12, 
2012).     
15 For a summary on race-based versus class-based disparity, see Vincent Navarro, “Race or Class 
versus Race and Class:  Mortality Differentials in the United States,” Lancet 336, 8725 (1990):  1238-1240.  
In 2003, the Institute of Medicine produced the benchmark government document on racial disparity in 
health care in the United States; see Smedley, et.al., Unequal Treatment.  The study, however, did not 
directly address class-based inequity because the United States is one of few Western nations that do not 
collect class-based data on health care utilization.  For a more recent overview of the issue of health 
disparity in the United States, see Ichiro Kawachi, Norman Daniels, and Dean E. Robinson, “Health 
Disparities by Race and Class:  Why Both Matter,” Health Affairs 24, 2 (March/April 2005):  343-352. 
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Historians of medicine have typically examined the bureaucratization of 
healthcare to explain these unequal measures of health.  Medical sociologists and 
physicians, on the other hand, have discounted such a relativist approach.16  Accepting 
biological differences as real, they have asked instead what these studies on health 
disparity actually measured and how those data have become embedded in policy.17  
There are benefits to each approach, and each in some way acknowledges how social 
context has historically shaped definitions of disease.18  But with the post-World War II 
connections that emerged between medicine, business, and the state – often dubbed the 
Medical-Industrial Complex – physicians working on the condition that would become 
gestational diabetes recognized that disease creation was influenced increasingly less by 
scientific endeavor and more by public policies and business structures that addressed 
issues like disparity in access to care.  In fact, the disparity that emerged with gestational 
                                                 
16 The bureaucratization of healthcare has a long history of U.S. federal government involvement, 
with early interventions such as health insurance for seamen in the 1790s, pensions for wounded Civil War 
veterans, and payouts to Civil War widows; see Theda Skocpol, Protecting Soldiers and Mothers:  The 
Political Origins of Social Policy in the United States (Cambridge:  Harvard University Press, 1992); and 
John Duffy, The Sanitarians:  A History of American Public Health (Urbana:  University of Illinois Press, 
1990).  While New Deal programs also increased the active role of the federal government in many areas of 
public life, in the arena of healthcare it was not until the 1965 passage of Medicare and Medicaid 
legislation that the federal government became an integral player in the third-party payer system that 
influenced healthcare costs and access to care; see Colin Gordon, Dead on Arrival:  The Politics of Health 
Care in Twentieth-Century America (Princeton:  Princeton University Press, 2003); Jonathan Oberlander, 
The Political Life of Medicare:  American Politics and Political Economy (Chicago:  University of Chicago 
Press, 2003); and Charles E. Rosenberg, Our Present Complaint:  American Medicine, Then and Now 
(Baltimore:  The Johns Hopkins University Press, 2007). 
17 The difference in approach, with medical sociologists examining what disparity is actually 
measuring and historians debating the social origins of health disparities, is exemplified in two companion 
articles; see M. Gregg Bloch, “American Medicine and the Politics of Race,” Perspectives in Biology and 
Medicine 48, 1 (Winter 2005):  S54-S67 and Stephen Stigler, “Correlation and Causation:  A Comment,” 
Perspectives in Biology and Medicine 48, 1 (Winter 2005):  S88-S94.  For a good introduction to the major 
debates in this historical discipline, see John Harley Warner and Janet A. Tighe, eds., Major Problems in 
the History of American Medicine and Public Health (Boston:  Houghton Mifflin Company, 2001).   
18 Rosenberg, “Disease in History.” 
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diabetes, from unequal access to care to disproportionate health problems, has not been 
solved – and cannot even be understood – without attention to its historical context.   
 
Diagnosing Gestational Diabetes 
In 1980, the World Health Organization (WHO) published the ninth revision to its 
International Classification of Diseases (ICD-9).  By the middle of the twentieth century, 
the ICD had become the internationally accepted source to create a common language for 
identifying diseases and for tracking the causes of death and debility.  Updating the 
compendium had become necessary because of rapid increases in medical knowledge and 
because of the never-ending development of new and different ways to name diseases, a 
development that if left unchecked stood to make meaningful diagnosis impossible across 
a wide range of diseases.19   
One of the revisions slated for the 1980 version of the compendium was the 
taxonomy for Diabetes Mellitus.  Even by mid-century, the existence of two types of 
diabetes was commonly agreed upon by medical professionals, but the convoluted 
naming rubrics to distinguish one type from the other had made understanding of the 
disease and distinctions between its patients difficult for even the most skilled doctor.20  
A clear naming rubric was devised to identify and separate the two forms of diabetes, 
with one becoming Type 1 Diabetes Mellitus to replace the various names of juvenile 
                                                 
19 World Health Organization, “History of the Development of the ICD,” 
http://www.who.int/classifications/icd/en/HistoryOfICD.pdf (accessed January 1, 2010). 
20 Elliott P. Joslin, L.I. Dublin, H.H. Marks, “Studies on Diabetes Mellitus,” American Journal of 
Medical Sciences 186 (1933):  753-773; Harold Percival Himsworth, “Diabetes Mellitus:  Its 
Differentiation into Insulin-Sensitive and Insulin-Insensitive Types,” Lancet 1 (1936):  127-130; and 
National Diabetes Data Group, “Classification and Diagnosis of Diabetes Mellitus and Other Categories of 
Glucose Intolerance,” Diabetes 28 (1979):  1039-1057. 
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diabetes, severe diabetes, or insulin-dependent diabetes, and the other becoming Type 2 
Diabetes Mellitus to encompass the plethora of names like fat, mild, non-insulin 
dependent, diet-controlled, or adult-onset diabetes.  But unexpectedly for most physicians 
who relied on the disease compendium for filing insurance claims and for filling out 
death certificates, a third form of diabetes also appeared in the ICD-9, Gestational 
Diabetes Mellitus (GDM).    
Gestational diabetes, at that time also called glycosuria of pregnancy or pre-
diabetes of pregnancy, was not a newly discovered disease in 1980, nor was it even rare 
or unknown.  Physicians had known for over a century about the appearance of 
glycosuria (or sugar in the urine) in some pregnant women, an event that most doctors of 
that time believed was confined to pregnancy.  With the development of more 
sophisticated laboratory tests, it became understood that women with glycosuria usually 
had an accompanying rise in blood sugar.  But after gestational diabetes was added to the 
taxonomy of Diabetes Mellitus, arguments arose among healthcare practitioners about 
diagnosing the disease – about how to test, who to test, and even whether to test at all.21   
While complicated, and involving quite a bit of laboratory science, the details are 
important in order to clarify the extent to which the policies that followed from these 
debates highlighted the social characteristics of certain groups of women who faced 
diagnosis.  Women from different racial/ethnic backgrounds and from different socio-
                                                 
21 R. W. Beard, M.D.G. Gillmer, N.W. Oakley, and Philippa J. Gunn, “Screening for Gestational 
Diabetes,” Diabetes Care 3, 3 (May-June 1980):  468-471; R.W. Beard and J.J. Hoet, “Criteria for 
Screening Tests for Gestational Diabetes,” American Journal of Obstetrics and Gynecology 144, 7 
(December 1, 1982):  768-773; and R.H. Knopp, S. Magee, M.P. Larson, and T. Benedetti, “Alternative 
Screening Tests and Birth Weight Associations in Pregnant Women with Abnormal Glucose Screening 
(Abstract),” Diabetes 37, Supplement 1 (1988):  110A. 
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economic levels did not have the same correlation between symptoms like glycosuria and 
physiologic responses to tests for the disease like a high number in a blood test.  For 
example, white women generally “spilled sugar” into their urine at much lower 
corresponding blood sugar numbers than African American women or women of Asian 
descent.  African American and Asian women had even higher prevalence rates when 
diagnosis switched from the symptom of glycosuria to a number in a blood test.  And 
Native American women had prevalence rates as much as eighteen times higher than 
whites with that switch.  Physicians wrestled with the question of whether changing to a 
number in a blood test incorrectly negated the higher “tolerance” that some non-white 
women’s kidneys seemed to have for managing blood sugar or whether it displayed a 
more accurate level of risk.  There would be no clear-cut answer as to whether it was 
appropriate to change the diagnostic standards in a way that dismissed fluctuations in 
physiology that had previously distinguished diverse populations.  Moreover, the blood 
test to be used for diagnosis, the Oral Glucose Tolerance Test (OGTT), came with its 
own set of problems, and disagreements ranged from which blood components should be 
used to how much of a glucose load was necessary.22   
                                                 
22 Not only is there variation in the correlation between glycosuria and blood sugar between social 
groupings of women, but variation exists within individuals as well.  See M.W. Carpenter and Donald R. 
Coustan, “Criteria for Screening Tests for Gestational Diabetes,” American Journal of Obstetrics and 
Gynecology, 144 (1982):  768-773; E.H. Philipson, S.C. Kalhan, M.G. Rosen, S.C. Edelberg, T.G. 
Williams, and M.M. Riha, “Gestational Diabetes Mellitus:  Is Further Improvement Necessary?” Diabetes 
34, Suppl. 2 (1985):  55-60; Boyd E. Metzger, D.E. Bybee, Norbert Freinkel, R.L. Phelps, R.M. Radvany, 
and N. Vaisrub, “Gestational Diabetes Mellitus:  Correlations between Phenotypic and Genotypic 
Characteristics of the Mother and Abnormal Glucose Tolerance during the First Year Postpartum,” 
Diabetes 34, Suppl. 2, (1985):  111-15; and John B. O'Sullivan, “Body Weight and Subsequent Diabetes 
Mellitus,” Journal of the American Medical Association, 248 (1982):  949-952.   
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Despite the appearance that debates over the logistics of testing were simply 
pragmatic, the dialogue was often fueled by concerns over the growing disparity in who 
was being diagnosed.  With some practitioners questioning whether gestational diabetes 
was even a disease, calls began immediately for a “systematic screening program,” for 
“unanimity in considering the criteria for … screening of these patients,” and for “better 
guidelines for detection and control.”23  Intense discussions ensued over uneven 
prevalence rates and even over what the disparity meant.  Donald Coustan, an 
obstetrician who was a member of the committee tasked with setting the initial 
guidelines, the National Diabetes Data Group (NDDG), said that no simple solution for 
these confounding arguments appeared on the horizon.  As the parameters for positive 
and negative test results were somewhat arbitrary to begin with because of the lack of an 
inflection point in the data, Coustan said, “It was a strawman to say that gestational 
diabetes isn’t really a disease.”24 
The premise of the OGTT was that the pregnant woman whose blood sugar 
response was still functioning but compromised would be revealed with an overload of 
                                                 
23 Steven G. Gabbe, “Diabetes Mellitus in Pregnancy:  Have All the Problems Been Solved?” 
American Journal of Medicine 70, 3 (March 1981):  613; X. de Muylder, “Gestational Diabetes:  The 
Urgent Need for a Consensus,” Journal of Gynecology, Obstetrics, and Reproductive Biology (Paris) 14, 2 
(1985):  213; and Terra Ziporyn, “Gestational Diabetes:  Panelists Set Guidelines for Detection, Control,” 
Journal of the American Medical Association 254, 4 (July 26, 1985):  466.  
24 Donald R. Coustan, interview with author, August 12, 2010, tape in author’s possession.  The 
“gold standard” for determining a threshold number, or range of numbers, that delineate the difference 
between normal and abnormal involves a process of balancing averages from large cohorts with the search 
for what is called an inflection point in the data – a point where the plotted line of results either levels out 
or changes slope, indicating a variation from the normal pattern.  For gestational diabetes, no studies have 
ever found an inflection point, including the recent Hyperglycemia and Adverse Pregnancy Outcomes 
(HAPO) Study for which Boyd Metzger was the principal investigator and Donald Coustan was a 
collaborator.  Both physicians discussed the HAPO results in their interviews and both explained that the 
absence of an inflection point meant that diagnostic thresholds were somewhat arbitrary.   
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sugar.  The test involved drinking a measured amount of liquid sugar and then having 
blood drawn at a series of time intervals to assess the physiological response to the 
“glucose load.”  Even determining the measured amount of sugar to be used in testing 
began with some confusion.  As Coustan explained, “In the non-pregnant world – men – 
seventy-five grams is the standard [amount of sugar] to use but in pregnancy it’s one 
hundred,” and that difference was the result of layers of policy changes.  The circle of 
changes began with the U.S. Army because, like nearly all laboratory tests in use today, 
the original test subjects were young men in the Army.  The U.S. Public Health Service 
(USPHS) first changed the test to 100 grams of sugar, in part to distance American 
researchers from their European counterparts.  A federally funded study at the Boston 
City Hospital, a congressional task force, and the World Health Organization (WHO) 
would also add changes to the design of the test and to the interpretation rubric.  In the 
end, “the world moved on to 75 grams” with the belief that blood sugar control in 
pregnancy should be as sensitive in the pregnant state as in the non-pregnant state, while 
“we [in the United States] were stuck with 100 grams.”25   
Adding to the disjuncture, different clinical groups decided that they would design 
their own procedures for the OGTT, based in large part on the laboratory technology with 
which they were familiar.  Some practices decided to use whole blood samples while 
others used plasma.  The glucose load for the test varied from 50 grams, to 75 grams, to 
100 grams because of confusion over screening versus diagnostic testing.  While some 
                                                 
25 Coustan interview. Also, see Donald R. Coustan, “Diabetes Mellitus,” Assessment and Care of 
the Fetus:  Physiological, Clinical, and Medicolegal Principles, eds. Robert D. Eden and Frank H. Boehm 
(Englewood Cliffs, NJ:  Appleton & Lange, 1990), 695-697. 
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facilities tested women after an overnight fast, others had their patients eat a “mixed 
meal” before testing.  Women might be diagnosed after a single test or might have a 
preliminary test that led to yet another set of tests with the standard three hours of blood 
draws.  Disagreement existed over the threshold or cutoff number for diagnosis.  And 
researchers debated whether population-specific criteria should be developed.26  
 In addition to the problems with the design of the OGTT, the interpretation of test 
results was complicated by unresolved questions about race and class in medicine and 
science.  Recognition of race- and class-based affinities for certain diseases had a long 
history, and such trends were once broadly held to be indications of physiological 
inferiority.  The higher rates of many diseases in African Americans and in non-white 
immigrant groups were still being investigated, but were spun in a new context in the 
latter part of the twentieth century.  For infectious illnesses, the fear of contagion had 
driven much of the medical inquiry.  For chronic diseases, however, researchers had 
begun looking for social artifacts that contributed to a disproportionate burden of disease 
on certain marginalized groups.  For example, when investigators began looking at the 
high rates of stroke deaths among African Americans, they tried to determine whether a 
cultural aversion by African Americans to seeking medical care had played a role, or 
whether a bias on the part of physicians had contributed to a dismissal of early 
symptoms.27   
                                                 
26 Ibid. 
27 W.M. Byrd, “Race, Biology, and Health Care:  Reassessing a Relationship,” Journal of Health 
Care in the Poor and Underserved 1 (1990):  278-296; Smedley, et.al., Unequal Treatment; and Wally R. 
Smith, Joseph R. Betancourt, Matthew K. Wynla, Jada Bussey-Jones, Valerie E. Stone, Christopher O. 
Phillips, Alicia Fernandez, Elizabeth Jacobs, and Jacqueline Bowles, “Position Paper:  Recommendations 
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As the disparity in prevalence rates for GDM increased throughout the 1980s, the 
widening gap prompted accusations that the diagnosis was merely a new form of 
scientific racism.  Yet the glycosuria, and later the high blood sugars, associated with 
gestational diabetes were very real and some women experienced potentially dangerous 
raised blood sugars during pregnancy.  Although gestational diabetes became 
encumbered with pejorative social images, claiming the existence of some type of broad 
conspiracy theory to relegate poor patients to demeaning roles through the ways in which 
their access to medical care has been defined is an unsustainable argument.28  On the 
other hand, being in a healthcare role – whether as a doctor, a pharmaceutical rep, or as a 
policy advisor – did not grant immunity to the influence of social and cultural perceptions 
of individuals and groups.   
By the end of the 1980s, African American, Hispanic, Asian, and Native 
American women would be much more likely to face a diagnosis of GDM than non-
Hispanic white women, ranging from about two times more likely for African American 
women up to ten times more likely for Native American women.29  Researchers tried to 
                                                                                                                                                 
for Teaching about Racial and Ethnic Disparities in Health and Health Care,” Annals of Internal Medicine 
147 (2007):  654-665.  For a good summary of the early studies on racial disparity in stroke and carotid 
endarterectomy, see Ethan A. Halm, Stanley Tuhrim, Jason J. Wang, Mary Rojas, Caron Rockman, 
Thomas S. Riles, and Mark R. Chassin, “Racial and Ethnic Disparities in Outcomes and Appropriateness of 
Carotid Endarterectomy:  Impact of Patient and Provider Factors,” Stroke 40, 7 (July 2009):  2493-2501. 
28 Greene discusses this issue as it relates to ideas about motivations to label patients, but his main 
point is that disease prevention efforts were not carefully concealed marketing deceptions; see Greene, 
Prescribing by Numbers, 5 and, as it specifically relates to screening for diabetes, 98-105. 
29 Sharon L. Dooley, Boyd E. Metzger, and Nam H. Cho, “Gestational Diabetes:  Influence of 
Race on Disease Prevalence and Perinatal Outcome in a U.S. Population,” Diabetes 40, suppl. 2 (December 
1991):  25-29; David J. Pettitt, Peter H. Bennett, Mohammed F. Saad, Marie A. Charles, Robert G. Nelson, 
and William C. Knowler, “Abnormal Glucose Tolerance During Pregnancy in Pima Indian Women:  Long-
term Effects on Offspring,” Diabetes 40, suppl. 2 (December 1991):  126-130; and Gertrude S. Berkowitz, 
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explain the increasingly visible racial and economic disparity in gestational diabetes that 
arose during the 1980s.  Some explanations were based on a supposition that certain 
groups of women were predisposed to deranged blood sugars during pregnancy because 
of an underlying metabolic defect or because bad health habits such as inactivity and poor 
diet were culturally ingrained.  Others countered that such explanations neglected to 
acknowledge that screening programs for gestational diabetes focused more on women 
who were non-white and poor.  As proof, healthcare analysts pointed out that indicators 
of socioeconomic status such as mode of payment for healthcare services, usually defined 
as private insurance versus federally- or locally-subsidized reimbursement programs, 
were correlated with the likelihood that a woman would be tested for GDM and more 
than doubled the likelihood she would be diagnosed with the disease.  Opposing factions 
could not agree on whether increased testing in these groups of women was good because 
it signaled better access to care, or if it was bad because it reflected social and cultural 
beliefs about maternal responsibility in historically marginalized groups of women.30  
The connection of race and class to risk for gestational diabetes seemed like a new 
phenomenon to many in the 1980s, but how much had the demographics of women at 
risk for gestational diabetes really shifted?  A look back at the seminal study on 
gestational diabetes, conducted at the Boston City Hospital from 1954 to 1964, suggests 
that at some level the perception of race- and class-based disparity had already existed 
much earlier than the 1980s.  Demographic data on the women were not included in the 
                                                                                                                                                 
Robert H. Lapinski, Rosemary Wein, and Deborah Lee, “Race/Ethnicity and Other Risk Factors for 
Gestational Diabetes,” American Journal of Epidemiology 135, 9 (1992):  965-973. 
30 Berkowitz, et.al., “Race/Ethnicity,” 968 and 970-972. 
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first published articles on the Boston Study (which came out in the 1960s).  In later 
papers, however, the principal investigator, John O’Sullivan, described the study cohort 
as “the lower half of the socioeconomic spectrum.”31  Donna Younger, a physician at the 
private-practice Joslin Diabetes Clinic across town at the same time, characterized 
O’Sullivan’s subjects as poor, non-white, and unable to pay for their medical care, “His 
population was people who came to the outpatient clinic at Boston [City Hospital], which 
in the 1950s and 1960s, well, that was not private practice, and it was poor 
socioeconomically.”  The women went to the “Free Clinic” at the Boston City Hospital 
because they had nowhere else to go and the research team, Younger said, understood the 
vulnerability that the women faced in trying to get medical care when they enrolled them 
in the study back in the 1950s and 1960s.32   
 
Screening for Gestational Diabetes 
In the mid-1980s, the American Diabetes Association (ADA) stepped into the 
debate over testing for gestational diabetes, with many of the physicians on the scientific 
board of the organization hoping for consensus on diagnostic standards.  The ADA’s 
work on debates over gestational diabetes resulted in one of the organization’s first 
official position statements.   The position statement on diagnosing GDM was published 
in diabetes-specific, general medicine, and obstetrical journals, which gives some 
indication of how widespread the controversy had become.  The ADA stated the 
                                                 
31 John O’Sullivan, “Establishing Criteria for Gestational Diabetes,” Diabetes Care 3, 3 (May-
June 1980):  437; and John B. O’Sullivan and Claire M. Mahan, “Criteria for the Oral Glucose Tolerance 
Test in Pregnancy,” Diabetes 13 (1964):  278-285.  
32 Donna M. Younger, interview with author, August 11, 2010, tape in author’s possession.   
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organization’s support for the use of a 100 gram test on all pregnant women, even though 
that contradicted the guidelines from the WHO.  Further, the ADA recommended 
laboratory analysis should be done on plasma instead of whole blood, even though data 
from earlier studies had been from whole blood samples.  And although sounding 
innocuous enough, the ADA recommended that physicians implement a screening 
program before actual diagnostic testing.  The suggestion was for a single-sample blood 
test that could cast a wide net and identify any potential blood sugar abnormality without 
regard to what researchers called a “false positive.”  Then, only those women who had an 
abnormal screening result faced the actual diagnostic testing for GDM.  The diagnostic 
test occurred between the 28th and 32nd weeks of pregnancy, which placed the test well 
inside the parameters of what is commonly denoted as the third trimester of pregnancy.  
The procedure for the diagnostic test involved a baseline blood draw at the initiation of 
the three hour test, immediately followed by the ingestion of a liquid with 100 grams of 
sugar and then a series of blood draws at specified times over the next three hours.33   
The ADA position statement only increased the disagreements.  Because the 
guidelines were in opposition to those established by the WHO, without any explanation 
for the discrepancy, physician groups responded with a slew of unofficial position 
statements of their own.  Family practice doctors generally advocated routine but not 
                                                 
33 The first official position statement on GDM was released by the ADA in 1986 and was sent to 
a variety of professional journals.  See, for example, American Diabetes Association, “Gestational 
Diabetes:  American Diabetes Association,” Diabetes Care 9, 4 (July-August 1986):  430-431; American 
Diabetes Association, “Gestational Diabetes:  American Diabetes Association,” Annals of Internal 
Medicine 105, 3 (September 1986):  461; and American Diabetes Association, “Position Statement on 
Gestational Diabetes Mellitus:  Formulated by the American Diabetes Association, Inc.,” American Journal 
of Obstetrics and Gynecology 156, 2 (February 1987):  488-489. 
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universal testing; public health workers wanted screening programs to be connected to 
public assistance programs like the nutrition services in the Women, Infant, and Children 
program (WIC); midwives advocated the screening of targeted populations only; and 
physician groups in certain low-incidence geographic areas designed recommendations 
specific to their patient populations.34  Many physicians actually supported the ADA’s 
recommendation for screening before testing in order to narrow the testing population.  
They were hesitant to endorse universal testing because they disagreed on who should be 
tested and on whether gestational diabetes was even a disease.  A sizable number of 
women facing diagnosis came from lower-income backgrounds and from non-white 
racial and ethnic groups and cost-efficiency seemed unlikely for gestational diabetes in 
that type of patient population.   
                                                 
34 The list of unofficial guidelines and organizational position statements presented by various 
factions during the 1980s was too long to include more than a sampling.  Although many medical 
practitioners in similar practice areas voiced similar concerns and suggestions regarding screening, medical 
fields were certainly not homogenous in their approaches.  Obstetricians voiced a wide range of opinions, 
ranging from strict adherence to the recommendations that came out of the First International Workshop-
Conference on Gestational Diabetes Mellitus in 1979, which served as the basis for the ADA guidelines in 
1986, to a risk-based assessment before implementing a screening protocol.  But, most family practitioners 
and most midwifery groups presented unified statements that advocated targeted screening programs.  See, 
for example, M. Swinker, “Routine Screening for Gestational Diabetes Mellitus in a Family Practice 
Center,” Journal of Family Practice 17, 4 (October 1983):  611-614; J.E. Scherger and T.W. Hudson, 
“Routine Screening for Gestational Diabetes Reconsidered,” Journal of Family Practice 21, 3 (September 
1985):  177-178; L. Macupa, “A Proposal for Detecting and Managing Gestational Diabetes by 
Coordinating Existing Services,” Public Health Reports 101, 1 (January-February 1986):  94-97; N.I. 
Jowett and S.G. Nicol, “Gestational Diabetes:  Are the Right Women Being Screened?” Midwifery 2, 2 
(June 1986):  98-100; C. Massion, P.J. O’Connor, R. Gorab, B.F. Crabtree, R.M. Nakamura, and J.L. 
Coulehan, “Screening for Gestational Diabetes in a High Risk Population,” Journal of Family Practice 25, 
6 (December 1987):  569-575; E.R. Evans, M.S. Rendell, A. Scheuneman, F. Hamilton, and J. Calvert, 
“Gestational Diabetes,” American Family Physician 36, 6 (December 1987):  119-126; A.M. Truscello, 
D.R. Hollingsworth, M.E. Felice, and P. Shragg, “Routine Screening for Gestational Diabetes in White, 
Black, and Mexican-American Teenagers,” Journal of Adolescent Health Care 9, 2 (March 1988):  150-
155; and R.K. Gribble and P.R. Meier, “Screening for Gestational Diabetes in Central Wisconsin,” 
Wisconsin Medical Journal 87, 2 (February 1988):  19-21.  
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The demographic trend toward lower-income status and non-white race and 
ethnicity was not restricted to the realm of gestational diabetes.  Many chronic diseases 
during the 1980s were “discovered” to affect non-white racial and ethnic groups in 
disproportionate numbers.35  Improvements in access to healthcare and increased 
laboratory-based screening for chronic diseases like diabetes and heart disease uncovered 
a multitude of previously unnoticed health problems in marginalized groups by the end of 
the 1970s.  But many of the women who would be diagnosed with gestational diabetes 
during the 1980s entered the U.S. healthcare market when they became pregnant and had 
to seek prenatal care through Medicaid programs.  Cost-efficiency and measurable 
reductions in health problems became complicated for these groups of women by the 
restrictive structure of Medicaid.   
Health disparity, then, was not a new controversy in the 1980s, not even for 
gestational diabetes.  In fact, as early as 1975 the National Commission on Diabetes (a 
congressional workgroup created with the 1974 National Diabetes Mellitus Research and 
Education Act) had proposed that all pregnant women in the United States should be 
tested for gestational diabetes in the third trimester of their pregnancies because of the 
need to protect the health of the fetus.36  The Commission’s recommendations called 
upon important social concerns in an attempt to prod policy makers to initiate federal 
fiscal support for programs.  They nodded to the national focus on diabetes and on drives 
                                                 
35 Smedley, et.al., Unequal Treatment. 
36 National Commission on Diabetes, “Report of the Workgroup on Pregnancy of the Committee 
on Scope and Impact,” Report of the National Commission on Diabetes to the Congress of the United 
States, Vol. III, Reports of Committees, Subcommittees, and Workgroups, Part 2, Scope and Impact of 
Diabetes (11), U.S. Department of Health, Education, and Welfare, DHEW Publication No. (NIH) 76-1022 
(Washington, D.C.:  Government Printing Office, 1976):  179-181. 
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to identify the unknown diabetics who loomed in the shadows as a potential financial 
nightmare.  The Commission had also engaged the new “perinatal movement” that 
expressed public concern for the health of unborn children.37  But with no government-
sponsored initiative and no agreement within the insurance industry to offset the costs of 
such a major health screening program, a recommendation to screen all pregnant women 
in the United States was impossible to implement.  Although physicians whose patients 
paid out of pocket or through private insurance reimbursement for their healthcare could 
conduct testing for their pregnant patients, physicians working with low-income women 
could not.   
The language of science and medicine in these arguments effectively clouded the 
role that social perceptions began to play in how to diagnose and treat the new disease.  
As the demographics of GDM women became poorer and less white during the 1980s, 
class and race increasingly shaped women’s experience with the disease, sometimes 
affecting whether they were screened at all and certainly changing what types of 
healthcare they could get once diagnosed.   Clinicians who were more likely to work with 
poorer patients, like public health nurses and family medicine physicians at inner-city 
clinics, argued for targeted screening based on their understanding that women in certain 
racial and ethnic groups were more likely to have higher blood sugars after drinking the 
sugary liquid used in testing.  Because of the increases in indigent clients that resulted 
                                                 
37 Pregnancy and healthcare costs became major issues in medical research by 1980.  By the late 
1970s and early 1980s, “reproduction and women’s health” was the top publication topic for health services 
researchers, and coming in at number seven on the list was “the uninsured and underinsured.”  See Daniel 
M. Fox, “The ‘Milbank Quarterly’ and Health Services Research, 1977-1990,” The Milbank Quarterly 69, 
2, Health, Society, and the “Milbank Quarterly”:  Essays in Honor of David P. Willis’ Editorship (1991):  
193.  
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from the expansion of Medicaid, community health clinics resisted the implementation of 
universal testing with the concomitant costs and treatment implications.38  By contrast, 
obstetricians and diabetes specialists supported universal testing.  They talked about the 
clear connection between interventional medicine and long-term costs.  Specialty practice 
physicians also lauded the benefits of early interventions that large-scale screening 
offered.  Their privately insured patients eagerly sought the new therapies being 
introduced into the healthcare market.39 
Throughout the 1980s, as disagreements about testing procedures for gestational 
diabetes filled medical journals and spilled over into other academic disciplines, the very 
public debates about testing predominantly focused on details associated with procedures, 
laboratory chemistry, technology, and the potential for diagnostic errors.  Though 
important issues to be tackled, those detail-oriented arguments obscured how the social 
characteristics of women facing diagnosis quietly shaped the debates and the policies 
being crafted.  Procedural and technical problems certainly abounded, as many factors in 
testing such as the component of blood used and the formulas for setting numerical 
thresholds were rife with problems.  But, as the 1980s progressed, many women who 
faced a diagnosis of gestational diabetes came from a lower-income bracket of American 
society and were more often African American, Hispanic, Asian American, or Native 
American.   
                                                 
38 Swinker, “Routine Screening for Gestational Diabetes Mellitus in a Family Practice Center”; 
Macupa, “A Proposal for Detecting and Managing Gestational Diabetes by Coordinating Existing 
Services”; and Jowett and Nicol, “Gestational Diabetes:  Are the Right Women Being Screened?” 
39 Committee on technical Bulletins of the American College of Obstetricians and Gynecologists, 
“Management of Diabetes Mellitus in Pregnancy,” ACOG Technical Bulletin 48 (1978). 
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By the end of the 1980s, the social concerns that undergirded these debates 
became more visible when the diagnosis and treatment of gestational diabetes became 
intimately connected to policies that governed Medicaid eligibility.  Many doctors 
continued to view screening for gestational diabetes as risk assessment (whether a woman 
had a greater chance of developing diabetes), but others posited that its disproportionate 
application to groups of women with conditional access to medical care made it function 
like a surveillance tool.  It was broadly understood by then that the disease was being 
identified more often in non-white and poor women.  Coupled with mounting interest, 
that focus helped to publicize the demographic issues.40   
Family Medicine physician Cheryl Levitt poignantly described the problem that 
many physicians had begun to struggle with.  A diagnosis of GDM labeled pregnant 
women as high risk, exposing them to “a cascade of interventions” such as ultrasound, 
more lab tests, and Cesarean section deliveries.  For the family medicine doctor trying to 
adhere to “low interventionist” obstetrics in order to avoid extra procedures and costs, 
Levitt said, following the official recommendations for testing and the rules on qualifying 
low-income patients for the recommended care, created at best a difficult situation.41   
                                                 
40 A PubMed search for gestational diabetes from 1980 to 1991 returned over ten thousand 
records.  When Boyd Metzger looked at trends just within the American Journal of Obstetrics and 
Gynecology, he found that only one paper per year was published between 1975 and 1979, but that trend 
doubled to two papers per year for the period of 1980 to 1984.  And, from 1985 to 1990 the journal 
published an average of one paper per issue.  See Boyd E. Metzger, “1990 Overview of GDM:  
Accomplishments of the Last Decade – Challenges for the Future,” Diabetes 40, suppl. 2 (December 1991):  
1.    
41 Cheryl Levitt, “Screening for Gestational Diabetes, Diagnosis and Control:  A Review,” 
Canadian Family Physician 34 (September 1988):  1961.  
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The panoply of different approaches that physician groups promoted to test for 
and diagnose gestational diabetes also exposed deep divides within the U.S. medical 
community in spite of the supposed unifying force of the mid-twentieth century 
professionalization of American medicine.42  Arguments for targeted screening discussed 
the logistics of testing procedures, but the intention of targeted screening was to limit the 
number of poor patients needing expensive treatments.  In 1980, for example, the 
Cleveland Regional Perinatal Network (CRPN) reported on a pilot project to test the 
feasibility of a simple, inexpensive blood sugar measurement as a pre-screening tool for 
gestational diabetes.  The report focused on the simplicity of the pre-screening test, and 
explained that it could be used well before the recommended testing in the third trimester 
of pregnancy.  But the purpose of pre-screening was to decrease the number of women 
referred for the Oral Glucose Tolerance Test (OGTT).  The impetus for the study was 
inextricably tied to the web of policies controlling healthcare reimbursement and the 
perceived fiscal burden of the clinic’s non-white, low-income, inner-city patient 
population.43   
                                                 
42 Paul Starr, The Social Transformation of American Medicine:  The Rise of a Sovereign 
Profession and the Making of a Vast Industry (New York:  Basic Books, 1982); and Jeremy A. Greene, 
Prescribing by Numbers:  Drugs and the Definition of Disease (Baltimore:  The Johns Hopkins University 
Press, 2007). 
43 Irwin R. Merkatz, Method A. Duchon, Toyoko S. Yamashita, and Harold H. Houser, “A Pilot 
Community-Based Screening Program for Gestational Diabetes,” Diabetes Care 3, 3 (May-June 1980):  
453.  While the study report did not characterize the clinic’s clientele except to say that it was 
“heterogeneous” racially and socioeconomically and that patients were supported by “diverse community 
groups,” the CRPN was created in 1975 with funds from the Robert Wood Johnson Foundation (RWJF).  
The Regional Perinatal Programs of the RWJF had been designed to address the high infant mortality rates 
among inner-city and rural low-income families.  In the 1980s, support for the CRPN was largely taken 
over by the philanthropic Cleveland Foundation and by the Ohio Department of Health, Bureau of Child 
and Family Health Services – programs also designed to assist poor women and their families.  For 
information on the development of the RWJ Foundation’s Regional Perinatal Networks, see Sharon Begley 
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Throughout the 1980s, concerns about the cost of healthcare for the indigent 
motivated many clinicians to claim that a universal testing program for gestational 
diabetes cast too wide a net.  Testing a population of women who had a higher likelihood 
of a laboratory result above the cutoff would be a disaster, they said, because many of 
those women did not have health insurance and thus had no resources to pay for the 
suggested extra diagnostic and treatment procedures.  Yet, if they raised threshold values 
to make the net smaller, women who may have been identified at corresponding private 
clinics, who may have needed the preventive interventions and could pay the extra costs, 
would then be missed.44  For example, at the Joslin Diabetes Clinic the clientele in 1980 
was overwhelmingly privately insured patients.  The Joslin continued to use the lowest 
values for testing even when calls came to revise them.  As Donna Younger explained, if 
the thresholds for diagnosing gestational diabetes were raised, even though gestational 
                                                                                                                                                 
and Ruby P. Hearn, “Children’s Health Initiatives,” in Robert Wood Johnson Foundation Anthology:  To 
Improve Health and Health Care (Robert Wood Johnson Foundation, 2001), 
http://www.rwjf.org/content/dam/web-assets/2001/01/children-s-health-initiatives (accessed December 1, 
2012). 
44 Private clinics with mostly insured patients disagreed with suggestions to raise diagnostic 
thresholds and some even called for lower thresholds.  On lower thresholds for diagnosis, see for example, 
R.W. Beard and J.J. Hoet, “Criteria for Screening Tests for Gestational Diabetes,” American Journal of 
Obstetrics and Gynecology 144, 7 (December 1, 1982):  768-773; Lois Jovanovic and C.M. Peterson, 
“Screening for Gestational Diabetes:  Optimum Timing and Criteria for Testing,” Diabetes 34, suppl 2 
(June-July 1985):  21-23; M.L. Dietrich, T.F. Dolnicek, and W.F. Rayburn, “Gestational Diabetes 
Screening in a Private, Midwestern American Population,” American Journal of Obstetrics and 
Gynecology 156, 6 (June 1987):  1403-1408; B.R. Rowe, C.J. Rowbotham, and A.H. Barnett, “Pre-
conception Counseling, Birth Weight, and Congenital Abnormalities in Established and Gestational 
Diabetic Pregnancy,” Diabetes Research 6, 1 (September 1987):  33-35; and R.K. Gribble and P.R. Meier, 
“Screening for Gestational Diabetes in Central Wisconsin,” Wisconsin Journal of Medicine 87, 2 (February 
1988):  19-21.  On supporting the use of even more complex and more costly screening procedures, see 
P.A. Weiss, H. Hoffman, R. Winter, P. Purstner, and W. Lichtenegger, “Gestational Diabetes and 
Screening during Pregnancy,” Obstetrics and Gynecology 63, 6 (June 1984):  776-780; M.A. Morris, A.S. 
Grandis, and J. Litton, “Glycosolated Hemoglobin:  A Sensitive Indicator of Gestational Diabetes,” 
Obstetrics and Gynecology 68, 3 (September 1986):  357-361; and P. Hollander, “Gestational Diabetes:  
Ensuring Optimal Outcome for Mother and Child,” Postgraduate Medicine 83, 8 (June 1988):  48-52, 57, 
and 61. 
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diabetes was only a small part of their practice, many of their GDM patients would have 
been missed.  The calls to raise the thresholds, Younger said, were generally from clinics 
and facilities with a much more varied population than what they saw at the Joslin.  
Younger elaborated, “In fact, we didn’t see many Blacks here … we were a private group 
practice but we would always try to give care to people who would submit their financial 
data.”  Poor pregnant women would gain better access to medical care for the condition 
during the 1980s.  But policies that connected testing for GDM to eligibility criteria for 
social welfare programs also created a link in the social perceptions of those public 
assistance programs with many of the women being diagnosed.  On many levels, 
Younger lamented, it was dilemma for clinicians.45   
 
Gestational Diabetes and Medicaid  
Several pieces of legislation during the 1980s that expanded Medicaid services 
also opened avenues for medical care to certain women facing a diagnosis of gestational 
diabetes.  Although the changes in Medicaid coverage make for a dense history of 
acronyms and convoluted rules, the complicated pieces of social legislation are important 
to understand because they became embedded in the developing definition of gestational 
diabetes.  During the 1980s, a series of government-contracted studies and legislative 
actions prompted both federal and state governmental bodies to broaden medical care 
coverage for pregnant women, and several of those actions were specifically important 
for women at risk of being diagnosed with GDM.   
                                                 
45 Younger interview. 
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Between 1980, when gestational diabetes was added to the World Health 
Organization’s disease classification manual (the ICD-9), and 1986, when the ADA 
published its first official position statement on the new disease, the most rapidly 
expanding groups of gestationally diabetic women were the same expanding groups of 
women becoming eligible for Medicaid.  And they were characterized by poverty, lower 
educational background, and non-white race.46  Even though no sophisticated 
demographic analyses of gestationally diabetic women existed at that time, there was 
broad acknowledgement that non-white race/ethnicity and lower socioeconomic status 
were strong predictors of GDM.47  In fact, even as early as 1980, both race and 
socioeconomic status had been listed as priority areas for further research on gestational 
diabetes.48  
As a background, it is important to remember that healthcare in the United States 
had a very different complexion prior to the advent of Medicare and Medicaid.  Before 
1965, expenditures for medical care made up only 5 percent of the U.S. economy and the 
government contributed less than a quarter of that.  Within five years, those numbers 
                                                 
46 Marilyn P. Rymer and Gerald S. Adler, “Children and Medicaid:  The Experience in Four 
States,” Health Care Financing Review 9 (Fall 1987):  1-20; Rachel Gold, Susheela Singh, and Jennifer 
Frost, “The Medicaid Eligibility Expansions for Pregnant Women:  Evaluating the Strength of State 
Implementation Efforts,” Family Planning Perspectives 25 (September/October 1993):  196-207; Jennifer 
S. Haas, Steven Udvarhelyi, Carl N. Morris, and Arnold M. Epstein, “The Effect of Providing Health 
Coverage to Poor, Uninsured, Pregnant Women in Massachusetts,” Journal of the American Medical 
Association 269 (January 26, 1993):  87-91; and Janet Currie and Jonathon Gruber, “Saving Babies:  The 
Efficacy and Cost of Recent Changes in the Medicaid Eligibility of Pregnant Women,” Journal of Political 
Economy 104, 6 (1996):  1289-1291.  
47 See, for example, some of the discussions in journal articles on race and socioeconomic status 
with regard to screening and diagnosis:  John B. O’Sullivan and Clare M. Mahan, “Insulin Treatment and 
High Risk Groups,” Diabetes Care 3, 3 (May-June 1980):  482-485; Merkatz, et.al., “A Pilot Community-
Based Screening Program,” 453-457; and Pettitt, et.al., “Gestational Diabetes,” 458-464.  
48 Norbert Freinkel and John Josimovich, “Summary and Recommendations,” Diabetes Care 3, 3 
(May-June 1980):  499-501. 
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more than doubled.  Title XIX of the 1965 Social Security Amendments to Public Law 
89-97 established a system of matching federal grants for state programs to assist families 
and individuals who could not afford medical care.  In one of the most far-reaching 
pieces of social legislation since the New Deal, low-income women’s access to 
healthcare expanded dramatically through the provision of government-subsidized 
medical care.49  Arnold Relman, former editor of the New England Journal of Medicine, 
explained that prior to the passage of Title XIX, “medical care in the United States 
consisted mostly of personal transactions between physicians and patients [who] usually 
paid their bills directly out of pocket if they could.”  Moreover, prior to Medicaid, most 
women did not have any form of health insurance as it was generally tied to the 
employment status of men.50     
Although Medicaid legislation broadened women’s access to healthcare, its 
impact was initially limited to very poor women.  Many pregnant women benefitted, but 
until the early 1980s eligibility was restricted to women who were already receiving cash 
payments through the Aid to Families with Dependent Children program (AFDC).  Since 
AFDC payments fluctuated with the sometimes arbitrary decisions of policy makers and 
                                                 
49 Health Insurance and Related Provisions of Public Law 89-97:  The Social Security 
Amendments of 1965 Prepared for the Special Committee on Aging of the U.S. Senate (Washington, D.C.:  
U.S. Government Printing Office, October 1965); M.A. Glasser, “Extension of Public Welfare Medical 
Care:  Issues of Social Policy,” Social Work 10 (October 1965):  3-9; E. Winston, “The New Medical 
Assistance Program,” Public Health Reports 81 (October 1966):  863-866; and D.E. Stump, “Some Major 
Aspects of Assistance under Title XIX,” Public Health Reports 81 (October 1966):  867-869. 
50 Arnold S. Relman, “The Health of Nations,” Physicians for a National Health Plan, March 7, 
2005, http://www.pnhp.org/news/Health_Nations.pdf (accessed July 1, 2012).  Also see Arnold S. Relman, 
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local oversight committees, only very poor, single women who already had children 
became consistently eligible for the variety of healthcare interventions that Medicaid 
offered, like prenatal care programs.  As historian Linda Gordon has explained, the 
inadequately funded programs of AFDC were incredibly stigmatizing because of their 
eligibility requirements and surveillance policies as compared to the “unemployment 
insurance” and “earned pensions” that Medicare granted to men and the old-aged.  The 
restrictive policies of Medicaid compared to the open, inclusive policies for aged men 
and women covered by Medicare created and perpetuated a socially bifurcated system of 
healthcare.  The scrutiny and stigma with Medicaid, as well as an inability to navigate the 
complexity of the system, likely prevented many eligible women from even trying to gain 
access to healthcare.51      
In 1983, the Institute of Medicine’s (IOM) Committee to Study the Prevention of 
Low Birth Weight reported to Congress that the two main factors preventing access to 
adequate prenatal care were financial and cultural – the inability to pay and a lack of 
understanding about prenatal care.  The IOM recommended congressional funding for 
programs to educate women about prenatal care and funding to increase access to 
                                                 
51 Linda Gordon, Pitied but Not Entitled:  Single Mothers and the History of Welfare, 1890-1935 
(New York:  The Free Press, 1994).  For an idea of the complexity of the application process, see the 
“Notes from the Field” section of the October 1986 issue of the American Journal of Public Health; Judith 
Jones, Deputy Director of the Center for Population and Family Health at Columbia University in New 
York, reported on a program at Presbyterian Hospital in a low-income neighborhood of New York City 
where they hired staff to assist clients with the ten-page application form which was available only in 
English and for which Medicaid reviewers would not help clients with completion.  See Judith E. Jones, 
Lorraine Tiezzi, and Jacqueline Williams-Kaye, “Overcoming Barriers to Medicaid Eligibility,” American 
Journal of Public Health 76, 10 (October 1986):  1247. 
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community-based programs.52  Congress acted on those recommendations with three 
specific pieces of legislation.  With the Deficit Reduction Act of 1984, the federal 
government mandated that all states that requested matching federal Medicaid funds had 
to begin providing access to prenatal care for single, pregnant women with no children (a 
group not entitled to welfare coverage up to that point) as long as those women satisfied 
the specified income criteria for AFDC eligibility.  Medicaid coverage for pregnant 
women who met AFDC requirements was then extended further with the Consolidated 
Omnibus Budget Reconciliation Act of 1985 by eliminating restrictions on family 
structure.  What would become important for women who had been diagnosed with 
gestational diabetes was that Medicaid coverage was extended for AFDC ineligible 
women during the third trimester of their pregnancy and for their first sixty days 
postpartum.  Finally, in 1986, the Omnibus Budget Reconciliation Act gave states the 
option to request matching funds in order to cover all pregnant women who fell below the 
federal poverty level (which was higher than the cut-off for AFDC eligibility) if they had 
“high risk” pregnancies.  The 1986 legislation also allowed states to expedite Medicaid 
applications for high risk pregnant women in need of prenatal care who were already in 
the third trimester of pregnancy at the time they presented for care.53   
                                                 
52 Institute of Medicine, Preventing Low Birth Weight (Washington, D.C.:  National Academy 
Press, 1985); and Deborah D. Ingram, Diane Makuc, and Joel C. Kleinman, “National and State Trends in 
the Use of Prenatal Care, 1970-1983,” American Journal of Public Health 76, 4 (April 1986):  415-423. 
53 Janet Currie and Jonathon Gruber, “Saving Babies:  The Efficacy and Cost of Recent Changes 
in the Medicaid Eligibility of Pregnant Women,” Journal of Political Economy 104, 6 (1996):  1269-1274; 
and Embry M. Howell and Marilyn Rymer Ellwood, “Medicaid and Pregnancy:  Issues in Expanding 
Eligibility,” Family Planning Perspectives 23, 3 (May/June 1991):  123-128. 
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What has been missed in historical examinations of these legislative changes is 
that the congressional responses to the needs of low-income pregnant women were 
intimately connected to the work of researchers in the field of diabetes and pregnancy.  In 
1983, after postwar diabetes detection drives throughout the United States had left an 
unpleasant taste with the directors of several government agencies because of the costs 
incurred and the confusion created among the lay public, a belief still remained in the 
value of detecting raised blood sugars in pregnant women.  Clinicians, Senators, agency 
heads, and international health organizations had moved away from large-scale screening 
efforts for diabetes in general, but they still articulated a belief that “pregnant women in 
particular should be singled out for diabetes screening because of the potential deleterious 
effect of diabetes on the outcome of pregnancy.”54   
Through their persistent efforts, researchers working on gestational diabetes kept 
alive a belief in the value of detecting raised blood sugars in pregnant women.  Clinical 
investigators like Norbert Freinkel, John O’Sullivan, and Boyd Metzger sat on legislative 
workgroups such as the National Diabetes Data Group, the National Commission on 
Diabetes, and the World Health Organization’s Expert Committee on Diabetes Mellitus.  
And they brought with them to meetings of those workgroups their knowledge about the 
demographics of the population of women facing pregnancies complicated by gestational 
diabetes.  Years after the National Commission on Diabetes abandoned the search for the 
                                                 
54 John B. O’Sullivan and William B. Kannel, “The Worth of Diabetes Screening Programs,” 
Journal of Public Health Policy 4, 2 (June 1983):  164.  Also see National Diabetes Data Group, 
“Classification and Diagnosis of Diabetes Mellitus and Other Categories of Glucose Intolerance,” Diabetes 
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“hidden diabetic,” it still listed as one of its main goals “diabetes case finding for all 
pregnant women.”55  The Commission reported as well on racial differences in the use of 
prenatal care and linked those findings to the changing demographic make-up of 
gestationally diabetic women.  During the early 1980s, for example, congressional task 
force reports stated that non-white women (African American, Hispanic, and American 
Indians) used prenatal care significantly less than white women, yet they had a higher 
likelihood of undetected blood sugar problems affecting their pregnancies.56   
Although Medicaid became the source of healthcare access for many of the new 
gestational diabetics that the public came to know, which suggested a simple and 
straightforward connection to social welfare policy, the reality was more complex.  As 
historians have pointed out, there exists an inherent bias in the American system of 
employment-based private insurance and the system of rights-based pension systems 
versus entitlement programs that often categorize individuals and groups as fiscal and 
                                                 
55 Report of the National Commission on Diabetes to the Congress of the United States, Vol. III, 
Part 1 (December 1975), 117; and Merkatz, et.al., “A Pilot Community-Based Screening Program,” 453.  
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social drains on the nation.57  One goal of Medicaid was, of course, to carve out a way for 
ill people to get a minimum standard of care regardless of their economic and social 
status.  Another goal, albeit less clear to the general public, was to protect the public from 
diseased individuals (sometimes because of contagion, but in today’s world more because 
of the burden of illness on the political economy).58     
Public policy to protect the nation’s health is not the monolithic entity that 
typically appears in studies on health policy and disease creation.59  The policies and 
structures that factor into disease definitions vary, and they do not influence disease 
definition in the same way.  Infectious diseases like tuberculosis, syphilis, or more 
recently AIDS (or HIV infection as the structural formula has reshaped its name) 
certainly entailed a whole laundry list of public protection efforts that chronic diseases 
like diabetes do not.60   
Beyond the caveats for infectious versus chronic disease, who encounters disease 
has played a significant role in policy formulas and it has shaped in very meaningful 
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ways the experience of disease both for the patients identified and for the public who see 
them.  For example, women have always had a more difficult time than their male 
counterparts in gaining consistent access to healthcare and, hence, their experiences with 
medical care and with being diagnosed with a disease have played out differently.61  
While men with private insurance could weigh treatment options and ask about the 
panoply of medications available to them, women who entered the healthcare system 
under Medicaid struggled simply to acquire the state-defined minimum level of care.  In 
the twentieth-century United States, health insurance developed as an employment-based 
system that left many women in a precarious position by the 1980s.  Few women gained 
health insurance through their own employment status because they struggled to gain jobs 
with the same benefits as men.  Rather, most women became add-ons or dependents to 
their husbands’ plans.  And women with no husband, or whose husband did not have 
adequate health insurance through his employer, found that they increasingly had to turn 
to programs like Medicaid as their “safety net.”62 
During the 1980s, Medicaid legislation dictated the financing of healthcare for a 
significant group of women who encountered gestational diabetes.  While a handful of 
clinicians drafted informal position statements on the screening, diagnosis, and treatment 
of gestational diabetes, the recommendations from physicians who had participated in the 
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First International Workshop-Conference on Gestational Diabetes Mellitus (FIWC) 
would mirror the language of Medicaid eligibility rules.63  Pregnant women should be 
tested between the 24th and 28th week of pregnancy, the third trimester of pregnancy.  
Medical management “should include high risk pregnancy surveillance and nutritional 
counseling.”  And younger women should be an acceptable group to test for GDM.64   
 
Table 2.  Summary of Medicaid policies and GDM guidelines, 1980 to 1986 
 
Year 
Legislative 
Index 
Medical Index Medicaid Policy GDM Guidelines 
1980 
 
FIWC 
Increased matching federal funds 
 
Women already receiving AFDC 
Universal screening 
 
Testing of groups with risk 
factors: 
1. Age 
2. Weight 
3. Prior pregnancies 
1983 
IOM Report to 
Congress 
 
Matching funds for prenatal education 
 
Research funds for cultural barriers to 
access for prenatal care 
ADA and ACOG call for prenatal 
education 
 
ADA promotes need for research 
on cultural barriers to access for 
prenatal care 
1984 
 
Deficit Reduction 
Act 
 
 
Prenatal care for first-time 
pregnancies 
Age (30, 25, or 24 yoa) dropped 
from most risk factor lists 
1985 
Consolidated 
Omnibus 
Reconciliation Act 
SIWC 
Coverage for AFDC ineligible 
women: 
1. During 3rd trimester 
2. For 60 days postpartum 
Screening week 24 to 28 
 
Testing for GDM after 28th week 
(3rd trimester) 
 
Retesting of GDM women within 
60 days postpartum 
1986 
Omnibus 
Reconciliation Act 
ADA Position 
Statement on GDM 
Prenatal care for all women below 
federal poverty level  
 
“High risk” pregnancies eligible 
Women with GDM classified as 
“high risk” pregnancy 
 
                                                 
63 During the 1980s, obstetricians, family medicine practitioners, public health nursing groups, and 
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The recommendations on gestational diabetes actually presaged many of the 
changes to Medicaid eligibility.  The language used by the FIWC committee appeared 
nearly verbatim in the expansion of Medicaid coverage.  The Omnibus Budget 
Reconciliation Act opened access to women with “high risk pregnancies.”  Access to 
prenatal care was streamlined for women in the third trimester of pregnancy with the 
Consolidated Omnibus Budget Reconciliation Act.  Medicaid eligibility shifted in favor 
of younger women with first pregnancies after the passage of the Deficit Reduction Act 
of 1984.  Pregnant women without children (generally meaning first pregnancies in 
younger women) were allowed into the Medicaid system.  Prior to that, women who did 
not already have at least one dependent child were ineligible for Medicaid because of the 
link to criteria for AFDC eligibility.65  Through the connection between GDM guidelines 
and the expansions in Medicaid eligibility, younger women from non-white racial groups, 
who were at increased risk of diabetes, gained better access to government-funded 
prenatal care.66   
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Massion, P.J. O’Connor, R. Gorab, B.F. Crabtree, R.M. Nakamura, and J.L. Coulehan, “Screening for 
Gestational Diabetes in a High Risk Population,” Journal of Family Practice 25, 6 (December 1987):  569-
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66 K.M. West, “Diabetes in American Indians and Other Native Populations of the New World,” 
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The Second Workshop on GDM 
In 1984, Norbert Freinkel’s research group at the Diabetes in Pregnancy Center at 
Northwestern University organized a second conference on gestational diabetes.  The 
purpose of the conference, which was an invitation-only workshop, was to clarify official 
recommendations and policy statements on testing for and diagnosing gestational 
diabetes, to review new research on the condition, and to examine the impact of new 
policies for the financing of healthcare delivery.  The workshop participants had all 
experienced the substantive changes in healthcare financing since the first conference, 
and many probably came to the second conference with a significantly different view of 
healthcare financing.67   
Medicare and Medicaid had both expanded since the first workshop, and both 
were being contracted out in some instances, with reimbursement depending on 
diagnostic and procedure codes approved by policy makers rather than physicians.  For 
the attendees of the second conference, the changes wrought by the growth of what 
Arnold Relman called the “new Medical-Industrial Complex” had resulted in their 
                                                                                                                                                 
America, eds. M.I. Harris and R.F. Hamman, DHHS publ. no. (NIH) 85-1468 (1985), 1-24; W.E. Winter, 
W.J. Riley, and N.K. McClaren, “Maturity Onset Diabetes in Young Black Americans,” New England 
Journal of Medicine 317 (1987):  380-382; and D.E. Bild and J.M. Stevenson, “Frequency of Recording of 
Diabetes on U.S. Death Certificates:  Analysis of the 1986 National Mortality Followback Survey,” Journal 
of Clinical Epidemiology 45 (1992):  275-281. 
67 To set some of the context for the professional discourse about the costs of care for gestational 
diabetes, consider that right after the first conference, Arnold Relman, the editor of the New England 
Journal of Medicine, published a very influential editorial that suggested the practice of healthcare, 
particularly for chronic diseases like diabetes, was moving away from a system that focused on the delivery 
of quality care toward an entrepreneurial system that focused on payment structures and reimbursement 
schedules from government agencies.  Relman’s editorial was commented on in various journals in the 
months after its publication, including diabetes journals, but by the time that the second workshop 
convened, Relman’s predictions had come to fruition.  Arnold S. Relman, “The New Medical Industrial 
Complex,” New England Journal of Medicine 303 (1980):  963-970. 
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medical practices being controlled to a large extent by “third-party payers” and by the 
chairs of House and Senate subcommittees on healthcare – individuals and groups who 
were well removed from real patients.68  Yet while many physicians sharply criticized the 
amorphous policies of Medicaid, some praised at least the intent of “providing the 
indigent with some aid in meeting health care costs.”69  For investigators working on the 
problems of access to care for women facing a diagnosis of gestational diabetes, working 
within the structure of this “new Medical-Industrial Complex” was a reality, not a 
conspiracy.70  
By the mid-1980s, guidelines concerning the diagnosis and management of GDM 
had become inextricably linked to policies that governed Medicaid eligibility.  Physician 
groups necessarily modified their approaches to accommodate the narrow eligibility 
criteria for Medicaid that many of their newer patients faced.  But women with GDM 
were certainly not a homogenous group and that fact complicated the formulation of 
                                                 
68 Relman reviewed the changes that occurred during the decade of the 1980s in a lecture he gave 
at the Annual Meeting of the Massachusetts Medical Society in Boston on May 18, 1991. See Arnold S. 
Relman, “Shattuck Lecture – The Health Care Industry:  Where Is It Taking Us?” New England Journal of 
Medicine 325, 12 (September 19, 1991):  856-857.  
69 Vertis R. Thompson, “President’s Column:  Crisis in Health Care for the Poor,” Journal of the 
National Medical Association 72, 11 (1980):  1038.  Vertis Thompson was the President of the National 
Medical Association (NMA), the black counterpart to the white-dominated American Medical Association 
(AMA).  The journal of the NMA published frequent editorials and position papers in support of 
expansions in Medicaid coverage, often suggesting that NMA physicians should be tolerant of 
administrative problems because of the lack of any other programs with as much potential opportunity to 
benefit black Americans.   
70 When the term “Medical-Industrial Complex” was first coined in the late 1960s, it came with a 
very negative connotation.  Those early tomes used the term to accuse physicians of participating in a broad 
conspiratorial campaign to demean marginalized patients and to insert themselves into an enlarging 
consumer market.  See Barbara Ehrenreich and John Ehrenreich, “The Medical Industrial Complex,” 
Health PAC Bulletin (November 1969):  1-9; Harold B. Meyers, “The Medical Industrial Complex,” 
Fortune 81 (January 1970):  9; and Barbara Ehrenreich and John Ehrenreich, American Health Empire:  
Power, Profits, and Politics (New York:  Random House, 1970), 95-123.   
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broad guidelines.  Although non-white and poor women faced an increasingly higher 
likelihood of becoming GDM patients, they were not the only pregnant women at risk.  
For example, women with their own health insurance who attended private clinics could 
certainly be diagnosed as well.  The increasing diversity of women at risk for GDM 
complicated the formulation of broad medical guidelines.  Moreover, not only was it hard 
to explain gestational diabetes to the general public, but confusion even ran rampant 
within the medical community as well.71   
The guidelines that came out of the first workshop on GDM showed up nearly 
verbatim in Medicaid policy, and the guidelines from the Second International 
Workshop-Conference on Gestational Diabetes Mellitus (SIWC) would also mirror that 
language.  The guidelines from the second workshop were published in 1985 and the 
ADA shortly followed with its first official position statement on gestational diabetes.  
The new guidelines from the second workshop came on the heels of the Deficit 
Reduction Act of 1984 and the Consolidated Omnibus Reconciliation Act of 1985.  
Those pieces of legislation had expanded Medicaid coverage to low-income pregnant 
women who were not eligible for AFDC if they were in the third trimester of pregnancy, 
and they had extended the period of coverage to include sixty days postpartum.  The 
recommendations from the second workshop, which were then echoed in the ADA 
                                                 
71 A more detailed look into the confusion and disagreement within the medical profession follows 
in this chapter.  To give one very telling example, though, in 1990 the Southern Medical Journal published 
a set of guidelines from the Southern Medical Association (SMA) regarding diagnosis and treatment of 
GDM.  In that position statement, the SMA recommended urine testing at every prenatal visit to screen for 
urinary sugar.  Glycosuria, or urinary sugar, had not been used for any form of diabetes screening or 
diagnosis for at least three decades by that point.  See William J. Watson, “Screening for Glycosuria during 
Pregnancy,” Southern Medical Journal 83, 2 (February 1990):  156-158. 
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statement, zeroed in on the third trimester of pregnancy as well.  And GDM guidelines 
from the second workshop added instructions for postpartum care, recommending that 
GDM women be retested at the first postpartum visit or at least within sixty days of 
delivery.  Women whose postpartum testing was normal were to be diagnosed as 
“previous abnormality of glucose tolerance,” while those women whose OGTT remained 
abnormal after pregnancy would be reclassified as either “impaired glucose tolerance” or 
“diabetes mellitus in nonpregnant adult.”  The post-partum diagnoses, then, continued the 
“high risk” eligibility category for Medicaid coverage.72   
Even though many women gained access to healthcare with the expansion in 
Medicaid coverage, it was not a panacea for gestationally diabetic women.  The summary 
of the second workshop made it clear that research on gestational diabetes had played a 
significant role in creating financial help for poor women in need of prenatal care and 
that, in turn, Medicaid policy had played a major role in the classification of GDM as a 
disease.  Indeed, the workshop’s summary justified the disease status for GDM in that it 
“communicates the need for ‘high risk’ surveillance to providers of third-party payments 
or others responsible for the financing of health care delivery.”73  Despite the expanded 
coverage, however, many women who faced an encounter with gestational diabetes when 
they became pregnant still had no way to get medical care.  There were women who were 
too poor to pay for healthcare but not poor enough to qualify for federal assistance.  And 
                                                 
72 Organizing Committee, “Summary and Recommendations of the Second International 
Workshop-Conference on Gestational Diabetes Mellitus,” Diabetes 34, suppl. 2 (June 1985):  123-126; and 
American Diabetes Association, “Position Statement:  Gestational Diabetes,” Diabetes Care 9, 4 (July-
August 1985):  430-431. 
73 Organizing Committee, “Summary and Recommendations,” 123.  
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those who became eligible for Medicaid still faced restrictions on where they could get 
care and on what conditions had to be met to continue their eligibility.   
Poverty was known to be a factor in poor health, but its connection to a specific 
diagnosis like gestational diabetes had not been established, and measures to help those 
women progressed haltingly.   A research study in the mid-1980s, however, examined the 
state of insurance coverage for people with diabetes and established a direct link between 
bad health and the inability to pay for healthcare.  The study also found that the problem 
worsened when the data were sorted by gender and race.  The researchers reported that 
non-white, female diabetics in poor health were more likely to be receiving Medicaid 
assistance or else were completely unable to pay for their healthcare.74 
The problem of gestational diabetes in the Gila River Community of the Pima 
Indians during the 1980s embodied the clash between programmatic issues and the ever-
increasing social concerns about uneven rates of diabetes diagnoses.  In 1980, a 
remarkable diabetes problem was unfolding for the Pima Indians of the Sonoran Desert 
of southern Arizona.  The prevalence of diabetes was as much as eighteen times higher 
(and rising) than in the rest of the United States, and nearly half of all pregnant Pima 
women could expect to have their pregnancies classified as gestationally diabetic 
according to the guidelines being supported by the ADA.  Researchers and physicians 
working on the reservation recommended increased diagnostic efforts and the creation of 
                                                 
74 Robert M. Anderson, William H. Herman, Jacina M. Davis, Ruth P. Freedman, Martha M. 
Funnell, and Harold W. Neighbors, “Editorial:  Barriers to Improving Diabetes Care for Blacks,” Diabetes 
Care 14, 7 (July 1991):  606.  The federally funded study that the authors referenced was Amy K. Taylor, 
“Medical Expenditures and Insurance Coverage for People with Diabetes:  Results of the National Medical 
Care Expenditure Survey,” Diabetes Care 10, 1 (January-February 1987):  87-94. 
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treatment and education plans.  But concerns about the cost of such high rates of 
diagnosis created calls for changing the diagnostic thresholds in order to bring the 
numbers of Pima women being diagnosed into line with other sectors of society.  In a 
trend that would become a common-place argument in racial disparity studies of the 
1990s, the idea to change diagnosis criteria was often presented as an effort to avoid 
scientific racism.75   
The enormous scope of the problem of gestational diabetes for Pima women was 
complicated by the structural changes in the Bureau of Indian Affairs (BIA) and in the 
Department of Health, Education, and Welfare (DHEW).  The Indian Health Service 
(IHS), formerly a committee within the Bureau of Indian Affairs, had been separated 
from the BIA and placed under the jurisdiction of the Department of Health, Education, 
and Welfare in the mid-1950s.  With that move, the IHS faced much stricter fiscal control 
than had been the case when it was still under the larger budget pool of the Department of 
the Interior.76   Then, in 1979, DHEW was restructured, with education being pulled out 
into a separate department and DHEW being renamed and restructured as the Department 
of Health and Human Services (DHHS).  Richard Schweiker (R-PA), the architect of the 
1974 Diabetes Research and Education Act, became the head of the newly reorganized 
                                                 
75 David J. Pettitt, William C. Knowler, H. Robert Baird, and Peter H. Bennett, “Gestational 
Diabetes:  Infant and Maternal Complications of Pregnancy in Relation to Third-Trimester Glucose 
Tolerance in the Pima Indians,” Diabetes Care 3, 3 (May-June 1980):  458-464.  
76 In 1954, healthcare was transferred out of the Bureau of Indian Affairs (BIA).  The BIA 
remained a part of the U.S. Department of the Interior, but Indian Health Affairs became an agency of the 
U.S. Department of Health, Education, and Welfare, where the majority of federally subsidized programs 
resided.  See the online history archives for the Department of Health and Human Services, 
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department.  Although Senator Schweiker’s interest in diabetes would seem to bode well 
for those working on the problems facing Pima women, it did not.   
The lack of support and, hence, the absence of increased funds to combat the 
gestational diabetes problem led to confusion among Pima women about the diagnosis.  
Women were tested and told that their blood sugars were raised, but then nothing 
changed in the course of their healthcare during pregnancy or afterward.  As Dr. David 
Pettitt explained, “The level of glucose intolerance associated with increased morbidity 
and mortality, and hence what constitutes gestational diabetes” was not easy to define for 
directors of federal agencies with no medical background.77  Colleagues of Pettitt called 
for skipping the screening procedure, which they deemed “a satisfactory method” 
because of the enormity of the problem.  But setting a different diagnostic threshold in a 
population of women whose healthcare was financed by the U.S. government was not 
going to be a decision left to a group of researchers.  The Indian Health Service’s (IHS) 
budget had already suffered cuts during the 1950s and 1960s and the problem of diabetes 
prevalence and the cost of dealing with diabetic health complications were only 
increasing.78   
Another program facing challenges, which served mostly Mexican American 
women, claimed that the NDDG guidelines let physicians decide to avoid testing some 
women.  The authors explained that GDM was a “serious and expensive health problem” 
among Mexican-Americans, who the authors also warned had “the highest fertility rate of 
                                                 
77 Ibid., 458.  
78 Beard, et.al., “Screening for Gestational Diabetes,” 469.  
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any race or ethnic group in the U.S.” and, yet, there was a complete lack of any published 
studies or funded proposals that focused specifically on this group of women.  Their 
overall experience with gestational diabetes was “unlike that reported by other academic 
obstetric clinics.”  Over 70 percent of their patients, the authors said, were non-white, 
poor, and lacking in access to prenatal and obstetric care because of the restrictive 
reimbursement policies of state-subsidized screening and treatment programs.  The 
authors concluded that the unique North American definition and approach to GDM 
hampered the implementation of cost-effective interventions for a significant population 
of women and their children because it allowed for subjective decision-making about 
screening and testing.79 
 
Conclusion 
The creation of gestational diabetes had involved a process of translating science 
into public policy, and many of the specific policies that guided that process fell under 
the large umbrella of social welfare.  The language used to define the new disease and its 
patients was fundamentally connected to the expansion and revisions that occurred to 
Medicaid legislation.  The connection to Medicaid was simple on the one hand because 
the increasing numbers of women during the 1970s and 1980s who were found to have 
the symptoms and laboratory results that defined gestational diabetes were 
disproportionately poor and non-white.  By the 1970s and 1980s, those women were 
                                                 
79 Dorothy R. Hollingsworth, Yvonne Vaucher, and Thomas R. Yamamoto, “Diabetes in 
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traditionally receiving their healthcare through government-subsidized clinics and 
Medicaid programs.  As the numbers of lower-income and non-white women who fit the 
criteria for being diagnosed with gestational diabetes increased, the language used for 
expanding Medicaid eligibility mirrored the language used in diagnosing and treating 
gestational diabetes.   
By the early 1980s, however, government-controlled programs like Medicare and 
Medicaid limited doctors’ reimbursement claims to conditions identified with approved 
ICD-9 codes only and to treatments specified with valid CPT codes.80  Already defined 
by the very public process of utilizing such government services as Medicaid, the 
growing number of low-income women who found their pregnancies complicated by 
GDM carried specific social labels with them into those medical clinics.  As economist 
Kenneth Arrow had predicted in 1963, the market-driven nature of healthcare 
necessitated programs like Medicaid, but little did Arrow know at that time how such 
programs would become embedded in the process of disease creation and definition.81   
As the growing prevalence rates of GDM became increasingly disparate, some 
healthcare providers argued that the diagnosis reflected a deep-seated scientific racism in 
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Centers for Disease Control at http://www.cdc.gov/nchs/icd/icd9cm.htm (accessed December 1, 2012).  
CPT (Current Procedural Terminology) codes are used for insurance billing and government 
reimbursement programs.  For a good explanation of diagnostic and billing codes, see a recent newsletter 
from the Indiana Academy of Family Physicians at http://www.in-afp.org/clientuploads/9-5-
11%20IAFP%20Anthem%20ICD%20Coding.pdf (accessed December 1, 2012). 
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American medicine.  However, the blood sugar fluctuations that came to be part of the 
definition of gestational diabetes were real events.  In fact, some women from non-white 
racial and ethnic groups, who had no prior diagnosis of diabetes, experienced potentially 
dangerous raised blood sugars during pregnancy.  Just as diabetes in general had taken on 
a pejorative image, the diagnosis of gestational diabetes became encumbered by negative 
social depictions.  As legal scholar Ruth Gordon has explained, being a black woman 
with diabetes had made her susceptible to doctors’ preconceptions for years.  In the early 
1990s, when she changed doctors, she said she began that first visit by stating that even 
though she was an overweight black woman with diabetes, she was a lawyer, “I ended 
that discussion before it even started.”82 
Florence Brown, director of the Diabetes in Pregnancy Center at the Joslin 
Diabetes Center in Boston, Massachusetts, explained that GDM took on multiple 
meanings because the complex eligibility and reimbursement strategies for government-
subsidized healthcare “resulted in a simple labeling process.”  Low-income women 
diagnosed with GDM gained access only to the diagnostic testing and therapeutic 
interventions approved by government committees, which were not necessarily the same 
as those recommended by physician groups.  For example, nutritional and educational 
interventions were not covered.  And even though physicians were the ones with direct 
contact with patients, Brown explained, “We [have had] to go through policy makers and 
the insurance industry, and it’s not to their advantage now to think about the long-term 
                                                 
82 Ruth Gordon, introductory commentary at The Duke University School of Law’s “Symposium 
on Race and Socio-Economic Class:  Unraveling an Increasingly Complex Tapestry,” January 23, 2009, 
Duke University School of Law, Durham, North Carolina.   
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cost of care later.”83  Gestational diabetes was a disease connected to state policy, but it 
had become as well a disease defined by race and class, and a disease for which treatment 
strategies were not completely under the purview of physicians. 
Brown’s insights were also based on a long history of women’s struggles with 
healthcare policy.  Legislation such as Aid to Families with Dependent Children (AFDC) 
and sections added to Medicaid that pertained to pregnancy and unborn children had 
already forced pregnant women to bow to state intrusions in order to attain any level of 
public assistance.  And even though welfare assistance for pregnant women and single 
mothers remained a predominantly “white” program throughout the 1970s, the popular 
perception was that state programs were supporting non-white women.84  Public 
sentiment, as echoed by eugenicists like William Shockley of Stanford University, was 
that programs like AFDC encouraged “dysgenic reproduction among blacks” and, hence, 
perpetuated “genetically carried disabilities.”85  Somewhere in the intersection between 
                                                 
83 Brown interview. 
84 The program Aid to Families with Dependent Children (AFDC) was originally titled Aid to 
Dependent Children (ADC) and originated with the creation of the Social Security Administration in 1935.  
Contrary to public perception, a 1961 Congressional Report on the program found that over half of the 
recipients were white, single women with one or two children and with no cohabiting male in the 
household.  See Robert H. Mugge, “Aid to Families with Dependent Children:  Initial Findings of the 1961 
Report on the Characteristics of Recipients,” The Bulletin, March 1963 (Washington, DC:  Social Security 
Administration, 1963).  Public Law 87-543, the Public Welfare Amendments of 1962, changed the name to 
AFDC.  In 1965, Public Law 89-97, the Social Security Amendments of 1965, added prenatal and postnatal 
care to Medicaid, and established a link between Medicaid eligibility and AFDC assistance; see Kaiser 
Commission on Medicaid and the Uninsured, “Medicaid Legislative History, 1965-2000,” 
http://www.kff.org/medicaid/loader.cfm?url=/commonspot/security/getfile.cfm&pageid=14255 (accessed 
July 29, 2012).   
85 On the views professed by William B. Shockley, see interview by Tony Brown, 1974, 
http://www.youtube.com/watch?v=sAszZr3SkEs (accessed July, 29, 2012). 
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medicine and policy, “GDM became the stepchild; it became the disease that nobody 
wanted but nobody could ignore.”86   
The main argument against increasing the number of women diagnosed with 
gestational diabetes was that the cost would be huge.  That argument was borne of the 
perception that GDM women did not pay for their medical care.  Hence, although 
“efficient, user-friendly, economical ways [to treat GDM]” were needed, those methods 
were up for debate by a wide array of non-medical groups who wanted to contain costs.  
Research on gestational diabetes required money.  Pharmaceutical companies, diagnostic 
companies, health insurance companies, and federal agencies supported that research, but 
by controlling the funding “they dictate[d] medical strategies.”87  
Dr. George Dunea epitomized the physician who opposed the expansion of 
government-subsidized healthcare programs like Medicaid.  A nephrologist at Cook 
County Hospital in inner-city Chicago, and also the editor of the British Medical Journal 
in the 1980s, Dunea voiced his displeasure with legislation that extended Medicaid 
coverage to a larger number of low-income pregnant women and poor children.88  He 
wrote a scathing editorial in 1979 on the proposed changes to Medicaid, claiming that 
cost containment and expansion of eligibility criteria were simply incompatible.  In his 
“Letter from Chicago” column, he charged President Carter with dispensing “placebo 
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therapy,” and he called Secretary of Health, Education, and Welfare Joseph Califano “a 
wet nurse.”89   
Dunea believed that his medical practice had been directly affected by a similar 
situation.  In the Social Security amendments of 1972, President Nixon had signed into 
law Section 2991 of Public Law 92-603.  That legislation pledged complete Medicare 
coverage for chronic dialysis in kidney patients.  With the proportion of lower-income, 
black Americans on dialysis already three times higher than their white counterparts by 
1972, Dunea’s inner-city, low-income clinic was charged with the care of a considerable 
number of dialysis patients for whom payment came from federal programs that he saw 
as inept, difficult to manage, and beleaguered by fraud and underfunding.90 
                                                 
89 George Dunea, “Letter from Chicago:  Coming of the Stork,” British Medical Journal 2, 6195 
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Gestational diabetes was “created” within the framework of social welfare policy 
out of necessity.  Because of the demographics of the most rapidly growing population of 
women being diagnosed with gestational diabetes during the 1980s, Medicaid policies 
became part and parcel of the definition of the disease.  The reframing of gestational 
diabetes occurred within the structure of government-subsidized healthcare, and the 
social understanding of the “new” disease and its patients took shape from a set of 
policies within that structure.  That process has resulted in the state gaining a substantial 
role in defining health and illness. 
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CHAPTER IX 
EPILOGUE 
 
 On Tuesday, September 5, 1989, Norbert Freinkel was attending a concert in 
Leningrad with his wife, Ruth.  He was sixty-three years old and at the height of a career 
that had brought him international influence.  He had travelled to Russia to establish a 
working relationship with several Russian physicians who were involved in research on 
gestational diabetes.  The international connections that Freinkel had been working on 
would culminate with the Third International Workshop-Conference on Gestational 
Diabetes Mellitus in 1991.  But Freinkel would not chair that conference in 1991.  He 
collapsed unexpectedly that night during intermission.  He had a heart attack and could 
not be revived.  On receiving the news back in Chicago, Boyd Metzger said, “I don’t 
even know how to explain the shock.”1   
The physicians and researchers who had worked on creating the diagnosis of 
gestational diabetes sought to increase access to care for groups of marginalized women 
in the healthcare market.  On Freinkel’s motivation, Metzger said, “Norbie genuinely 
believed that he had scientific insight of such value that it could allow clinicians to 
maybe change the trajectory of a person’s life before they were even born.”  Yet he 
struggled with policy makers, who often called his work “theoretical.”  And they insisted, 
                                                 
1 Boyd E. Metzger, interview with author, October 26, 2009, tape in author’s possession. 
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Metzger continued, that policies needed to be based on data and cost-benefit analyses, not 
theory.2   
Gestational Diabetes Mellitus (GDM) was created within the framework of social 
welfare policy because, as Donald Barnett suggested, “It could be no other way.”3  The 
institutional process of creating gestational diabetes – through public policies and 
healthcare business plans – assigned to women facing the diagnosis a consumer identity 
in the healthcare market.  Many of the women diagnosed with the new disease accessed 
their healthcare through programs like Medicaid.  Coupled with the increasingly negative 
portrayal of diabetes in general, as a disease of bad lifestyle choices and great public cost, 
gestationally diabetic women’s health behaviors also came under scrutiny.  Florence 
Brown posited that the perception of GDM women as undesirable consumers in the 
healthcare market and as irresponsible patients evolved as well from the “politics of 
healthcare that treated women patients differently.”4   
The disease concept of gestational diabetes took shape within a collision between 
science, business, and politics.  The discovery and marketing of insulin attached a 
consumer identity to diabetes patients.  And when insulin therapy allowed diabetics to 
survive long enough to take on adult social gender roles, pregnancy became the central 
focus for diabetic women.  The gendering of diabetes care played an important role in 
bringing attention to the condition of glycosuria of pregnancy, and that attention would 
help to create a billion dollar medical research industry.  Within that framework, 
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3 Donald Barnett, interview with author, August 11, 2010, tape in author’s possession. 
4 Florence Brown, interview with author, August 11, 2010, tape in author’s possession. 
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redefining glycosuria of pregnancy, a condition once thought to be of little importance, 
into a disease that required testing all pregnant women became a process that involved 
the production of public policies on access to healthcare.  When the growing numbers of 
women who faced a diagnosis of gestational diabetes came increasingly from low-income 
groups, those policies were crafted under the umbrella of social welfare.   
As Boyd Metzger took over the leadership of the Diabetes in Pregnancy Center at 
Northwestern University after the death of Norbert Freinkel, planning for the workshop 
in 1991 continued.  Metzger also took over the planning of what would become the 
largest research study to date on gestational diabetes, the Hyperglycemia and Adverse 
Pregnancy Outcomes Trial (HAPO).5  Data collection for the study was completed in 
2006, but the results would not be published until 2008.  HAPO was a long-range, 
prospective study of blood sugar levels in pregnant women around the world.  One of the 
main goals of HAPO was to establish the range “above which the risk was very high and 
below which the risk was very low.”6   
But HAPO only continued the controversy.  The data showed no inflection point, 
a position on the graphed data comparing blood sugar level to bad events, where the slope 
                                                 
5 Preliminary results for HAPO began to be published in 2008, with the main study results coming 
out in 2010.  See Boyd E. Metzger, L.P. Lowe, D.R. Dyer, E.R. Trimble, U. Chaovarindr, D.R. Coustan, 
D.R. Hadden, D.R. McCance, M. Hod, H.D. McIntyre, J.J. Oats, B. Persson, M.S. Rogers, and D.A. Sacks, 
“Hyperglycemia and Adverse Pregnancy Outcomes,” New England Journal of Medicine 358, 19 (May 
2008):  1991-2002; Boyd E. Metzger, “International Association of Diabetes and Pregnancy study Groups 
Recommendations on the Diagnosis and Classification of Hyperglycemia in Pregnancy,” Diabetes Care 
33,3 (March 2010):  676-682; Donald R. Coustan, Lynn P. Lowe, and Boyd E. Metzger, “The 
Hyperglycemia and Adverse Pregnancy Outcomes (HAPO) Study:  Can We Use the Results as a Basis for 
Change?” Journal of Maternal-Fetal and Neonatal Medicine 23, 3 (March 2010):  204-209; and Donald R. 
Coustan, Lynn P. Lowe, Boyd E. Metzger, and Alan R. Dyer, “The Hyperglycemia and Adverse Pregnancy 
Outcomes (HAPO) Study:  Paving the Way for New Diagnostic Criteria for Gestational Diabetes Mellitus,” 
American Journal of Obstetrics and Gynecology 20, 6 (June 2010):  654e.1-654e.6.  
6 Coustan interview. 
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of the plotted line significantly changes grade (signifying a change in risk).  And when 
the study group convened a committee to select the point where they believed the level of 
risk required intervention, “it had to be arbitrary … and people were shocked that then 
seventeen percent of the population would be identified as having gestational diabetes.”7  
Florence Brown summarized, “We’re missing a lot of people by using the old criteria … 
and a labeling process is not going to help us much, but a long-term treatment approach 
will.”8  Metzger explained that the intent of HAPO “was not to capture people at risk for 
the diagnosis as much as to capture people who were so at risk that the pejorative 
baggage was outweighed by the potential problems.”  He continued, “Our objective 
wasn’t to belittle people’s behavior.”9 
Disease creation has been characterized by historians as a process where a 
biological event is defined – or redefined – by shifts in its social understanding.10  But the 
history of GDM suggests that changes in social understanding are not always the 
catalysts.  The making of GDM involved nearly a century of scientific and bureaucratic 
efforts.  Those efforts formed a conceptual framework to address the potential problems 
that the condition posed for women, their unborn children, and the general public.  
Physicians and researchers collaborated with businesses in the diabetes healthcare market 
and with legislators who held the purse strings for funding on scientific efforts.  Although 
debates about gestational diabetes were structured around the language of science and 
                                                 
7 Ibid.; and Metzger interview. 
8 Brown interview. 
9 Metzger interview. 
10 Charles E. Rosenberg, “Disease in History:  Frames and Framers,” Millbank Quarterly 67, 
supplement 1 (1989):  1-15. 
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medicine, they were grounded in economic, legislative, and ideological considerations.  
While historians of medicine emphasize the social construction of disease, that formula 
does not work for the history of gestational diabetes.  Much like with pharmaceutical 
companies’ diffusion of risk factor ideology and with the selection of study subjects in 
medical research designs, the mechanics of creating gestational diabetes informed our 
social understandings of the women who became patients.11   
                                                 
11 Jeremy A. Greene, Prescribing by Numbers:  Drugs and the Definition of Disease (Baltimore:  
The Johns Hopkins University Press, 2007); and Steven Epstein, Inclusion:  The Politics of Difference in 
Medical Research, Chicago Studies in Practices of Meanings (Chicago:  University of Chicago Press, 
2007).  
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